answer question matter annual report question answer mission question adapt business model succeed current healthcare environment answer question consumer healthcare business answer question share price sector perform outlook gsk answer question research development pipeline perform answer question improve healthcare develop world answer website glaxosmithkline website wwwgskcom give additional information group information available website constitute annual report notice limitation director liability english law company act safe harbour limit liability director respect statement omission report director contain page english law director liable company party report director contain error result recklessness know misstatement dishonest concealment material fact liable report director page inclusive consist report director draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual reportchairman ceo summary mission question answer global quest improve quality human life enable people feel well live long report director business review spirit corporate governance undertake quest remuneration report enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency financial statement director statement responsibility independent auditor report consolidated income statement consolidate balance sheet consolidate cash flow statement consolidate statement recognise income expense note financial statement financial statement glaxosmithkline plc investor information financial record shareholder information taxation information shareholder glossary term index inside cover gsk annual report srotcerid eht troper stnemetat laicnanif noitamrofni rotsevni contentsannual report annual review history development company report annual report glaxosmithkline plc year glaxosmithkline plc public limited company incorporate end december prepare accordance unite december english law share list kingdom requirement approve board director london stock exchange new york stock exchange february publish february december company acquire glaxo wellcome plc smithkline beecham plc english public limited company summary report year annual review way scheme arrangem ent merger prepared accordance united kingdom requirement company glaxo wellcome smithkline beecham intend investor need detail annual major global healthcare business report produce separate document include joint statement chairman chief executive officer gsk plc subsidiary associate undertakings constitute summary review operation summary financial statement major global healthcare group engage creation discovery summary remuneration report annual review issue development manufacture marketing pharma ceutical shareholder annual report issue shareholder consumer healthrelate product elect receive document available gsk corporate head office london operational gsk website headquarters philadelphia research triangle park usa report glaxosmithkline group gsk mean operation country product sell glaxosmithkline plc subsidiary undertaking company country principal research development facility mean glaxos mithkline plc glaxosmithkline share mean usa belgium italy japan spain products ordinary share glaxosmithkline plc american depositary currently manufacture country share ad represent glaxosmithkline share major market group products usa france business performance japan italy germany spain business performance supplemental nonifrs measure business segment primary performance measure management gsk operate principally industry segment present exclude cost relate new operational excellence programme commence october pharmaceutical prescription pharmaceutical vaccine management believe exclusion item provide well onsumer healthcare overthecounter medicine oral care reflection way business manage give nutritional healthcare useful indication underlie performance group information provide addition total result brand name appear italic report prepare ifrs give assist shareholder gain clear trademark own andor license glaxosmithkline understand underlying performance business associate company exception baycol levitra increase comparability period present trademark bayer bonivabonviva trademark roche citrucel trademark merrell pharmaceuticals entereg trademark exchange rate adolor corporation usa hepsera trademark gilead group operate country earn revenue incur science country include usa humaxcd cost currency result group report trademark genmab integrilin trademark millennium sterling affect movement exchange rate pharmaceutical lymphostat trademark human genome sterling currency average exchange rate prevail science nicoderm trademark sanofiaventis pfizer canada period translate result cash flow elan novartis merrell glaxosmithkline vesicare trademark overseas subsidiary associate joint venture sterle astella pharmaceutical country yamanouchi period end rate translate net asset entity pharmaceutical certain country certain currency influence translation country licence group dollar euro japanese yen order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate commentary report present term cer state gsk annual report review chairman ceo summary natural stakeholder want know face see result investment challenge fastchange healthcare environment year gsk receive record product approval file plan convert strategic direction profitable result product application new product launch return value shareholder tykerb breast cancer veramystavamys allergic rhinitis altabaxaltargo treatment skin infection cervarix annual report aim answer question vaccine prevention cervical cancer demonstrate strategic focus research development deliver improve pipeline productivity enhance currently new product opportunity file return shareholder longterm success regulator commence new phase iii clinical development consumer healthcare business strong performance programme present key asset phase key pharmaceutical vaccine product current portfolio iii registration stage provide strong contribution growth help lead way deliver business performance earning share ep growth future remain challenge gsk determine constant exchange rate cer result remain industry leader front high end guidance pipeline progress efficiency initiative continue balance need shareholder fulfil responsibility community worldwide commitment improve healthcare community world october announce significant new billion operational feel right thing thing excellence programme improve operational efficiency financial performance outlook productivity expect deliver annual pretax saving total sale billion business performance ep million board declare dividend global community investment contribution year continue deliver positive influence live people pharmaceutical turnover level billion impact worldwide proud play generic competition usa decrease avandia grateful dedicated people effort passion sale globally key product sale seretideadvair contribute success extend company asthma copd rise billion lamictal thank shareholder continue support epilepsy bipolar disorder increase billion vaccine business grow billion consumer healthcare change management team past generate strong sale growth billion month include departure david stout president pharmaceutical operation rupert bondy senior vice president see launch large share buyback industry general counsel leave gsk end march share repurchases billion thank contribution gsk programme billion expect expect year welcome professor sir roy anderson board repurchase billion share programme mid nonexecutive director andrew witty chris viehbacher article new england journal medicine executive director suggest cardiovascular risk associate overall confident gsk strength organisation avandia second large product follow intense expertise deal change environment medium coverage despite effort explain entirety datum confirm risk sale avandia drop face significantly second half thank support decline avandia sale increase generic competition usa adversely impact earning expect midsingle digit percentage decline business performance eps cer look ahead remain confident gsk future fast grow vaccine business resurgence consumer healthcare division strong performance key pharmaceutical product provide contribution growth momentum latestage pipeline continue enhance business produce significant sir christopher gent garni renewal product line chairman chief executive officer message sir christopher gent chairman agm see retirement chief executive officer thank behalf board stakeholder gsk garnier serve gsk great style distinction andrew witty new chief executive officer merger december bring wit wisdom hugely agm work andrew experience impressive business acuman role directly responsible enthusiastic wellrespecte inside gsk innovation seven year include doubt ensure gsk fulfil rich potential introduction centre excellence drug discovery look forward work alongside transform way approach drive renew focus energy vaccine business gsk annual report consult stakeholder way shareholder patient government nongovernment organisation payer employee hear different question year annual report focus key question lie heart business summary market change evolve rapidly reflect new environment wellpositione relative peer broadbase geographicallydiverse balanced business mprove pipeline productivity nnovative programme reduce expenditure adapt work closely customer business model succeed position advantage opportunity grow healthcare economy current healthcare environment reduce expenditure cost remain major issue customer demand diversity balance healthcare continue increase drive age population operate fastchange market regulatory rise expectation commit working government payer perspective regulator increasingly risk conscious reduce total healthcare cost lower expenditure payer cost conscious imperative pharmaceutical operate efficiently profitably lower price company include gsk modernise evolve reflect environment enable continue investment market change time adopt flexible creative forward change environment approach product pricing alert opportunity share position relative peer broadbase risk customer mean demonstrate great geographicallydiverse wellbalance group encompass belief medicine expect reward pharmaceutical vaccine consumer healthcare medicine deliver anticipate benefit intellectual property system relatively short patent operational excellence programme important exclusivity traditional small molecule chemical pharmaceutical strategy mean improve efficiency yearonyear biological medicine vaccine consumer healthcare work hard low cost develop product product generally significantly long product life cycle outsource area business lowercost presence sector continue grow enable country continue assess capture opportunity well balance risk sustain growth reduce cost grow pipeline seize global opportunity recent year pipeline expand flow quickly globalisation increasingly important factor business seven year ago relatively product landscape past derive growth latestage pipeline today project clinical development establish economies usa europe japan countries nce new vaccine include key asset brazil russia india china know bric market late stage development large population increasingly able afford good quality healthcare open significant new market significant transformation drive largely change important future growth area gsk research development hardware software radically change infrastructure breaking invest people traditional big bureaucratic pharma model centre reach potential support talent excellence drug discovery cedd time highly motivated people ambition place great evolve adapt culture help talented people people apply energy passion difference improve quality science management world skill intellect key component successful implementation strategy continue invest continue ensure create new medicine recruit train good scientist professional target unmet medical need focus develop medicine way allow regulator clear assessment relative risk benefit gsk annual report summary consumer healthcare business key gsk profitable logical complement pharmaceutical operation powerful portfolio healthy pipeline utstande performance double digit sale growth consumer xcellent prospect particularly develop economy healthcare business pportunity share expertise resource business healthy performance consumer healthcare important business steady longterm growth help balance provide excellent balance pharmaceutical operation pharmaceutical business thrive business right deliver strong performance shareholder consumer healthcare show significant acceleration line share strength performance sale growth powerful consumer healthcare pharmaceutical business portfolio include lucozade sensodyne panadol horlicks stand entity complementary synergistic aquafresh brand benefit investment number important area back science launch new brand extension see successful endorse strategy focus launch alli overthecounter otc weight loss aid approve food drug administration fda grow trend worldwide patient manage currently review european regulatory authority healthcare choose otc product rely consumer healthcare business expertise prescription behaviour consumer healthcare sale marketing place partner choice professional richly experience able draw switch product bring prescription skill knowledge pharmaceutical business share otc market cost resource share expertise resource area regulatory matter marketing distribution consumer healthcare product turnover procurement product turnover get balance right pharmaceutical business operate tough climate increase legislation cautious regulatory regime pricing pressure lucozade key challenge face pharmaceutical company aquafresh time patent framework pharmaceutical product sensodyne tends result relatively short life cycle panadol successful treatment horlick contrast consumer healthcare business offer longterm capitalise longterm potential steady cash flow broad portfolio pharmaceutical otc global healthcare market state change example product help mitigate impact loss generic help increase trend government cut state healthcare cost smooth volatile nature pharmaceutical market influence switch prescription generic otc product look ahead healthcare consumercentre people expect able access medical knowledge influence treatment otc product destination everyday healthcare expect high rate growth healthcare business drive develop emerge economy otc foundation healthcare country china example otc account drug expenditure compare north america western europe gsk annual report summary ensure remain industry leader addressing issue face pharmaceutical sector investment achieve industry lead productivity new billion operational excellence programme share price sector increase dividend pay perform shareholder large share buyback programme outlook gsk industry sector challenge ttracte retain good employee year sustain value creation shareholder pharmaceutical sector suffer derate begin main factor derate productivity take action create longterm value integral growth pharmaceutical industry board management continually review gsk business strategy decline share price valuation past include value external environment view achieve growth longerterm potential pipeline currently case sustainable basis time level generic competition intensify industry longterm investment cycle drive primarily gsk able withstand pressure well time takes develop new pharmaceutical product peer broad nature product line flow new year decision take seven year improve product pipeline great protection experience productivity gsk time major impact vaccine consumer healthcare business revenue investor confident fact year merger end deliver strategy key pipeline product market begin increase sale cer despite challenge market condition factor share price financial term period total return shareholder time focus take action enhance gsk peer group total return gsk return shareholder accelerate efficiency programme shareholder period performance return cash shareholder dividend share buy peer group back board approve increase dividend avandia factor july gsk announce large share buyback programme gsk share price fall compare increase industry ftse index disappointing investor quarter announce significant new billion significant number employee operational excellence programme improve efficiency started strongly achieve important milestone productivity operation expect deliver annual saving include launch tykerb fda approval alli million quarter beat expectation deliver eps growth reduce cost mean cut talent gsk respected market receive positive news share price worldwide group good people good work outperform peer article continue attract retain reward bright employee new england journal medicine nejm suggest sale team line scientist cardiovascular risk associate avandia second large forefront discover new therapy product follow intense medium coverage despite effort explain entirety datum confirm risk doctor reluctant prescribe avandia new patient fda guidance sale avandia drop significantly negative impact share price follow clarification fda october new approve label ahead clarity gsk annual report summary good year team number important product potential product move pipeline achieve important objective key asset phase iiiregistration hree new chemical entity approve new vaccine research new product opportunity file development pipeline regulator perform ine new phase iii clinical development programme commence good year pharmaceutical merger hree latestage development programme see gsk good year group form inlicense undoubtedly great stride seven year remain achieve benefit look forward investment pipeline deliver october receive encourage safety efficacy year new chemical entity new vaccine datum vaccine protect malaria currently approve veramyst allergic rhinitis tykerb breast cancer phase development result give confidence altabax skin infection cervarix prevent cervical cancer large scale phase iii trial begin progress range product pipeline second half position future total new phase iii adapt change environment programme start large scale trial seek respond way challenge ascertain safety prove unequivocally efficacy productivity face company pharmaceutical medicine submit approval sector network cedd focus skill resource target initiative inlicense potential treatment continue disease area cedd create spirit small rdled team bring new latestage programme gsk move large pharmaceutical organisation allow latestage development improve ability nimble productive approach reload sustain pipeline need open new cedd immunoinflammation infectious disease head worldclass scientist nature carry inherent risk please year disappointment notable important element strategy access broad diversity termination odiparcil prevent blood clot number think way partner academic centre product line extension delay hope worldwide open new clinical imaging centre gain final regulatory approval usa include lamictal hammersmith hospital london research concentrating requip cancer stroke neurological disease second key strand sure gsk wellrepresente cut promise progress vaccine edge science practise open new fully integrate large promising vaccine pipeline project research institute china clinical development include seven phase iii trial file regulator gsk active external partnering strategy enter external product licensing collaboration cervarix hpv vaccine prevent cervical cancer number partnership develop utilise novel approve country world licensing science technology pharmaceutical biological application submit country include japan usa fda issue complete response letter cervarix continue review actively therapeutic area strategy december plan submit response letter examine area presence prioritise second quarter continue discussion demonstrate potential aim derive application fda pipeline biopharmaceutical present increase investment neuroscience cervarix highprofile vaccine vaccine oncology research vaccine progress rotarix rotavirus disease cause severe childhood diarrhoea file usa whilst remain tough challenge discover medicine vaccine june follow approval country worldwide level understand scientific advancement breakthrough file synflorix vaccine prevent pneumococcal disease europe unprecedented believe gsk opportunity discover international market end year meningitis new product great vaccine menacwy innovative magea vaccine treatment non small cell lung cancer enter phase iii trial gsk annual report summary gsk industry leader provide access medicine develop world preferential pricing ensure poor benefit treatment vaccine investment helping build rich pipeline reflect need develop world innovative partnership create breakthrough improve healthcare treatment vaccine neglect disease community investment activity help promote develop world education well healthcare get balance right actively involve support commercial organisation like gsk balance patient develop world strike return shareholder desire improve access product particularly patient preferential pricing develop world provide vaccine preferential price develop hivaid worsen healthcare crisis subsaharan world year africa bring worldwide attention poverty mean hivaid malaria treatment offer notforprofit deny education die malnutrition lack price public sector customer notforprofit organisation clean drinking water ability pharmaceutical company develop country subsaharan africa address healthcare problem develop world include global fund eligible programme notfor see broad context profit price available country offer antiretroviral arvs antimalarial innovative partnership notforprofit price addition significant community product viable commercial market truly neglect investment activity corporate responsibility report tropical disease work publicprivate partnership provide detail effort improve access medicine technology manufacturing distribution expertise develop develop world information academic institution provide research disease area knowledge community partnership programme public sector partner government organisation feel well live long gate foundation help fund project assist get hivaid tuberculosis malaria killing people medicine people need fund usually day believe play right thing channel organisation alliance thing malaria vaccine initiative contribute action area preferential pricing programme transform neglect disease arvs antimalarial vaccine invest example pipeline malaria treatment richest disease develop world community investment activity world see partnership foster effective healthcare grant voluntary license allow generic manufacturer innovative partnership produce version key arvs hivaid healthcare crisis africa pressure global capacity manufacture arvs meet group attack industry intellectual property system world need challenge medicine people important understand rely generate need fund enable invest billion community investment continue stress like january see anniversary commitment environment weaken eliminate lymphatic filariasis know elephantiasis date investment muchneede new reach million people million child medicine vaccine require delicate balance bear area lffree believe achieve benefit shareholder patient currently support significant hivaid education world programmes africa india china mexico programme face different challenge importance education people marginalise society common community investment programme include personal hygiene sanitation education phase focus simple act wash hand prevent diarrhoeal disease save life gsk annual report business review business review discuss gsk financial nonfinancial activity resource development performance outline trend factor likely affect future development performance overview financial trend ratio optimise performance market product deliver product pipeline patient good place good people well work improve access medicine corporate responsibility community investment global manufacturing supply regulatory environment world market product competition financial review financial position resource outlook risk factor financial review accounting presentation report prepare accordance international financial reporting standard ifrs adopt european union ifrs issue international accounting standard board datum market share market growth rate gsk estimate base recent datum independent external source appropriate value sterle relevant exchange rate figure quote product market share reflect sale gsk licensee business performance business performance supplemental nonifrs measure primary performance measure management present exclude cost relate new operational excellence programme commence october management believe exclusion item provide well reflection way business manage give useful indication underlie performance group information provide addition total result prepare ifrs give assist shareholder gain clear understanding underlying performance business increase comparability period present exchange rate group operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterling currency average exchange rate prevail period translate result cash flow overseas subsidiary associate joint venture sterling period end rate translate net asset entity currency influence translation dollar euro japanese yen order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate commentary report present term cer state gsk annual report srotcerid eht troper weiver ssenisub performance overview gsk performance drive number important strategy key performance indicator turnover business performance earning share growth total shareholder return strategy turnover optimise performance market product cer growth pharmaceutical consumer healthcare business focus way improve return group intellectual property maximise sale key product gsk activity include achieve worldwide sale force excellence achieve pharmaceutical consumer healthcare marketing excellence maintain high ethical standard improve costeffectiveness operation business performance earning share penny cer growth deliver product pipeline patient gsk aim create good product pipeline industry benefit society include develop focus strategy support pipeline manage life cycle compound launch prescription medicine potentially overthecounter product total shareholder return gsk measure productivity number level innovation product create ability address unmet patient need good place good people well work gsk commit create good place good people well work recruit develop good people industry gsk total return index gsk pharma peer return index support culture high reward high performance ftse total return index ensure good communication employee involvement maintain diverse healthy workforce share price improve access medicine gsk find innovative way bring medicine vaccine health education patient country include suffer epidemic neglect disease maximise total shareholder return tsr gsk continue work maximise tsr eps growth dividend increase share repurchase share price adr price february share price adr calculation business performance supplemental nonifrs measure describe note financial statement presentation financial statement gsk annual report srotcerid eht troper weivrevo ecnamrofrep key development group turnover billion constant exchange rate compare pharmaceutical product seretideadvair million imigranimitrex million vaccine product million flixotideflovent million avandia product million coreg million lamictal million seroxatpaxil million valtrex million augmentin million key pharmaceutical growth driver arixtra avodart boniva requip deliver combined sale million consumer healthcare product lucozade million panadol million aquafresh million horlick million sensodyne million launch alli usa june successful sales million achieve business performance operating margin improve percentage point turnover detail february gsk pharmaceutical vaccine project clinical development compare february major product opportunity phase iii development registration include elesclomol metastatic melanoma promacta thrombocytopenia entereg postoperative ileus rezonic chemotherapyinduce nausea vomit pandemic flu vaccine synflorix pneumonia nontypeable haemophilus influenzae ofatumumab rheumatoid arthritis tykerb armala inflammatory breast cancer late stage project terminate include odiparcil prevention blood clot detail group carry global leadership survey manager year survey show strong commitment performance integrity management work address area improvement group commit encourage diversity employee global management population female detail global community investment value million total profit tax lymphatic filariasis elimination programme continue million albendazole treatment donate make million treatment total gsk ship million combivir tablet nearly million epivir tablet develop country notforprofit price approximately million tablet supply generic manufacturer license gsk international humanitarian product donation total million detail business performance eps cer total eps cer dividend declare new share buyback programme billion year announce july billion spend billion expect gsk annual report srotcerid eht troper weivrevo ecnamrofrep financial trend ratio total result growth growth cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny business performance result turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny research development total pharmaceutical consumer healthcare total net finance cost cover net finance cost cover time time time net finance cost cover profit tax plus net finance cost divide net finance cost tax rate total tax rate business performance borrowing net debt gearing gearing ratio calculate net debt percentage total equity cer represent growth constant exchange rate sterling represent growth actual exchange rate calculation business performance supplemental nonifrs measure describe note financial statement presentation financial statement gsk annual report srotcerid eht troper soitar dna sdnert laicnanifbusiness review optimise performance market product gsk annual report srotcerid eht troper stcudorp detekram ecnamrofrep eht gnisimitpo marketing code gsk undertake range activity gsk commit ethical responsible patientcentred maximise commercial potential marketing group pharmaceutical marketing promotional intellectual property introduce activity policy govern marketing activity apply employee supplier contractor agent policy require innovative product accelerate market promotional activity base valid scientific process bring evidence comply applicable law regulation market possible increase brand policy support regional marketing practice code recognition improve access europe gsk international region japan usa new medicine code apply ethical standard reflect difference market structure national healthcare system regulation incorporate principle industry code practice worldwide pharmaceutical sale force excellence european federation pharmaceutical industry association gsk sale force rank high survey healthcare international federation pharmaceutical manufacturer association professional worldwide sale force excellence wsfe aim japan pharmaceutical manufacturers association pharmaceutical improve customer satisfaction research manufacturers america marketing code time available physician learn new medicine generation clinical study precious wsfe initiative sale pharmaceutical business create implement representative strengthen product knowledge learn deliver generation operating model advertising agency patientspecific treatment option efficiently design model aim improve creativity productivity effectively research show sale visit highly effective achieve significant cost saving involve number key area representative engage physician dialogue patient result professional brand account consolidated type support message visual aid illustrate single agency increase access good talent streamline clinical result account management reduce rate team institute single global sale model introduce focus key change agency review create financial parameter treat patient dialogue resource guide improve decision making process gsk medicine appropriate effective health literacy administer safely field staff gsk key market help patient understand basic information disease train new approach entire sale organisation involve treatment option pharma launch health literacy wsfe bring cultural change raise ethical standard programme employee agency staff go help build longterm trusting relationship healthcare training learn improve material goal community addition dashboard key performance indicator help patient learn disease manage product knowledge certification process effective leadership result obvious improvement patientdirecte material training programme establish make easy read trim content incorporate superior product knowledge essential serving need userfriendly design include stepbystep instruction healthcare professional physician rely gsk abreast health behaviour health literacy gain ground part change prescribe information new clinical study involve gsk colleague begin adopt concept simple clear gsk medicine key goal wsfe gsk expand annual patient communication certification program country representative consumer healthcare marketing excellence pass certification test pathology prescribe information team comprise marketing dedicated key message lead product score consistently seven global brand focus deliver pipeline representative achieve perfect score global marketing programme incountry commercial team pharmaceutical marketing excellence execute effort drive significant sale growth large number patient suffer effect disease continue market large brand dominant market unable benefit innovative medicine treatment available territory dedicated team drive example europe patient suffer lead market brand dominant market chronic obstructive pulmonary disease copd diagnose remain asset term enterprise brand locally manage receive regular maintenance drug therapy inmarket commercial team retain entrepreneurial spirit local relevance gsk marketing initiative implement programme overcome barrier proper diagnosis treatment provide accurate balanced information product allow people possible benefit gsk medical advance programme begin effect need societal cost disease decreasebusiness review deliver product pipeline patient metabolic research triangle park usa gsk spend billion ncology upper providence usa employ staff acrolide drug discovery zagreb croatia number major product opportunity eurology harlow phase iii registration increase sychiatry verona italy year stand espiratory stevenage cedd responsible identify target relevance therapeutic area building lead compound transfer research development pharmaceutical mdr produce potential medicine fundamental step gsk develop robust pipeline potential turn lead compound medicine optimise new medicine industry pharmaceutical potency efficacy safety define biology animal actively manage project human clinical trial human medicine test effect right globe deliver pipeline patient safely efficiently patient group number goal candidate compound select cedd responsible focus patient undertake clinical study necessary demonstrate beneficial objective unite people work gsk effect sufficient declare proof concept indication pharmaceutical staying focus patient patient new medicine work base programme drives discover potential treatment disease profile safety efficacy decision develop innovative medicine offer true benefit patient progress medicine latestage drug development reach speak patient family gsk commitment pursue good science understand impact disease live work world centre excellence external drug community essential gsk know patient discovery ceedd established ceedd wait focus patient driver deliver good objective cedd deliver medicine latestage day development establish manage longterm pharmaceutical gsk organise discovery strategic collaboration biotech small mediumsize development medicine patient discovery conduct pharmaceutical company ceedd exercise gsk centre excellence drug discovery cedd option bring compound clinical development development gsk medicine development centre mdcs anticancer inhibitor exelixis way group provide critical scientific input strategic intent gsk establish conduct important experiment aid manage dedicated centre shanghai china focus process group describe detail research neurodegeneration objective create new discover potential medicine medicine severe disorder multiple sclerosis parkinson component need discovery new medicine disease alzheimer disease centre eventually direct identification important molecular target global discovery development activity therapeutic potential impact human disease discovery compound area drugtarget identification latestage clinical study modulate target alleviate disease effective collaborate research institution china safe way country establish china reflect gsk commitment ally talented researcher locate molecular discovery research mdr produce lead compound encourage contest idea need create interact target form basis drug discovery new medicine effort gsk cedd mdr progress preclinical drug discovery programme perform hundred develop medicine patient assay week provide cedd lead progression latestage development refer gsk medicine development consist optimise physical gsk design cedd integrate group product property medicine chemical step scientist clinician organise work specific formulation require manufacture deliver disease area intent produce nimble entrepreneurial large scale confirm study efficacy safety discovery unit activity responsibility preclinical development gsk cedd base europe usa responsibility clinical development development operation team combination result biopharmaceutical stevenage step regulatory file submission regulatory agency ardiovascular urogenital upper merion usa approval patient use responsibility regulatory centre excellence external drug discovery team integration step coherent project upper merion usa responsibility project team group therapeutically mmunoinflammation stevenage medicine development centre role describe infectious disease upper merion research triangle detail follow park usa gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue preclinical development pcd include wide range activity safety datum routinely collect development entire medicine development process addition programme report national regional regulatory function involve enhancement exist product agency line applicable regulation devise convenient formulation early development gsk chief medical officer work global safety board process metabolism safety compound evaluate ultimately accountable oversight major decision laboratory animal test human test require patient safety gsk global safety board responsible internally animal highly regulate animal research approve pivotal study investigate issue relate process support analytical method drug synthesis patient safety arise development programme product formulation delivery scale meet increase information gsk clinical trial widely easily available supply requirement lead technical transfer clinical trial register gsk website process method manufacture new product supply inlicense process partnership global manufacturing gsk continue identify compound company supply ensure robust product develop largescale enhance portfolio create innovative collaboration commercial manufacturing launch ensure group regard partner choice medicine development collection therapeutically large small company align mdc mdc ultimate accountability develop subject acquisition inlicense comarketingcopromotion experimental drug regulatoryapprove medicine patient future option arrangement include mdc responsible creating value execution product development plan ensure strong partnership enoport phase iii rls phase rest gsk particular cedd latestage neuropathic pain development group epracor lunestalunivia exclude usa canada mexico japan gabaa agonist insomnia pende filing mdc base major usa site align ynta sta hsp upregulation melanoma sarcoma follow therapeutic area solid tumor phase iii ardiovascularmetabolic olerx anticd mab autoimmune disease phase nfectious disease include disease develop argacept phase acute postoperative pain world ddw novel lead central nervous system disease musculoskeletalinflammationgastrointestinalurology nacor novel candidate viral bacterial disease preclinical euroscience psychiatryneurology ncome cancer stem cell therapeutic preclinical ncology alapago novel antibacterial antiviral preclinical espiratory antaris novel antiviral agent preclinical manage portfolio mdc discharge responsibility project team medicine development project team responsible key project reach significant milestone review month maximise worldwide development opportunity product management board pmb responsible product remit information determine medicine meet criterion pass need support registration safety programme pricing phase development formulary negotiation available commercial input global progress portfolio communicate investor product strategy commercial operation ensure regional medium regular interval year detail gsk product marketing need integrate development plan development pipeline give page early stage risk development operation drive operational excellence pharmaceutical nature inherently risky execution project clinical study establish venture time potential medicine discover integrate planning ensure consistent predictable drug approve medicine year project plan supply clinical operation capability molecule start human clinical trial reach development operation manage clinical trial regulatory approval fail discontinued active patient handle patient recruitment datum variety reason insufficient safety threshold lack management project planning efficacy manufacturing hurdle discontinuation office chief medical officer charge safety occur despite extensive predictive testing latestage project patient involve clinical trial proper filing terminate include ariflo copd odiparcil finding regulatory authority clinical trial sponsor stroke prevention gsk irrespective place conduct accord international standard good clinical practice applicable law regulation protocol review external regulatory agency relevant country require protocol consider ethic review committee responsibility cover site study place gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue research development vaccine disease develop world gsk vaccine division activity include research clinical continue investment research disease disproportionately development regulatory strategy commercial strategy scaling affect develop world essential longterm vaccine production packaging support function improvement health people live region discovery development new vaccine complex process gsk response challenge operate drug discovery require longterm investment scientist unit base tre canto spain primarily dedicated find new devoted develop new vaccine costeffective medicine malaria tuberculosis additional research site convenient combination vaccine prevent infection cause usa focus discover new medicine medical problem worldwide gsk vaccine division treat hivaids drug resistant bacteria vaccine research develop therapeutic immunotherapeutic aim educate conduct rixensart belgium patient immune system identify attack cancer cell medicine vaccine enter clinical trial take highly specific manner thank use innovative technology development regulatory process dedicate group base global business model gsk fastgrowe vaccine maker usa belgium effort gsk deliver value contribute health wellbeing address prevention treatment world people generation world health organization priority infectious disease recently vaccine discovery involve collaboration academia gsk develop scoredtablet key antiretroviral product biotech industry identify new vaccine antigen simplify treatment child live hiv express yeast bacteria mammalian cell purify gsk currently clinical programme relevance high level develop world seven aim produce vaccine follow formulation clinical lot vaccine medicine disease disproportionately affect develop involve mix antigen select gsk novel proprietary country adjuvant system combination select adjuvant publicprivate partnership ppps remain essential fund research design enhance immune response step commercially viable market potential product evaluate safety efficacy candidate vaccine gsk leader working ppps continues collaborate preclinical setting usually involve animal model candidate closely government academic centre united nations vaccine test clinical trial healthy individual evaluate agency global funding body area maximise safety effectiveness induce immune response protect expertise knowledge dual benefit encourage body infection encounter later natural set phase research development accelerate access medicine iii largescale field trial healthy individual follow establish develop world safety efficacy cross section population phase iii animal research result obtain clinical trial datum ethical regulatory scientific reason research animal development quality largescale production process remain small vital research development new facility combine regulatory file submit medicine vaccine gsk use animal authority country vaccine alternative number require test group available strive exceed regulatory standard care use launch post marketing study considerable size set animal use undergoe internal external review assure assess vaccination programme monitor vaccine safety standard phase vast majority experimental method use animal vaccine manufacture particularly complex requires use gsk actively engage research develop validate innovative technology living microorganism sophisticated test avoid use animal research reduce quality assurance quality control procedure place ensure number need animal research unnecessary quality safety vaccine commonly include pain suffering scrupulously avoid animal use accord health authority requirement gsk understand use animal research purpose biological nature individual health authority subject vaccine command high level public interest glaxosmithkline public second control guarantee high quality standard policy position care ethical use animal research gsk increase capacity supply vaccine information report available gsk website develop global manufacturing network global secretariat manufacture supply gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue research development consumer healthcare product file vodart alpha blocker coprescription focus identify develop novel product ervarix usa japan benefit consumer overthecounter otc oral healthcare ntereg poi nutritional healthcare market achieve significant increase vaccine innovation internal external source inrix usa remodelled deliver valuable pipeline product amictal usa change specific task perform low cost outside univia gsk transfer external development partner romacta usa transfer headcount reduction saving release equip usa substantial fund investment additional innovation project otarix usa remodelling build consumer healthcare operating ynflorix international model global brand mirror commercial reximet structure branddedicate team pair commercial olibris brand team locate innovation centre weybridge parsippany usa gsk expect sustained flow new product year detail development information gsk pipeline important launchesfiling gsk outlook begin february gsk nearly pharmaceutical content drug development portfolio change time vaccine project development clinic new compound progress discovery development comprise nce ple vaccine compare development market owe nature drug development process compound especially month gsk commence new phase iii clinical early stage investigation terminate progress development programme include vaccine development phase nce multiple indication key asset phase iiiregistration count nce later phase count indication competitive reason new project preclinical compound phase iiiregistration development disclose project type identify gsk policy seek obtain patent protection protectable invention discover develop activity patent protection new active ingredient available significant market protection obtain example new pharmaceutical formulation manufacturing process medical use special device administer product intellectual property gsk maintain momentum deliver latestage pipeline receive product approval file product application currently new product opportunity file regulator development programme progress phase iii elimumab lymphostat lesclomol agea therapeutic vaccine enacwy vaccine fatumumab romacta hep ykerb armala ibc ykerb head neck gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnirevile business review deliver product pipeline patient continue key inlicense alliance relationship party maa marketing authorisation application europe date submission nda new drug application usa date regulatory approval maa phase evaluation clinical pharmacology usually conduct volunteer approval letter phase determination dose initial evaluation efficacy conduct date approvable complete response letter receive indicate small number patient ultimately approval give subject resolution phase iii large comparative study compound versus placebo andor establish outstanding query treatment patient establish clinical benefit safety bla biological license application estimate submission date disclose month date chart date represent likely year submission consider reasonably high probability successfully meeting date assume clinical datum meet expect endpoint clinical trial estimate submission date compound type indication phase maa nda cardiovascular metabolic cardiovascular project high affinity nicotinic acid receptor dyslipidaemia hma agonist rilapladib lppla inhibitor atherosclerosis kinase inhibitor atherosclerosis chronic obstructive pulmonary disease copd neuropathic pain rheumatoid arthritis kinase inhibitor atherosclerosis copd depression rheumatoid arthritis darapladib lppla inhibitor atherosclerosis lliii coreg ace inhibitor beta blocker angiotensin converting hypertension fix dose combination iii enzyme inhibitor volibris endothelin antagonist pulmonary arterial hypertension submit smar arixtra synthetic factor inhibitor treatment acute coronary syndrome approve aaug alfeb sep metabolic project remoglifozin etabonate sodium dependent glucose transport sglt obesity inhibitor ppar gamma partial agonist type diabetes bile acid receptor agonist type diabete otelixizumab trx anticd monoclonal antibody type diabete remoglifozin etabonate sglt inhibitor type diabete syncria glucagonlike peptide agonist type diabete avandamet ppar gamma agonist metformin type diabete extend release iii avandia ppar gamma agonist atherosclerosis type diabete iii avandia simvastatin ppar gamma agonist statin type diabete iii avandia ppar gamma agonist prevention disease progression submit sfeb infectious disease ribosome inhibitor treatment bacterial infection topoisomerase inhibitor treatment bacterial infection hiv integrase inhibitor hiv infections farglitazar ppar gamma agonist hepatic fibrosis sitamaquine aminoquinoline treatment visceral leishmaniasis tafenoquine aminoquinoline plasmodium vivax malaria gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue estimate submission date compound type indication phase maa nda musculoskeletal inflammation gastrointestinal urology monoclonal antibody rheumatoid arthritis parathyroid hormone agonist osteoporosis motilin receptor agonist delay gastric empty androgen modulator sarcopaenia interleukin antagonist rheumatoid arthritis belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus antibody pazopanib multikinase angiogenesis inhibitor agerelate macular degeneration cancer indication oxytocin antagonist threaten preterm labour gselective oestrogen receptor modulator treatment menopausal symptom selective ino inhibitor rheumatoid arthritis kinase inhibitor oral rheumatoid arthritis atherosclerosis copd neuropathic pain kinase inhibitor oral rheumatoid arthritis atherosclerosis copd depression corticotrophin release factor crf antagonist irritable bowel syndrome depression anxiety ronacaleret calcium antagonist osteoporosis fracture healing solabegron beta adrenergic agonist irritable bowel syndrome solabegron beta adrenergic agonist overactive bladder avodart alpha reductase inhibitor reduction risk prostate cancer iii avodart alpha blocker alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fix dose combination iii belimumab antib lymphocycte stimulator monoclonal systemic lupus erythematosus iii antibody bosatria mepolizumab antiil monoclonal antibody hypereosinophilic syndrome severe asthma nasal iii polyposis entraregentereg peripheral muopioid antagonist opioidinduce bowel dysfunction iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis cancer indication iii entraregentereg peripheral muopioid antagonist post operative ileus approvable aljul alnov neuroscience antagonist depression anxiety histamine antagonist dementia monoclonal antibody neuronal injury antagonistssri depression anxiety crf antagonist depression anxiety crf antagonist depression anxiety dopamine antagonist drug dependency dopamine antagonist drug dependency ampa receptor modulator schizophrenia monoclonal antibody alzheimer disease sodium channel inhibitor bipolar disorder type glycine transport inhibitor schizophrenia orvepitant antagonist depression anxiety histamine antagonist narcolepsy triple htnoradrenalinedopamine reuptake depression inhibitor glycine antagonist smoking cessation orexin antagonist sleep disorder kinase inhibitor neuropathic pain atherosclerosis copd rheumatoid arthritis antagonist dementia mix htdopaminergic antagonist schizophrenia noncannabinoid agonist inflammatory pain kinase inhibitor depression atherosclerosis copd rheumatoid arthritis crf antagonist depression anxiety irritable bowel syndrome voltagegate calcium channel modulator migraine prophylaxis voltagegate calcium channel modulator neuropathic pain casopitant antagonist depression anxiety zunrisarezonic chemo therapy induce postoperative nausea vomit firategrast dual alpha integrin antagonist vla multiple sclerosis voltagegate calcium channel modulator restless leg syndrome iii lamictal sodium channel inhibitor epilepsy partial generalise tonicclonic seizure iii oncedaily rosiglitazone ppar gamma agonist alzheimer disease iii lunivia nonbenzodiazepine gaba agonist insomnia submit sjul lamictal sodium channel inhibitor epilepsy partial seizure oncedaily approvable alsep treximet agonist naproxen migraine fix dose combination approvable aljun aug requip modutabxl nonergot dopamine agonist parkinson disease oncedaily control release approve amar aldec formulation gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue estimate submission date compound type indication phase maa nda oncology pololike kinase inhibitor cancer akt kinase inhibitor cancer centromereassociate protein cenpe cancer inhibitor armala pazopanib multikinase angiogenesis inhibitor colorectal cancer iboctadekin rituximab immunomodulator anticd nonhodgkin lymphoma monoclonal antibody totrombopag thrombopoietin agonist thrombocytopaenia cmet kinase inhibitor papillary renal cell carcinoma gastric cancer head neck squamous cell carcinoma ofatumumab anticd human monoclonal antibody relapse diffuse large cell lymphoma armala pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer armala pazopanib multikinase angiogenesis inhibitor ovarian cancer armala pazopanib multikinase angiogenesis inhibitor sarcoma armala pazopanib multikinase angiogenesis inhibitor erbb metastatic breast cancer tyverbtykerb epidermal growth factor receptor egfr dual kinase inhibitor armala pazopanib multikinase angiogenesis inhibitor erbb cancers tyverbtykerb egfr dual kinase inhibitor revoladepromacta thrombopoietin agonist chemotherapyinduce thrombocytopaenia tyverbtykerb erbb egfr dual kinase inhibitor head neck squamous cell carcinomas unresectable disease tyverbtykerb erbb egfr dual kinase inhibitor refractory inflammatory breast cancer armala pazopanib multikinase angiogenesis inhibitor renal cell cancer iii armala pazopanib multikinase angiogenesis inhibitor erbb inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor elesclomol sta oxidative stress inducer metastatic melanoma iii hycamtin topoisomerasei inhibitor ovarian cancer firstline therapy iii ofatumumab anticd human monoclonal antibody refractory chronic lymphocytic leukaemia iii rheumatoid arthritis ofatumumab anticd human monoclonal antibody refractory follicular lymphoma rheumatoid arthritis iii revoladepromacta thrombopoietin agonist hepatitis iii revoladepromacta thrombopoietin agonist longterm idiopathic thrombocytopaenic purpura iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer brain metastasis iii tyverbtykerb erbb egfr dual kinase inhibitor breast cancer firstline therapy iii tyverbtykerb erbb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii zunrisarezonic antagonist chemotherapy induce postoperative nausea iii vomiting depression anxiety revoladepromacta thrombopoietin agonist shortterm idiopathic thrombocytopaenic purpura submit sdec hycamtin topoisomerase inhibitor oral small cell lung cancer secondline therapy approve smay aoct tyverbtykerb erbb egfr dual kinase inhibitor refractory breast cancer approve soct amar respiratory interleukin antagonist cystic fibrosis histamine dual antagonist oral allergic rhinitis histamine dual antagonist intranasal allergic rhinitis lipoxygenase activate protein flap inhibitor respiratory disease longacte beta agonist copd copd asthma combination glucocorticoid agonist longacting beta agonist copd copd asthma combination glucocorticoid agonist pde inhibitor inhale copd pde inhibitor inhale asthma pde inhibitor intranasal allergic rhinitis muscarinic acetylcholine antagonist copd longacting beta agonist copd copd asthma combination glucocorticoid agonist monoclonal antibody severe asthma kinase inhibitor oral copd atherosclerosis neuropathic pain rheumatoid arthritis glucocorticoid agonist asthma copd asthma combination longacte beta agonist avamysveramyst allergic rhinitis kinase inhibitor oral copd atherosclerosis depression rheumatoid arthritis novel glucocorticoid agonist asthma muscarinic antagonist beta agonist copd darotropium muscarinic acetylcholine antagonist copd mepolizumab antiil monoclonal antibody severe asthma nasal polyposis hypereosinophilic syndrome avamysveramyst glucocorticoid agonist allergic rhinitis approve ajan aapr gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review deliver product pipeline patient continue estimate submission date vaccine type indication phase maa bla paediatric vaccine hibmencytt conjugate neisseria meningitis group disease iii haemophilus influenzae type disease prophylaxis menacwytt conjugate neisseria meningitis groups disease iii prophylaxis infanrixipvkinrix subunit inactivate diptheria tetanus pertussis poliomyelitis prophylaxis submit sapr boosterth dose synflorix conjugate streptococcus pneumoniae disease nontypeable submit sdec haemophilus influenzae prophylaxis child rotarix live attenuate oral rotavirusinduce gastroenteritis prophylaxis approve afeb sjun vaccines cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv infection prophylaxis pneumoniae adult recombinant conjugate streptococcus pneumoniae disease prophylaxis dengue fever attenuate tetravalent vaccine dengue fever prophylaxis epsteinbarr virus recombinant ebv infection prophylaxis hepatitis virus recombinant hepatitis prophylaxis mosquirix recombinant malaria prophylaxis tuberculosis recombinant tuberculosis prophylaxis varicella zoster virus recombinant varicella zoster prevention flu pandemic inactivated split monovalent pandemic influenza prophylaxis iii quebec flu prepandemic inactivate split monovalent pandemic influenza prophylaxis iii quebec new generation flu inactivate split trivalent seasonal influenza prophylaxis elderly iii vaccine simplirix recombinant genital herpe prophylaxis lll boostrix subunit adult booster diphtheria tetanus pertussis submit sfeb flu pandemic inactivated split monovalent pandemic influenza prophylaxis submit sfeb dresden flu prepandemic inactivate split monovalent pandemic influenza prophylaxis submit sjan dresden cervarix recombinant human papilloma virus infection prophylaxis approve asep aldec antigen specific cancer immunotherapeutic asci magea asci recombinant treatment melanoma magea asci recombinant treatment nonsmall cell lung cancer iii gsk annual report srotcerid eht troper stneitap rof enilepip tcudorp eht gnireviledbusiness review good place good people well work gsk annual report srotcerid eht troper krow tseb rieht elpoep tseb eht rof ecalp tseb eht gnieb business ethic reputation gsk employ people gsk expect employee meet high ethical standard aspect country business conduct activity honesty integrity commit create good place adhere corporate responsibility principle comply applicable law regulation gls show good people good work believe people department show commitment performance integrity agree report recruitment talent management leadership development unethical practice fear reprisal halfday workshop attract recruit good people critical enhance ethical decisionmaking extend sustain gsk performance recruiter gsk focus elearning module implement gsk actively target good talent assess fit commitment gsk code conduct reinforce senior organisation key role gsk seek recruit people management certification programme year high level integrity interview question specific ethical manager certify complied performance integrity component develop inclusion integrity principle gsk audits operation regularly ensure standard interview questionnaire relevant standard marketing practice reach annual performance development planning pdp exceed process ensure employee set businessaligned objective diversity behavioural goal pdps review year diversity inclusion initiative focus improve performance culminate end year review factor fifth year annual multicultural marketing diversity compensation decision annual talent management cycle awards award win project repeatedly demonstrate identifie high perform people business key business value understand diverse perspective leverage talent develop tailor management leadership difference positive difference workplace programme exposure management programme customer community serve chief executive forum stretch assignment pool global management population male female potential successor identify vicepresident position detail diversity measure group corporate critical role group responsibility report performance reward group commit employment policy free reward system design support culture high performance discrimination exist potential staff ground attract retain good people performance base pay age race ethnic national origin gender sexual orientation faith bonus share award share option align employee interest disability gsk commit offer people disability meet business target access range recruitment career opportunitie communication employee involvement effort retain support employee group conduct global leadership survey gls disabled working group year recent survey conduct healthy high performance manager gauge opinion critical issue healthy energise engage employee healthy culture confidence group future score morale sustainable way work contribute performance engagement steadily increase compare group global policy employee health support favourably global benchmark topranke company mandatory standard integrate employee health survey manager proud gsk safety environmental requirement commitment flexible gladly refer friend family member work working flexitime teleconferencing remote work gsk business develop action plan address area flexible work schedule recognise employee work improvement base result gls survey good environment help integrate work group consult employee change affect personal life discuss development business european employee group employee health management function actively consultation forum similar body country deliver implement team personal resilience national practice programme available language employee number region partnership group leadership development function energy performance training introduce order improve potential employee usa europe asia pacific japan middle east africa latin america canada business review improve access medicine gsk annual report srotcerid eht troper senicidem ssecca gnivorpmi look ahead gsk commit contribute gsk continue build product pricing partnership health improvement sustainable commitment help improve healthcare develop world manner develop world significant increase fund global community need important maintain incentive include notforprofit pricing protection intellectual property community investment programme achieve sustainable progress occur innovative solution significant barrier stand way well access develop world focus patient healthcare tackle share responsibility sector global assistance programme society government international agency charity academic institution pharmaceutical industry access healthcare develop world access medicine develop world access healthcare develop country remain major programme usa challenge global community problem root gsk work provide access medicine people limited poverty demand significant mobilisation political additional financial resource prescription drug insurance resource true spirit partnership gsk continue play marked launch gsk new patient assistance vital role commitment disease particularly programme gsk access eligible patient enrol medicare prevalent develop world programme notfor prescription drug plan enrolment new programme profit price antiretroviral arvs antimalarial vaccine encourage multimillion dollar national advertising community investment programme campaign major magazine newspaper willingness seek innovative solution voluntary licensing arrangement uninsure americans qualify medicare medicaid gsk pharmaceutical company create preferential pricing programme access programme qualified individual offer reduction gsk offer vaccine key organisation vaccination pharmacy cost medicine programme develop country preferential price access cardholder save million year group set single notforprofit price arvs antimalarial wide range customer gsk participate partnership prescription assistance ppa develop country definition subsaharan africa national service help match people need prescription country coordinate mechanismproject fully fund medicine access programme date ppa provide patient global fund fight aid malaria presidents usa information assistance obtain necessary medicine emergency plan aid relief pepfar launch tykerb help access medicine tykerb gsk commit contribute health improvement care single point contact physician patient tykerb sustainable manner price arvs antimalarial care provide reimbursement support adherence support set level profit direct cost service like pretherapy counselling train oncology nurse cover allow supply sustain long require patient advocacy gsk ship develop country million tablet patient advocacy initiative demonstrate significant progress notforprofitprice combivir million tablet notfor inception initially launch programme profitprice epivir gsk licensee supply key critical initiative gsk patient advocacy team market significant way usa europe share good practice establish process offer notforprofit price require sustainable framework optimise interaction patient group typically relationship combine gsk commitment preferential pricing commitment provide mutual opportunity learn patient need government develop world avoid price referencing priority patient group develop understand drug preferentially price medicine government help development challenge prevent product diversion gsk take step minimise threat gsk continue work patient group educate diversion registration specific access pack access tablet issue mutual concern advocate access medicine differentiate red tablet oppose traditional white key treatment improve reputation government arvs gsk remain group register arvs medium effort promote transparency gsk consider european union antidiversion regulation trustworthy partner patient group develop innovative solution guideline procedure work patient group gsk show industry leadership grant voluntary licence imitate industry generic company manufacture supply arvs programme country public private sector subsaharan africa gsk group introduce orange card provide discount leader collaborate publicprivate partnership enable new certain gsk prescription medicine eligible patient number drug discovery development place effectively country nature discount vary country way healthcare system operatesbusiness review corporate responsibility community investment gsk annual report srotcerid eht troper tnemtsevni ytinummoc dna ytilibisnopser etaroproc gsk cash giving target primarily health education gsk product cash initiative follow donation value million support community programme world health education art culture commitment corporate responsibility environment gsk commit connect business decision ethical social environmental concern corporate responsibility integral embed way gsk business gsk contribute million continue gsk publish set corporate responsibility principle programme charitable activity support organisation provide guidance standard group commit health medical research science education art set approach area standard ethical environment conduct research innovation product customer access programme north america focus improve public medicine employment practice human right community education access well healthcare child senior investment caring environment leadership advocacy nationally locally fund million national engagement stakeholder group report annually philanthropy day usa gsk receive excellence progress uphold principle corporate responsibility corporate philanthropy award committee encouraging report available gsk website corporate philanthropy cecp partnership success gsk operate single charitable foundation gsk work partner underserve community develop community investment programme number country develop world support programme innovative base foundation grant foundation sustainable bring real benefit community include investment total group engage numerous external stakeholder fund community lead initiative world donate medicine global health programme support humanitarian effort community base healthcare eliminate lymphatic filariasis group effort eliminate disable disease lymphatic community investment filariasis world continue close partnership government country disease endemic gsk global community investment activity value partner organisation gsk commit donate million equivalent group total profit tax antiparasitic drug albendazole require treat comprise product donation million cash give billion people risk country million million inkind donation million plus cost million albendazole treatment worth million wholesale acquisition manage deliver community programme country cost donate country global elimination product donation follow programme start cumulative total million albendazole treatment donate positive action hivaid patient assistance program positive action gsk pioneer global programme work million community affect aid start support albendazole communitybase organisation deliver effective hiv aid million education prevention healthcare service humanitarian product donation positive action work partner support programme million country positive action large programme operate mexico kenya india china cambodia vietnam product donation value wholesale acquisition cost wac glaxosmithkline african malaria partnership gsk malaria advocacy programme mobilising malaria launch country coalition malaria belgium france ethiopia cameroon increase awareness malaria mobilise resource innovation grant malaria advocacy award organisation africa working nigeria congo senegal uganda benefit gsk previous behavioural development programme target malaria african country continue seenbusiness review corporate responsibility community investment continue gsk annual report srotcerid eht troper tnemtsevni ytinummoc dna ytilibisnopser etaroproc phase education initiative phase programme personal hygiene sanitation education gsk continue support institute initiate gsk provide education thousand competitive workforce business coalition staff business school child kenya uganda zambia nicaragua peru mexico civic leadership center chamber commerce tajikistan bangladesh improve health hygiene aim improve education create skilled workforce fight infectious disease group commit year future funding million extend programme indonesia gsk support range local initiative usa example bolivia partnership save children usa science summer free librarybase science education include fund introduce phase millennium village programme philadelphia area teach basic scientific concept project employ sciencebased intervention meet continue receive support grant nearly gsk millennium development goal major sponsor university north carolinas humanitarian product donation travel science laboratory destiny inception gsk donate essential product antibiotic destiny serve approximately underserve secondary school nonprofit partner include americare direct relief reach student year international map international project hope support gsk help launch crest star investigator education humanitarian relief effort community healthcare total initiative programme develop partnership value group international humanitarian product donation british association advancement science provide million exclude albendazole donate science activity award school club primary group commitment lymphatic filariasis elimination school school child expect take programme product donation value wholesale acquisition cost wholesale list price include discount standard industry method valuation secondary school science teacher england chemistry specialist chemistry nonspecialist community initiative develop royal society chemistry train teacher teach gsk dedicated strengthen fabric community chemistry confidence flair enthusiasm gsk support provide health education initiative support local civic programme donation year cultural institution improve quality life employee involvement gsk contribution improve healthcare include grant gsk employee encourage contribute local community million year children health fund expand employee volunteer scheme support include employee referral management initiative rmi site philadelphia time cash donation charity employee volunteer include delaware valley community health center rmi matching gift programme ensure continuity specialist medical care highrisk child homeless usa group match employee retiree gift value million group match mark tenth anniversary annual glaxosmithkline million employee donation gsk annual united impact award recognise excellence work nonprofit way campaign gsk program provide grant community health organisation great organisation employees philadelphia area usa year charity receive volunteer unrestricted award work deal diverse difficult social issue domestic violence sexual health service gsk make difference programme provide grant young people community health support counselling service nearly nonprofit organisation register charity base employee involvement medical research provide medical charity primary immunodeficiency association research age wellchildbusiness review global manufacturing supply gsk annual report srotcerid eht troper ylppus dna gnirutcafunam labolg operational excellence gsk manufacturing operation comprise gms operational excellence provide capability drive network site country improvement process robustness quality performance customer service operational excellence underpin extensive employ people education culture continuous improvement vision factory gsk manufacture large portfolio product range tablet gsk introduce vision factory initiative work toothpaste inhaler complex capsule simple efficient operating model gms vision factory different pack size presentation enable manufacturing operation accelerate improvement manufacture medicine start development performance cost control therapeutic active ingredient bulk active select formulation quality global manufacturing supply gms develop manufacture quality organisation oversee product quality supply process scale volume production active compound chain supplier party manufacturer primary manufacturing site secondary site convert manufacture supply operation deliver product active compound finish medicine market quality organisation focus improve quality year gms produce tonne bulk active compliance increase product quality understand billion pack sell country harmonise quality approach site support new product line extension launch external supplier year gms spend billion annually external supplier adopt leading edge practice develop people purchase active ingredient chemical intermediate packaging gms provide component partfinishe finished product take appropriate step protect supply chain disruption secure source supply high quality product ompliance regulatory requirement procurement customer expectation widely recognise industry analyst good practice leader good class cost procurement work collaboratively develop implement source strategy ensure gsk receive good value organisation buy good service gsk leverage procurement activity group gms operate single global network site country site group supply division base common vaccine supply chain business driver area expertise commercial activity gsk global vaccine manufacture network manage support vaccine division headquarters belgium present major region gsk aim ensure effective supply vaccine primary supply globe primary supply site country supply high quality competitively price bulk active division focus europe vaccine manufacturing locate primarily rixensart improvement primary technology process wavre belgium site france germany hungary site extend new product global supply new product global supply site seven country north america gsk establish vaccine production network site work closely rd development team ensure major acquisition production site right technical competency place support rapid hamilton montana manufacturing mpl key component gsk successful new product introduction site ensure secure novel proprietary adjuvant system vaccine production site supply key brand sell market division marietta pennsylvania flu vaccine manufacture facility focal point develop introduce new secondary laval ste foy quebec canada manufacturing technology gm international region new vaccine production facility regional pharma supply build india singapore china packaging regional pharma supply operate supply key product particular activity perform shanghai region market tailor packaging meet specific local manage vaccine supply chain involve anticipate market requirement division focus reduce cost allow gsk need flexible approach able meet fluctuation compete effectively market regional demand base forecast different market pharma supply site country firm order health authority mass vaccination campaign consumer healthcare supply production bulk vaccine fill packaging activity consumer healthcare supply deliver highquality competitively carefully balanced plan store vaccine help manage price product support rapid new product introduction shortterm increase demand increase result disease highly innovative competitive business far short time outbreak increase demand public prompt disease frame pharmaceutical new technology awareness campaign fundamental platform drive innovation lower cost provide flexibility operation site countriesbusiness review regulatory environment regulatory environment international region continue gsk operate highly regulate evolve gsk participate number regional regulatory environment encompass product initiative example china propose change regulatory framework provide gsk opportunity approval pricing restriction work directly state food drug administration sfda gsk maintenance intellectual property continue include broad set patient population environmental health safety international region global development programme order responsibility increase global patient access new innovative medicine optimise regulatory approval price control regulation pharmaceutical country price pharmaceutical product gsk operate highly regulate environment regional control law government influence price countryspecific law regulation define datum require control national healthcare organisation bear safety efficacy pharmaceutical product govern large cost supply medicine consumer test approval manufacturing labelling market drug recent government healthcare reform country france regulatory requirement major factor determine spain germany restrict pricing reimbursement marketable product successfully develop time expense associated development usa recent legislative proposal healthcare reform cross border trade acceleration generic market comparative usa fda continue seek encourage innovation effectiveness increase focus pricing currently drug development critical path initiative new tool government price control private sector purchase process pursue enhance development safe federal law require pharmaceutical manufacturer pay effective drug gsk pharmaceutical industry prescribe rebate certain drug eligible reimbursement collaborate fda national institutes health medicaid state federal healthcare programme number area include evaluation new biomarker presidential election healthcare lead benefitrisk assessment domestic issue price discussion increasingly drug safety remain primary focus fda congressional lead candidate propose health reform address oversight committee europe evaluation benefit chronic disease primary healthcare cost driver risk continue paramount consideration approval medicare new drug new legislation pass fda amendment medicare program federally fund healthcare act renew user fee system drug review mandate insurance programme benefit senior citizen certain disabled rigorous fda review safety approval post americans include coverage prescription medicine marketing phase product legislation provide coverage voluntary include brandname generic drug fda new tool require sponsor complete postmarkete open million americans medicare coverage study labelling change number compete private organisation provide benefit regulation require development prescription drug premium subsidise government benefit satisfy biologic paediatric population reauthorise minimum standard outline federal law law provide congress similarly europe new paediatric regulation incentive manufacturer negotiate price private health implement gsk fully support objective ensure insurance plan provide government price control development well medicine child government provide additional help million europe pharmaceutical company government regulator people medicare limited income resource continue implement new medicine legislation introduce qualify beneficiary pay reduced premium deductible end involve significant change low copayment prescription regulatory system include change product approval benefit prove marked success competition procedure postmarkete requirement manufacture control reduce estimate total cost congressional labelling requirement pharmacovigilance process increase budget office billion year period recent poll transparency regulatory process medicare beneficiary enrol new benefit satisfaction regulator engage well regulation initiative rate cut red tape overregulation pharmaceutical industry value money gsk welcome recognition unnecessarily burdensome payer world concern cost healthcare regulatory requirement damage competitiveness price medicine requirement satisfy healthcare negatively impact public health active support purchaser value money additional hurdle initiative product acceptance regulatory test safety efficacy quality gsk annual report srotcerid eht troper tnemnorivne yrotalugerbusiness review regulatory environment continue appropriate payer seek value money term patent country set period purchase medicine translate costcontainment filing date typically year effective term depend measure delay patient access new medicine long product development launch lead difficult significantly improve therapy achieve price variation patent term product product basis reflect add value healthcare budget manage number market include usa europe possible strategic longterm manner focus shift value certain circumstance obtain partial restoration patent term cost pricing reflect value value define broadly compensate length development process matter medicine work respond medical patent position respect active ingredient significant patient need reward appropriately product follow payer allocate resource efficiently provide advairseretide patent specific combination salmeterol good health outcome attention focus area xinafoate fluticasone propionate expire prevention innovation well management chronic disease usa europe patent reissue triple solution innovative medicine vaccine patent trademark office usptoe litigation patent play key role prevent provide well treatment protect product ongoe certain european marketse expensive disease cervical cancer breast cancer asthma patent revoke court patent alzheimer diabetes individual ingredient expire patent salmeterol possible predict extent group xinafoate usa august france december business affect future legislative regulatory development italy relate specific pharmaceutical product price avandia avandamet avandaryl patent rosiglitazone expire usa europe patent regulation consumer healthcare commercial form active ingredient rosiglitazone maleate consumer healthcare industry subject national regulation expire usa europe litigation testing approval manufacturing labelling market challenge validity patent protect product product country high standard technical appraisal usae settle term allow generic entry late involve lengthy approval process new product launch quarter national regulatory authorisation require approve switch avodart patent dutasteride expire product prescription otc requirement include long usa europe litigation challenge validity term experience quality safety efficacy product patent protect product usa ongoinge wide patient population datum confirm relevant avamysveramyst patent fluticasone furoate condition selflimite easily diagnose consumer expire usa europe boniva gsk copromotion right patent intellectual property ibandronate expire usa intellectual property key business asset gsk effective legal europe litigation challenge validity patent protect protection intellectual property critical ensure reasonable product ongoing usae return investment intellectual property protect combivir patent specific combination lamivudine patent trademark register design copyright domain zidovudine expire usa registration europe litigation challenge validity patent protect certain market include usa canada combination ongoing usae provide period regulatory data exclusivity qualify drug coreg gsk exclusive licensee patent carvedilol new chemical entity new formulation expire coreg protect formulation use market drug manufacturer generic drug patent expire usa patent follow period datum exclusivity launch attempt launch active form carvedilol phosphate expire generic version patent drug prior normal patent expiry litigation challenge validity patent active argue relevant patent invalid andor form ongoing usae infringe product significant litigation concern challenge summarise note financial statement epivir patent lamivudine expire legal proceeding usa europe patents imigranimitrex patent sumatriptan expire gsk policy seek obtain patent protection protectable usa expired europe italy december invention discover develop activity patent litigation challenge validity patent protect protection new active ingredient available significant product usa settle allow generic entry market protection obtain example new fourth quarter pharmaceutical formulation manufacturing process medical use lamictal patent lamotrigine expire special device administer product patent protect usa litigation challenge validity patent usa new active ingredient generally apply early settle term allow generic entry tablet form development process mid europe correspond patent expire generic competition exist gsk annual report srotcerid eht troper tnemnorivne yrotalugerbusiness review regulatory environment continue levitrad gsk copromotion right patent vardenafil expire lexivatelzir gsk exclusive licensee patent fosamprenavir expire usa europe lovaza formulation omega acid ethyl ester protect patent expire usa paxilseroxat patent commercial form paroxetine expire generic competition exist paxil instant release forms usa europe market litigation relate patent protect product ongoing usae paxil protect patent issue june relate delay control release formulation paroxetine hydrochloride litigation relate patent settle term allow generic entry strength paxil later fourth quarter requip patent ropinirole expire usa expire november europe patent relate use ropinirole parkinson disease expire usa europe litigation challenge validity parkinson use patent usa dismiss court generic entry expect expiry patent serevent patent salmeterol xinafoate expire august usa europe patent expire france december italy trizivir patent method treatment combination lamivudine zidovudine abacavir expire usa europe tykerbtyverb patent lapatinib expire usa europe valtrex patent valaciclovir expire usa europe greece spain august litigation challenge validity patent usa settle term allow generic entry late wellbutrin wellbutrin zyban patent active ingredient expire generic competition sustain release instant release dosage form wellbutrin usa litigation usa relate formulation patent cover wellbutrin settle term allow generic entry form europe regulatory data exclusivity provide protection market ziagen patent abacavir expire usa europe zofran patent ondansetron expire usa europe italy november patent use treat emesis expire generic competition exist usa europe market include grant pende patent term restoration hatchwaxman act include grant pende extension term national european supplementary protection certificate include grant pende extension term paediatric exclusivity register trademark bayer note financial statement legal proceeding gsk annual report srotcerid eht troper tnemnorivne yrotaluger trademark gsk pharmaceutical product protect register trademark major market local variation example usa trademark paxil instead seroxat advair instead seretide trademark protection generally extend long trademark renew necessary gsk trademark pharmaceutical product important maintain brand identity product expiration patent consumer healthcare trademark particularly important business brand orient product patent protection responsibility environment health safety environment health safety eh key element corporate responsibility group high priority responsibility ehs high level corporate department report general counsel overall responsibility provide governance leadership ehs issue head department make regular report corporate executive team cet audit corporate responsibility committee board business executive manager responsible ehs support sitebase ehs occupational medical staff eh strategy plan gsk year strategic plan ehs extend annual action plan plan align gsk business driver include management objective performance measure target gsk progress evaluate target set focus ehs stewardship building sustainable business involve care present thinking future make decision support aspiration plan embed ehs business environmental sustainability open transparent stakeholder relation accomplishment limate change comprehensive strategy climate change energy efficiency approve available gsk website climate change energy reduction team form manage special fund support climate change project team identify project reduce energy consumption increase gsk use renewable energy anufacture efficiency ongoing effort improve efficiency manufacturing process significantly decrease purchase raw material production waste gsk select good candidate medicine improvement mass efficiency process development continues improve progress achieve target double mass efficiency halve waste unit product manufacturing process phase iii compound late stage product evaluate efficiency improvement average certain market product know market potential select improvement efficiency manufacturing processesbusiness review regulatory environment continue workplace chemical exposure occupational hygiene measure select similar report measurement complete gsk task company recommend global reporting initiative involve exposure potent material result longterm multistakeholder international undertaking develop exposure adequately control respiratory disseminate globally applicable sustainability report guideline protective equipment wear verify respirator free target set eliminate chlorofluorocarbon cfc mean respiratory protection necessary immediate action use year reduce nonhazardous waste dispose take control exposure instance level reduce water use volatile organic compound voc find higher predict manufacture site release air reduce pollution wastewater measure target respirator free end chemical oxygen demand reduce energy usage process safety gsk process safety management system relate greenhouse gas emission year enhance new engineering standard training programme target set reduce energy usage greenhouse gas emission development standard design new target normalise process plant upgrade exist plant need sale base constant exchange rate training programme increase process safety awareness gsk remain track eliminate use cfc competency engineer chemist manager meet target energy use relate external stakeholder addition ongoing stakeholder greenhouse gas emission progress energy group meeting march panel stakeholder meet october relate greenhouse gas emission target expect accelerate provide input ehs issue perspective benchmark annual target meet reduction assessment environmental programme carry water use wastewater pollution gsk meet target charity business environment gsk rank nonhazardous waste disposal voc release air case company gsk include ftse good index nonhazardous waste disposal dow jones sustainability index increase solid waste disposal vaccine business expansion programme development launch ehs audits new vaccine case voc release governance responsibility gsk conduct ehs audits product mix change solvent recovery equipment site operate entity key supplier assess management manufacturing site inadequate completely capture key risk impact performance gsk global ehs recycle certain solvent manufacturing process standard include provide audit site quantitative performance information highlight area risk reduction final ehs performance data explanation improvement operating entity audit trend publish corporate responsibility report achieve audit score well reflect long gsk website term goal site score site score sustainability seven critical finding raise work sustainability gsk address economic correct ensure continuous improvement progress monitor environmental social issue research manufacture sale corrective preventive action plan arise audits distribution medicine consumer healthcare nutritional commitment corporate responsibility product sustainability start healthcare solution find proactive management gsk manufacture supply base continue innovation improve efficiency current potential supplier assess process manufacturing process new product reduce resource evaluate management key ehs risk impact include use turn lower waste cost low cost fire explosion risk aspect process safety loss prevention product available wide population world control exposure hazardous substance environmental future ehs plan excellence propose investigate protection core human right issue base group use renewable resource manufacturing requirement supplier recommendation group seek dialogue external stakeholder consider improvement need potential supplier view develop approach sustainable development fail achieve gsk recommendation gsk plan partner information ehs programme performance successful candidate improve overall environment find gsk website health safety loss prevention performance eh target ehs plan target set year baseline year target gsk select measure performance improvement base potential adverse impact people environment business continuity business reputation gsk annual report srotcerid eht troper tnemnorivne yrotalugerbusiness review world market world economy world market pharmaceutical global economy continue broadly positive global pharmaceutical sale billion compare buoy growth develop market china billion mortgagerelate issue usa adverse effect country world gross domestic product gdp growth ease world market value growth geographic region total international monetary fund forecast global gdp growth usa europe equity market struggle backdrop record france break oil price continue concern situation germany iraq afghanistan oil price average barrel year rise later year inflation italy oecd country expect increase japan asia pacific economy weaken significantly lead slump new latin america housing start exacerbate subprime lending crisis gdp middle east africa growth slow canada analyst expect fall mark dow total jones industrial index gain period interest rate drop significant cut january market decrease represent take dollar continue global prescription pharmaceutical market compare decline euro sterling fall decade ago year dollar worth november low point september gsk hold second position world pharmaceutical market market share pfizer chinese economy continue sound progress grow market share gsk world growth forecast dip slightly pharmaceutical product avandia lamictal seretideadvair particularly problem usa impact demand valtrex chinese export japan gdp nikkei fall year mark annual decline world market value growth year indian brazilian economy achieve doubledigit therapeutic class total growth central nervous system eurozone gdp growth slow cardiovascular expect fall france expand alimentary tract metabolic germany spain antineoplasticimmunomodulatory european central bank interest rate close year antiinfective bacterial end rate start year rise viral fungal exclude step fall yearend vaccine ftse index gain weak annual performance respiratory note datum base month september exchange currency influence group result dollar euro japanese yen dollar fall sterling yearend yearend rate euro strengthen japanese yen sterling gsk annual report srotcerid eht troper tekram dlrowbusiness review product competition requip specific dopamine receptor agonist indicate prescription pharmaceutical treatment parkinson disease restless leg syndrome rls consumer healthcare industry antiviral highly competitive despite combivir combination retrovir epivir consolidate second large pharmaceutical company position reverse transcriptase inhibitor world gsk share cornerstone multiple antihiv product regimen physician acceptance clearly demonstrate value place minimise world market pill burden face patient ziagen reverse transcriptase inhibitor product potency pharmaceutical product ease use resistance profile allow play significant role glaxosmithkline principal pharmaceutical product currently direct variety highly active tolerate simplified hiv main therapeutic area analysis sale therapeutic area treatment regimen description principal product set trizivir combination combivir ziagen combine antihiv therapie tablet twicedaily administration turnover therapeutic area epzicomkivexa approve use usa europe respiratory combination epivir ziagen take tablet central nervous system oncedaily dose hivaid combination antiviral antihiv drug metabolic vaccine lexivatelzir protease inhibitor treatment hiv cardiovascular urogenital tolerate convenient agenerase supersede antibacterialsantimalarial lexiva taken twicedaily oncedaily boost oncology emesis ritonavir zeffix approve marketing usa europe china markets treatment chronic hepatitis product formulation approve valtrex treatment episodic genital herpe long indication market available term suppression reduction transmission genital herpe zoster shingle cold sore chicken pox valtrex supersede respiratory zovirax treat herpe infection seretideadvair combination serevent flixotide offer longacte bronchodilator antiinflammatory single metabolic inhaler approve treatment asthma copd avandia potent insulin sensitise agent act underlie pathophysiology type diabetes flixotideflovent becotidebeclovent inhale steroid treatment inflammation associated asthma copd avandamet combination avandia metformin hci target insulin resistance decrease glucose production serevent longacte bronchodilator treat asthma convenient pill copd ventolin selective shortacting bronchodilator treat bronchospasm avandarylavaglim combination avandia amaryl sanofi aventis product avandarylavaglym target insulin resistance veramystavamys flixonaseflonase beconase steroid intra stimulate pancreatic insulin production nasal preparation treatment perennial seasonal rhinitis bonvivaboniva longacte bisphosphonate available central nervous system cns monthly oral quarterly injection form treatment seroxatpaxil selective serotonin reuptake inhibitor ssri osteoporosis copromote roche treatment major depressive disorder panic obsessive compulsive disorder post traumatic stress disorder social anxiety disorder vaccine generalise anxiety disorder control release formulation paxil gsk market vaccine worldwide half available usa combination vaccine protect child adolescent andor adult disease time wellbutrin antidepressant available usa european international market normal sustainedrelease infanrix gsk range paediatric vaccine combination infanrix oncedaily formulation provide protection diphtheria tetanus pertussis whoop cough infanrix penta europepediarix usa canada provide additional imigranimitrex receptor agonist treatment protection hepatitis polio infanrix hexa add protection severe frequent migraine cluster headache haemophilus influenzae type cause meningitis reference product sector naramigamerge boostrix available add protection pertussis whopping cough receptor agonist indicate treatment migraine routine tetanusdiptheria booster administer teenager lamictal establish treatment epilepsy indicate gsk hepatitis vaccine range havrix protect hepatitis bipolar disorder engerixb hepatitis gsk annual report srotcerid eht troper noititepmoc dna stcudorpbusiness review product competition continue twinrix available combine hepatitis vaccine fraxiparine lowmolecular weight heparin indicate prophylaxis protect disease vaccine available thromboembolic disorder particularly deep vein thrombosis adult paediatric strength europe fendrix vaccine pulmonary embolism general surgery orthopedic surgery prevent hepatitis patient renal insufficiency include high treatment deep vein thrombosis prevention clot risk group prehaemodialysis haemodialysis patient haemodialysis available year age onwards integrilin iibiiia inhibitor approve prevention gsk add fluviral portfolio product acquire early myocardial infarction patient unstable angina canadian vaccine manufacturer biomedical corporation nonqwave december fluviral market canada follow fda antibacterial antimalarial approval usa approve active immunisation augmentin broadspectrum antibiotic suitable treatment adult year old influenza disease wide range common bacterial infection particularly brand flulaval fluviral flulaval add fluarix gsk seasonal flu effective respiratory tract infection augmentin vaccine distribute country include usa extra strength suspension specifically design treat child gsk market priorix measle mump rubella vaccine recurrent persistent middle ear infections augmentin typherix vaccine protection typhoid fever varilrix extend release formulation treatment patient vaccine varicella chicken pox priorixtetra gsk new community acquire pneumonia acute bacterial sinusitis combination vaccine prevent measle mump rubella altabaxaltargo approve topical treatment varicella mmrv launch germany august certain bacterial skin infection represent new class addition group market range vaccine prevent topical antibiotic approve fda nearly decade meningitis umbrella mencevax gsk new hib menc vaccine menitorix available gsk meningitis ceftinzinnat oral antibiotic primarily community vaccine portfolio complement new meningitis conjugate acquire infection lower respiratory tract vaccine near future malarone oral antimalarial treatment paediatric franchise gsk continue roll prophylaxis malaria cause plasmodium falciparum launch vaccine rotavirus induce gastroenteritis oncology emesis rotarix launch country worldwide rotavirus tykerb oral treatment patient advance metastatic vaccination include national vaccination calendar breast cancer tumour overexpress latin american country rotarix available receive prior therapy include anthracycline taxane free public health clinic governmental paediatric trastuzumab tykerb approve usa immunisation programme submit european approval cardiovascular urogenital hycamtin second line treatment ovarian cervical small coreg alphabeta blocker prove effective cell lung cancer treat patient mild moderate severe heart failure heart attack hypertension gsk sole marketing right bexxar treatment patient follicular non usa canada control release formulation coreg hodgkin lymphoma transformation available usa generic version coreg available disease refractory rituximab relapse usa canada follow chemotherapy levitra pde inhibitor indicate male erectile dysfunction arranon nelarabine treatment patient tcell acute gsk copromotion right usa lymphoblastic leukaemia tcell lymphoblastic lymphoma markets zofran prevent nausea vomiting associate avodart ari inhibitor currently indicate benign prostatic chemotherapy radiotherapy cancer available hyperplasia large clinical study underway examine efficacy oral injectable form approve use prevention reduce risk prostate cancer treatment postoperative nausea vomit vesicare antimuscarinic indicate overactive bladder gsk copromotion right astellas usa major competitor category include betnovate high potency dermovate detrol ditropan xlgeneric oxybutynin enablex new cutivate topical antiinflammatory steroid product treat skin disease eczema psoriasis arixtra selective factor inhibitor indicate treatment relafen nonsteroidal antiinflammatory drug treatment deep vein thrombosis dvt pulmonary embolism arthritis zantac treatment peptic ulcer disease prevention dvt patient undergo major orthopaedic range gastric acid relate disorder surgery abdominal surgery acutely ill medical patient arixtra indicate treatment patient acute coronary unstable angina nstemi stemi gsk annual report srotcerid eht troper noititepmoc dna stcudorpbusiness review product competition continue pharmaceutical competition antiviral gsk pioneer hiv market launch azt retrovir pharmaceutical industry highly competitive gsk principal epivir today available combivir single competitor range small large pharmaceutical company tablet cornerstone hiv combination therapy launch substantial resource company ziagen agenerase trizivir lexiva epzicom broaden major product mention group portfolio hiv product major competitor hiv pharmaceutical subject competition product market include gilead bristol myers squibb abbott roche period patent protection patent boehringer ingelheim generic version manufacturer generic product typically valtrex strengthened group position antiherpe bear significant research development education area gsk valtrex zovirax compete novartis famvir marketing development cost consequently able offer valtrex market leader whilst zovirax face competition product considerably low price brand competitor generic acyclovir hepatitis market gsk zeffix research development base pharmaceutical company antiviral market gilead hepsera second group normally seek achieve sufficiently high profit margin sale secure marketing right hepsera key market volume period patent protection repay original investment generally substantial fund research metabolic future competition generic product generally occur major competitor avandia takeda chemical acto patent major market expire increasingly patent challenge copromotion eli lilly usa end takeda prior patent expiry claim innovator patent market actoplusmetcompetact combination metformin valid andor infringe generic product follow hci actos usa markets duetact loss patent protection generic product rapidly capture large combination glimepiride actos usa share market particularly usa monthly bonivabonviva competes mercks weekly fosamax gsk believe remain competitive dependent proctor gamblesanofiaventis twicemonthly actonel discovery development new product effective novartis reclastaclasta dose annual infusion marketing exist product pharmaceutical industry generic fosamax alendronate available market introduction new product process competitor include usa germany canada affect pricing level result change pattern product vaccine use assurance product vaccine market dominate key player gsk major outmoded notwithstanding patent trademark protection competitor sanofi pasteur merck novartis wyeth addition increase government pressure physician paediatric vaccine field infanrixs main competitor sps patient use generic pharmaceutical brand range dtpabase combination vaccine infanrix hexa medicine increase competition product combination available hexavalent paediatric combination long protect patent europe merck joint venture merck europe respiratory market new vaccine rotavirus induce infection hpv gsk respiratory franchise drive growth seretideadvair respectively compete rotarix cervarix major respiratory competitor singulair merck especially cardiovascular urogenital usa symbicort astrazeneca spiriva pfizer gsk markets coreg usa major competitor toprol boehringer ingelheim generic betablocker avodart compete directly merck proscar cns disorder bph enlarge prostate market group copromotion major competitor usa paxil generic form right usa levitra face competition pfizer viagra generic fluoxetine generic form eli lillys prozac generic lillys cialis major competitor arixtra low molecular sertraline generic form pfizer zoloft cymbalta eli lilly weight heparin enoxaparin product market sanofiaventis forest laboratory celexa lexapro effexor wyeth antibacterial antimalarial principal competitor usa wellbutrin generic form generic version augmentin ceftinzinnat available bupropion generic form ssris lexapro effexor usa augmentin face generic competition cymbalta generic competition seroxatpaxil occur european country augmentin augmentin compete number market broad range brand generic antibiotic major competitor lamictal epilepsy jjs dilantin malarone safety profile convenient dose regiman generic phenytoin novartis egretoltegretol generic help product strong position versus mefloquine carbamazepine ucbs keppra abbot depakotedepakote malaria prophylaxis bipolar major competitor generic lithium altabaxaltargo compete topical antibiotic market antiepileptic include abbotts depakotedepakote number generic competitor include generic mupirocin atypical antipsychotic include astrazenecas seroquel major fusidic acid altabaxaltargo offer frequent short duration competitor imitreximigran astrazenecas zomig mercks therapy lack cross resistance establish class maxalt pfizer relpax antibacterial gsk annual report srotcerid eht troper noititepmoc dna stcudorpbusiness review product competition continue oncology emesis overthecounter medicine major competitor diverse therapeutic market include roche lead product panadol widely available paracetamol genentech novartis sanofiaventis bristol myers squibb acetaminophen analgesic nicorette gum usa nicoderm gsk therapeutic portfolio lead recently approve tykerb niquitin nicabate range smoking control product tum hycamtin currently hold relatively small market position zofran calciumbase antacid citrucel laxative contac treatment provide gsk leadership position antiemetic market cold abtei natural medicine vitamin range zovirax competitor company include roche mgi merck abreva treatment cold sore recent addition generic competitor available late portfolio include breathe right nasal strip gently lift open nasal passage provide well breathe fiberchoice daily fibre consumer healthcare product supplement acquisition cns inc switch orlistat prescriptiononly status united states glaxosmithkline principal consumer healthcare product overthecounter market weight control product alli major area analysis sale area set oral care lead oral care product toothpaste mouthwashe aquafresh odol sensodyne macleans brand name otc medicine range toothbrush sell aquafresh good oral care name addition denture care product available principally nutritional healthcare polident poligrip corega brand name nutritional healthcare lead product category lucozade energy sport major product necessarily sell market drink ribena blackcurrant juicebase drink horlick range category product milkbase malt food chocolate drink overthecounter medicine consumer healthcare competition analgesic panadol dermatological zovirax gsk hold lead global position key consumer product abreva area worldwide large oral care otc external nasal dilator breathe right medicine nutritional healthcare hold leading position gastrointestinal tum india ireland citrucel environment consumer healthcare business respiratory tract contac operate challenging beecham smoke control commit consumer demand well quality well value nicorette improve performance nicoderm etailer consolidate globalise strengthen niquitin negotiation power nicabate manufacturers consolidate lead aggressive natural wellness support abtei competition element marketing mix fiberchoice weight control alli ycle times innovation reduce oral healthcare aquafresh main competitor include major international company good colgatepalmolive johnson johnson procter gamble unilever maclean wyeth addition company odol compete gsk certain market polident major competitor product otc medicines poligrip usa metamucil laxative pepcid indigestion private sensodyne label smoking control product nutritional healthcare lucozade lemsip cold remedy nurofen anadin analgesic ribena nicorette nicotinell smoking control treatment horlick oral care major competitor colgatepalmolive colgate procter gamble crest nutritional healthcare major competitor horlick ovaltine milo malt food chocolate drink competitor ribena primarily local fruit juice product lucozade compete energy drink gsk annual report srotcerid eht troper noititepmoc dna stcudorp gsk annual report srotcerid eht troper weiver laicnanif business review financial review cns gsk turnover grow cns sale decrease billion sale decrease business performance eps grow usa europe reflect generic competition seroxatpaxil dividend raise region international sale grew include growth paxil japan total seroxatpaxil sale decline share repurchase billion million total wellbutrin sale decline million billion expect owe generic competition wellbutrin srir wellbutrin tablet pharmaceutical turnover sale lamictal treatment epilepsy bipolar disorder growth rate include review turnover constant grow billion drive sale usa exchange rate cer state sterling growth rate million benefit new indication lamictal find table pharmaceutical turnover therapeutic area medicine longterm clinical datum demonstrate geographic region total pharmaceutical delay onset depressive episode bipolar disorder turnover million compare million gsk expect respond fdas approvable letter lamictal line turnover cer sterling term total middle pharmaceutical turnover decrease percentage point sale requip parkinson disease restless leg syndrome cer principally strength sterle dollar rls grow million requip new oncedaily formulation parkinson disease approve pharmaceutical turnover therapeutic area european country launch seven market european gsk turnover line highvalue growth approval anticipate usa gsk expect product offset low avandia sale generic response fda application requip competition coreg flonase wellbutrin zofran half highvalue growth product include seretideadvair vaccine antiviral lamictal valtrex requip avodart boniva total sale hiv product billion competition respiratory old product combivir million epivir gsk continue global leader respiratory pharmaceutical million largely offset strong sale growth sale key product seretideadvair flixotideflovent new product epzicomkivexa grow million serevent amount billion total sale lexivaagenerase million seretideadvair asthma copd rise billion sale valtrex herpe rise million sales usa sale grow billion europe sale grow million drive increase use product billion international market sale grow prevention disease transmission sale europe grow million enhanced launch japan june million international grow million sale market share value antiasthma copd therapy class relenza antiviral treatment flu million europe usa million drive primarily oneoff government order stockpile possible flu pandemic market share value seretideadvair metabolic sale avandia product group type diabete decline billion usa sale fall million fourth quarter sale million follow publication article new england journal medicine article suggest cardiovascular risk associate avandia despite gsk effort doctor reluctant start new patient avandia guidance fda follow clarification fda october new approve label avandia outside usa sales europe grow year million europe usa international markets sale decline million september september gsk record turnover million share copromotion gsk continue increase use seretideadvair treatment income bonivabonviva oncemonthly oral bisphosphonate copd ongoing discussion fda expand treatment postmenopausal osteoporosis indication use patient group include assessment datum support claim reduction exacerbation vaccine vaccine sale increase billion good performance region sale rise million european sale grow million sale international million sale hepatitis vaccine grow million drive growth business review financial review continue gsk annual report srotcerid eht troper weiver laicnanif pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare antibacterial augmentin oncology emesis zofran hycamtin tykerb zantac cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give financial record page business review financial review continue infanrixpediarix grow million drive growth sale constant exchange rate growth region sale new twodose vaccine rotarix prevent rotavirus gastroenteritis double million strong growth europe international sale cervarix gsk vaccine prevent cervical cancer million approve country licensing application submit country include japan gsk prepandemic influenza vaccine cer achieve sale million discussion order growth continue number government cer cardiovascular urogenital growth sale coreg heart disease fall million follow cer introduction generic competition coreg september sale decline coreg launch march million avodart benign prostatic hyperplasia enlarge prostate continue perform strongly sale million positive datum combat study assess use avodart alpha blocker tamsulosin combination therapy recently publish usa europe international journal urology gsk file coprescription indication usa europe international market response individual government determine pricing medicine expect fda second quarter country europe result wide price variation antibacterial product parallel trade occur party exploit antibacterial sale decline million reflect generic price differential purchasing product market low price competition region enforce selling government purchaser market high price agree parallel trade oncology emesis permit single market rule european union gsk tykerb achieve sale million year million derive benefit profit resale high price arise usa follow launch march sales zofran decline million reflect generic competition usa europe result management believe european region international sale decline respectively turnover market invoice basis present properly represent consumption product therapeutic area market gsk employee base market instrumental sale zantac fall million decline region promotion group product market regional analysis create product sale final consumption market pharmaceutical turnover geographic region follow table give adjustment order restate invoice basis turnover market europe turnover create basis turnover report table represent sale invoice pharmaceutical turnover europe region gsk local entity customer local market plus turnover create basis promotion income market region growth region invoice adjustment create invoice adjustment create major market total cer major markets usa europe france europe france italy germany italy spain germany europe spain europe adjustment gsk estimate base recent international datum independent external source value sterle relevant asia pacific exchange rate management believe turnover create japan basis report turnover market provide well reflection middle east africa performance business market europe latin america total turnover europe region unaffected canada restatement parallel trade occur occasionally world sufficiently material affect significantly turnover datum represent growth constant exchange rate represent growth actual exchange rate market present invoice basis gsk annual report srotcerid eht troper weiver laicnanif business review financial review continue pharmaceutical turnover geographic region europe turnover create basis discussion individual market performance europe region turnover market europe adjust effect turnover create basis parallel trade turnover basis country sale europe contribute pharmaceutical turnover product finally consume product sell gsk grow billion strong sale seretide region growth vaccine offset impact generic competition number major market total cer product continue price cut result government usa healthcare reforms europe major market record growth exception italy france adversely impact pricing restriction generic competition major growth driver seretide gsk large italy sell product europe growth vaccine germany franchise spain generic competition adversely impact sale seroxat europe lamictal zofran imigran international sale antibacterial decrease combination asia pacific weak flu season generic competition japan sale avandiaavandamet grow middle east africa latin america international canada international region report year year turnover growth fast grow market include japan china middle eastafrica modest cer represent growth constant exchange rate represent growth sale growth canada australia latin actual exchange rate turnover quarter give financial record page america canadian sale performance reflect low sale avandia generic competition zofran whilst australian usa business adversely impact government pricing low sale usa decline billion reflect generic government order relenza competition wellbutrin zofran flonase coreg good performance japan drive launch year decline respectively decline adoair strong demand relenza partially offset sale avandia product partly offset growth sale decline old product zantac zovirax advair antiviral vaccine lamictal requip remain market international key product sale avandia product group decline follow drive growth seretide grow record sale publication article new england journal medicine million valtrex grow million vaccine suggest cardiovascular risk associate franchise record growth achieve sale avandia follow clarification fda october million hiv product grow million new approve label avandia avandia range product decline million advair sale grow million owe increase use decline canada korea partly offset growth australia treatment copd sale antiviral therapeutic area grow million consumer healthcare sale herpe product hiv product hiv analysis consumer healthcare sale set competition old product combivir epivir follow table partly offset growth new product epzicomkivexa growth lexiva valtrex herpe grow million cer drive patient switch suppression therapy sale relenza otc medicine antiviral treatment flu million primarily drive oneoff analgesic government order stockpile possible flu pandemic dermatological vaccine grow million reflect good performance gastrointestinal hepatitis family product pediarix fluarixflulaval respiratory tract launch boostrix smoking control natural wellness support sale lamictal treatment epilepsy bipolar disorder weight management grow million benefit new indication treat form epilepsy primary generalise oral care tonicclonic seizure nutritional healthcare sale requip parkinson disease restless leg syndrome rls grow million follow launch rls indication gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue otc medicine research development overthecounter medicine sale grow billion expenditure decline include charge relate new panadol million alli sale million operational excellence programme million nil launch usa june smoking control product decline benefit arise low impairment charge windingdown million strong competition market breathe previous restructuring activity exclude item expenditure right fiberchoice add portfolio acquisition decline year pharmaceutical expenditure represent cns december achieve combine sale million pharmaceutical turnover oral care operating income oral care sale grow billion sale aquafresh operating income include royalty income equity investment million help success new aquafresh disposal impairment product disposal fair value white tray sensodyne grow strongly year adjustment financial instrument operate income million drive successful launch sensodyne pronamel million million increase primarily high royalty income million compare nutritional healthcare million favourable fair value movement financial nutritional healthcare product sale grow million instrument million compare million lucozade grow million horlick grow roche litigation settlement relate carvedilol million ribena sale million partially offset low asset disposal profit operate profit total result operate profit overall operate profit margin decrease percentage point total result include restructure cost relate new operational operating profit decrease sterling term million excellence programme commence october operating profit increase constant exchange rate growth cer margin increase percentage point reflect flat sga cer expenditure high operating income partially offset turnover increase cost sale cost sale year gain asset disposal million million sell general cost legal matter million million administration fair value movement financial instrument result research income million income million charge development relate old restructure activity million million operating charge relate new operational excellence income programme million nil total operating profit impact item million charge operating profit million charge cost sale profit taxation total result cost sale percentage turnover increase percentage point constant exchange rate cost sale percentage net finance cost turnover increase percentage point reflect charge relate new operational excellence programme finance income million nil unfavourable product regional mix interest finance income compare fair value adjustment hedge sell general administration sell general administration sga cost percentage turnover reduce percentage point constant exchange rate finance cost decrease percentage point reflect flat expenditure interest cost compare prior year turnover growth sga unwind discount liability cost include charge relate new operational excellence fair value adjustment hedge programme million nil advertising promotion increase selling distribution increase general administration expenditure decline finance cost increase owe increase level debt finance share buyback programme gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue share tax profit associate joint venture sell general administration share profit associate arise principally group sell general administration sga cost percentage hold quest diagnostic inc turnover reduce percentage point constant exchange rate decrease percentage point reflect decline profit taxation total result expenditure compare prior year turnover growth take account net finance cost contribution sga cost low sell general associate total profit taxation million compare administration expenditure partly offset high advertising million increase constant exchange promotion advertising promotion increase account rate sterling decline increase total sga selling distribution decline general administration expenditure decline collectively operational excellence item account decline total sga october gsk announce significant new billion percentage point low charge relate legal matter operational excellence programme improve effectiveness research development productivity operation expenditure decrease partly result low impairment new programme expect deliver annual pretax saving charge windingdown previous restructuring activity million gsk expect realise majority exclude item expenditure flat pharmaceutical annual saving year programme expenditure represent pharmaceutical approximately million expect million turnover saving partly mitigate expect impact operating income earning generic competition low avandia sale operating income include royalty income equity investment associate adverse impact gsk gross margin oneoff charge disposal impairment product disposal fair value million tax relate programme record adjustment financial instrument operate income significant acquisitionrelate restructuring million million increase primarily cost incur high royalty income million compare significance new programme columnar million favourable fair value movement financial presentation adopt income statement order instrument million compare million illustrate gsk underlie performance analysis roche litigation settlement relate carvedilol operating profit subsequent discussion exclude restructure partially offset low asset disposal profit cost relate new operational excellence programme operating profit commence october management believe exclusion overall operate profit margin increase percentage point item provide useful reflection way operating profit increase sterling term million business manage accordingly supplemental information operating profit increase constant exchange rate provide addition contain consolidated income margin increase percentage point reflect decline sga statement prepare accordance ifrs expenditure turnover growth high operating income operating profit business performance year gain asset disposal million growth million cost legal matter million cer million fair value movement financial instrument result turnover income million million charge relate cost sale old restructuring activity million million sell general operating profit impact item million charge administration million research development profit taxation business performance operate net finance cost income operate profit finance income interest income cost sale fair value adjustment hedge cost sale percentage turnover increase percentage point constant exchange rate cost sale percentage turnover increase percentage point reflect unfavourable finance cost product regional mix interest cost unwind discount liability fair value adjustment hedge gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue share tax profit associate joint venture gsk use good advice determine transfer pricing share profit associate arise principally group methodology seek manage transfer pricing hold quest diagnostic inc taxation issue satisfactory conclusion basis external professional advice continue believe profit taxation business performance adequate provision liability likely arise open take account net finance cost contribution assessment ultimate liability matter vary associate business performance profit taxation amount provide dependent outcome litigation million compare million increase proceeding negotiation relevant tax authority cer flat sterling term profit year taxation growth cer total profit taxation corporation tax year overseas taxation total profit attributable current taxation shareholder defer taxation basic earning share penny basic earning ad charge taxation total profit amounting million business performance profit represent effective tax rate charge taxation year taxation business performance profit amount business performance profit million represent effective tax rate attributable shareholder group balance sheet december include tax payable adjust earning share penny liability million tax recoverable asset million adjust earning ad weight average number group main open tax issue usa canada shares millions japan dilute total earning share penny gsk continue dispute revenue customs dilute total earning ad hmrc primarily respect transfer pricing control weight average number foreign company cfc matter year date hmrc share million formalise claim respect matter gsk seek resolve discussion hmrc continue total result include restructuring cost relate new wide difference group hmrc operational excellence programme produce basic eps position ultimately settle litigation compare increase cer term follow audit period internal revenue compare decline sterling term service irs notice propose adjustment challenge business performance profit year million increase deduction arise intercompany financing arrangement sterling term profit attributable minority interest year gsk disagree vigorously million profit attributable shareholder contest gsk estimate irs claim tax interest million increase sterling term interest cost december net federal tax relief year share buyback programme adversely impact group profit million gsk believe support external professional advice benefit ep business performance eps increase reflect claim merit adjustment warrant high profit reduction weight average number contrary gsk view irs prevail argument share result group share buyback programme court gsk expect additional liability actual rate exchange earning share increase year unaudite period proportionate liability unfavourable currency impact ep percentage point reflect year audit period event gsk strengthen sterle dollar compare able resolve issue irs court decision percentage point unfavourable currency impact turnover expect dividend low court japan uphold claim tax authority board declare fourth interim dividend penny share yen billion million relate japanese cfc legislation gsk result dividend year penny penny increase pay fully provide tax pursuing claim dividend penny share equivalent refund japanese supreme court canada court hearing fourth interim dividend receivable adr holder cent respect transfer pricing early complete july ad base exchange rate exdividend gsk await court judgement date february record date february payment date april gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue critical accounting policy historical experience customer return gsk record accrual estimate sale return apply historical consolidated financial statement prepare accordance experience customer return amount invoice ifrs adopt use european union market relate information stock level wholesaler ifrs issue iasb follow accounting policy approve anticipate price increase competitor activity board describe note financial statement accounting policy management require estimate reconciliation gross turnover net turnover assumption affect amount asset liability revenue pharmaceutical business follow expense report financial statement actual amount result differ estimate critical accounting policy adopt relate follow area gross turnover urnover chargeback axation manage care gpo egal dispute rebate medicare mpairment property plant equipment ntangible asset government ension postemployment benefit state programme cash discount information judgement estimate area customer return give note financial statement key accounting prior year adjustment judgement estimate item respect turnover accounting policy group large total deduction business pharmaceutical market net turnover complex arrangement rebate discount allowance follow briefly describe nature arrangement chargeback increase result significant sale existence group pharmaceutical business product government stockpile customer rebate fall compare result product traditionally gsk arrangement certain indirect customer high rebate percentage subject generic competition customer able buy product wholesaler reduce price replace sale new product low rebate chargeback represent difference invoice price percentage wholesaler indirect customer contractual discount price accrual estimate chargeback calculate base term total accrual rebate discount allowance return agreement historical experience product growth rate pharmaceutical business follow customer rebate offer key manage care group purchasing organisation gpo direct indirect december december customer arrangement require customer achieve certain performance target relate value product purchase chargeback formulary status predetermine market share relative manage care gpo competitor rebate give medicare include medicare rebate category medicare programme introduce government state programme replace government medicaid subsidy cash discount individual subsidise coverage provide private customer return prescription plan accrual rebate estimate base specific term agreement historical experience product growth rate total medicaid programme stateadministere programme monthly process operate monitor inventory level provide assistance certain poor vulnerable patient wholesaler abnormal movement process use gross medicaid drug rebate program establish sale volume prescription volume base party datum source reduce state federal expenditure prescription drug gsk information receive key wholesaler aim participate provide rebate state accrual medicaid maintain inventory consistent level year year base rebate calculate base specific term individual pattern consumption basis pharmaceutical state agreement combination historical experience inventory level wholesaler distribution channel product population growth anticipate price increase december estimate approximately impact contracting strategy month turnover calculation use party information accuracy totally verify believe cash discount offer customer encourage prompt sufficiently reliable purpose payment accrue time invoicing adjust subsequently reflect actual experience gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial position resource financial position property plant equipment gsk business sciencebase technologyintensive highly regulate governmental authority group allocate significant financial resource renewal maintenance asset property plant equipment minimise risk interruption noncurrent asset production achieve compliance regulatory standard property plant equipment number process use chemical hazardous material goodwill total cost group property plant equipment intangible asset december million net book value investment associate joint venture million land building represent million plant investment equipment million asset construction defer tax asset million gsk invest million new renewal derivative financial instrument property plant equipment mainly relate large noncurrent asset number project renewal improvement expansion total noncurrent asset facility worldwide site property mainly hold freehold new investment finance group liquid resource current asset december gsk capital contractual commitment future inventory expenditure million operating lease commitment current tax recoverable million gsk believe facility adequate trade receivables current need derivative financial instrument liquid investment group observe stringent procedure use specialist skill cash cash equivalent manage environmental risk activity environmental asset hold sale issue date operation modify discontinue report responsibility environment total current asset health safety note financial total asset statement legal proceeding liability goodwill current liability goodwill increase year million shortterm borrowing december million increase reflect goodwill trade payable arise acquisition reliant pharmaceutical million domantis million strengthen derivative financial instrument overseas currency translation exist foreign currency current tax payable goodwill balance shortterm provision intangible asset total current liability intangible asset include cost intangible acquire noncurrent liability party computer software net book value longterm borrowing intangible asset december million defer tax provision million increase reflect addition pension post million currency movement partly offset employment benefit amortisation impairment exist intangible large provision element addition million relate acquisition derivative financial instrument reliant pharmaceuticals inc add range speciality noncurrent liabilitie medicine combat heart disease gsk portfolio include marketing right lovaza total noncurrent liability investment total liability gsk hold investment include associate joint venture net asset carry value december million million market value december equity million million large investment share capital associate quest diagnostics inc book value share premium account december million million retain earning investment include equity stake company group reserve research collaboration provide access biotechnology shareholder equity development potential interest interest company arise business divestment minority interest total equity gsk annual report srotcerid eht troper secruoser dna noitisop laicnanifbusiness review derivative financial instrument asset total equity gsk hold noncurrent current derivative financial summary movement equity set instrument hold fair value million million increase primarily reflect fluctuation far forward valuation foreign exchange contract hedge intercompany loan total equity beginning year deposit exchange movement largely change euro total recognise income expense dollar yen market rate year trade receivables dividend shareholder trade receivables million increase ordinary share issue reflect impact strengthe overseas currency ordinary share purchase held translation foreign currency receivables partly offset low vat treasury share recoverables ordinary share purchase cancel derivative financial instrument liabilitie consideration receive share transfer gsk hold noncurrent current derivative financial esop trust instrument hold fair value million million ordinary share acquire esop trust relate primarily hedge exchange translation currency sharebase incentive plan asset consolidation increase reflect impact tax sharebase incentive plan euro dollar yen currency fluctuation change minority interest shareholding minority interest trade payable trade payable amount million total equity end year marginally increase impact strengthen overseas currency translation foreign currency payable december total equity increase partly offset decrease customer return rebate accrual million december million increase arise principally retain earning actuarial gain define provision benefit pension plan year partially offset purchase group carry defer tax provision shortterm treasury share noncurrent provision million december million respect estimate future liability share purchase million related legal dispute employee share ownership plan esop trust acquire provision legal dispute indemnify million share gsk plc nil share hold disposal liability cost restructure programme trust satisfy future exercise option award extent balance sheet date actual constructive group share option award scheme proportion share obligation exist reasonably estimate held trust respect award rule scheme require gsk satisfy exercise market purchase pension postemployment benefit issue new share share hold trust group account pension postemployment match option award grant arrangement accordance ias net deficit allow deferred taxation million december esop trust hold million gsk million pension arrangement million share future exercise share option share award million unfunded postemployment liability pension carrying value million deduct liability decrease follow improvement asset value reserve market value share million special funding contribution pension fund gsk repurchase million share hold million million pension scheme treasury share purchase million cancellation strengthen longterm interest rate include increase july gsk announce increase buyback programme rate discount pension liability billion represent billion increase compare benefit partly offset improvement mortality continuation exist programme new programme rate high inflation assumption expect complete year period include billion net debt exact time future purchase extent repurchase share hold treasury share cancel determine company cash cash equivalent dependent market condition factor december liquid investment gsk hold million share treasury share cost borrowing repayable year million deduct retain earning borrowing repayable year million share purchase period january net debt february cost million purchase publicly announce buyback programme net debt increase million primarily high share repurchase acquisition business partly offset increase cash inflow operating activity gsk annual report srotcerid eht troper secruoser dna noitisop laicnanif financial position resource continuedbusiness review financial position resource continue commitment contingent liability gsk formalise agreement trustee financial commitment summarise note financial pension scheme additional contribution statement commitment contingent liability million year addition normal contribution obligation respect short longterm debt set note year period end december order eliminate financial statement contingent liability note pension deficit ias basis point table financial statement net debt opposite show commitment exclude normal ongoing annual funding requirement approximately million gsk amount provide pension postretirement benefit commit eliminate future deficit arise set note financial statement pension roll fiveyear period commitment postemployment benefit amount provide restructuring past december information pension programme legal environmental dispute set obligation note financial statement pension note financial statement provision postemployment benefit contractual obligation commitment contingent liability follow table set group contractual obligation follow table set contingent liability comprise commitment december fall payment discount bill performance guarantee letter credit total yrs yrs yrs item arise normal course business expect expire loan total yrs yrs yrs interest loan finance lease obligation guarantee finance lease charge contingent liability operate lease commitment total intangible asset property plant equipment normal course business gsk provide indemnification guarantee respect business disposal investment legal dispute subsequently arise provision purchase commitment reasonable estimate likely outcome pension dispute include note financial statement commitment provision total group policy provide settlement cost assert commitment respect loan future interest payable loan claim environmental dispute reasonable estimate disclose take account effect derivative prior point liability record legal environmental cost discuss risk factor page group enter number research collaboration note financial statement legal proceeding develop new compound pharmaceutical company term arrangement include upfront fee equity gsk use good advice determine transfer pricing investment loan commitment fund specify level methodology basis external professional advice research addition group agree continue believe adequate provision payment future milestone achieve liability likely arise open taxation assessment ultimate agreement relate compound early stage development liability matter vary significantly amount provide milestone payment continue number year dependent outcome litigation proceeding compound successfully development process negotiation relevant tax authority discuss generally close product marketing approval great note financial statement taxation possibility success payment show intangible asset represent maximum pay milestone achieve number new commitment licensing agreement include arrangement anacor pharmaceuticals inc oncomed pharmaceuticals inc santaris pharma targacept inc gsk annual report srotcerid eht troper secruoser dna noitisop laicnanifbusiness review financial position resource continue cash flow free cash flow million increase summary consolidated cash flow statement set principally reflect impact tax settlement partly offset high level capital expenditure free cash flow cash generate business meeting obligation interest tax dividend pay minority interest capital expenditure noncurrent tangible net cash inflow operating activity intangible asset net cash outflow investing activity net cash outflow financing activity free cash flow gsk management planning reporting purpose discussion presentation increasedecrease cash bank overdraft investment analyst rate agency gsk free cash flow exchange adjustment measure define ifrs measure directly comparable similarly describe measure cash bank overdraft beginning year company reconciliation net cash inflow operating cash bank overdraft end year activity close equivalent ifrs measure free cash flow show cash bank overdraft end year comprise reconciliation free cash flow cash cash equivalent overdraft net cash inflow operating activity purchase noncurrent tangible asset net cash inflow operating activity taxation pay purchase noncurrent intangible asset million increase million arise mainly gross taxation payment billion billion disposal noncurrent tangible fix asset transfer pricing dispute settlement interest pay note financial statement taxation interest receive dividend receive joint venture net cash outflow investing activity million associate undertaking increase million reflect increase capital dividend pay minority interest expenditure purchase business include reliant pharmaceutical million domantis million free cash flow net cash acquire cash return shareholder movement net debt net debt begin year increasedecrease cash bank overdraft cash outflow liquid investment net increase longterm loan net increase inrepayment shortterm loan exchange movement net debt end year gsk annual report srotcerid eht troper secruoser dna noitisop laicnanif dividend buybacksbusiness review financial position resource continue investment appraisal treasury management group tmg chair group gsk formal process assess potential investment proposal chief financial officer meet monthly basis review treasury order ensure decision align group overall activity member receive management information relate strategy process include analysis impact project treasury activity corporate executive team cet review earning return invest capital assessment monthly finance report focus operational finance issue return base discount cash flow discount rate group internal auditor review treasury internal control perform financial analysis decide internally allow determination environment regularly extent investment cover group cost capital capital management specific investment discount rate adjust gsk operate globally primarily subsidiary company account country risk weighting establish market group trade significant capital expenditure financial investment level patent protection group product compete largely cash payment tangible intangible fix asset amount product efficacy price selling margin sufficient million million disposal realise million cover normal operating cost group operating subsidiary million cash payment acquire equity investment generally cash generative million million year sale operate cash flow fund investment research equity investment realise million million development new product routine future cash flow outflows capital expenditure tax dividend repayment group expect future operating cash flow sufficient mature debt july gsk announce increase share buy fund operating debt service cost satisfy normal level programme billion period july capital expenditure meet obligation exist licensing result substantially increase borrowing agreement meet routine outflow include tax group policy borrow centrally variety capital dividend subject risk factor discuss page market issue borrow facility meet anticipate gsk time time additional demand finance funding requirement acquisition access source liquidity short longterm capital market bank borrowing cash generate operation financial institution addition cash flow operation onlent contribute equity certain subsidiary need fund group billion share buyback programme complete july payment policy liquidity group company responsible monitoring manage group manage net borrowing requirement work capital term sale collection supplier payment portfolio longterm borrowing include bond reflect local commercial practice shortterm finance billion commercial paper programme december group billion company subsidiary commit undrawn bank facility policy ensure supplier pay time particular company seek group european medium term note programme settle term payment supplier agree term billion billion issue december transaction shelf registration billion december billion billion issue tmg monitor cashflow ensure supplier aware agree term forecast gsk monthly basis payment abide term payment group longterm borrowing mature date february gsk longterm standard policy include arrangement accelerate payment poor debt rating revise negative outlook small supplier stable time standard poor revise gsk short payment performance term rating paper issue group commercial paper december average number day purchase programme moodys investor services rate gsk represent trade fix asset creditor parent company negative outlook longterm debt short nil nil respect company term debt change gsk rating moodys subsidiary aggregate day day july light likely increase commercial paper issuance result treasury policy increase share buyback programme gsk increase glaxosmithkline plc report sterling pay dividend commit bank facility million billion addition sterling profit role corporate treasury gsk manage group maintain substantial cash liquid investment monitor group external internal funding requirement amount billion december financial risk support group corporate objective treasury activity govern policy procedure approve board director recently october gsk annual report srotcerid eht troper secruoser dna noitisop laicnanifbusiness review financial position resource continue financial asset liabilitie analysis net debt give note financial statement net debt analysis financial asset liability carry value fair value give note financial statement financial instrument relate disclosure group continue benefit strong positive cash flow operating activity group net debt decrease significantly year december group purchase share market billion acquisition approximately billion financial asset liability december representative treasury policy strategy gsk apply july time gsk announce change financial strategy involve increase share buyback programme billion result substantially increase borrowing july onwards gsk tighten criterion hold cash equivalent liquid investment response credit crisis gsk suffer loss principal result crisis gsk annual report srotcerid eht troper secruoser dna noitisop laicnanif treasury operation objective treasury activity manage posttax net cost income financial operation benefit group earning corporate treasury operate profit centre gsk use variety financial instrument include derivative finance operation manage market risk operation derivative principally comprise forward foreign currency contract interest rate currency swap swap borrowing liquid asset currency require group purpose manage exposure funding risk change foreign exchange rate interest rate gsk hold issue derivative financial instrument speculative purpose group treasury policy specifically prohibit activity transaction financial instrument undertake manage risk arise underlie business activity speculation foreign exchange management foreign currency transaction exposure arise normal trade flow respect external intragroup trade hedge exposure overseas operating subsidiary transaction risk minimised match local currency income local currency cost purpose intragroup trading transaction match centrally intragroup payment term manage reduce risk exceptionally foreign currency cash flow hedge selectively management corporate treasury group manage centrally shortterm cash surplus borrowing requirement subsidiary company use forward contract hedge future repayment originate currency group seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterle certain borrowing swap currency require group purpose borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset ratio borrowing asset review currency monthbymonth basis tmg interest rate risk management gsk policy interest rate risk management require minimum net borrowing fix rate increase ratio forecast interest payable trading profit fix float ratio review monthly tmg group use limited number interest rate swap redenominate external borrowing interest rate coupon require group purpose duration swap match duration principal instrument interest rate derivative instrument account fair value cash flow hedge relevant asset liabilitiesbusiness review outlook risk factor outlook new product candidate appear promise development significant investment fail reach market sale growth exist product launch new product limited commercial success example key driver gsk business sale growth key product result efficacy safety concern inability obtain necessary seretideadvair vaccine valtrex high potential regulatory approval difficulty excessive cost manufacture product avodart arixtra boniva expect continue erosion patent term result lengthy development period sale growth expect new product lovaza infringement patent intellectual property right cervarix tykerbtyverb rotarix veramystavamys altabax inability differentiate product adequately altargo sale growth avandia gsk product diabete compete adversely impact follow publication metaanalysis health authority fda european medicines agency japan pharmaceuticals medicine device agency typically sale exist product decline dramatically generic increase focus safety assess benefitrisk competition introduce patent expiry early balance drug light increase scrutiny factor successful challenge group patent generic reduction number new drug gain competitor coreg enter market regulatory approval recent year example fda approve product exposed generic competition usa new drug low singleyear total include wellbutrin requip lamictal paxil imitrex gsk engage legal proceeding risk unplanne loss patent validity infringement group patent relate patent infringement litigation product discuss risk factor group patent common patent challenge note financial statement legal proceeding time effort generic manufacturer involve challenge validity enforceability patent assertion gsk expect sustained flow new product generic product infringe group patent year thirteen new product opportunity currently file group successful defend attack patent regulator include promacta usa rotarix usa treximet maintain exclusive right market major usa synflorix international gsk currently key product particularly usa group high asset phase iii developmentregistration turnover margin group turnover margin publish earning guidance gsk expect adversely affect note financial statement legal impact low avandia sale increase generic proceeding discussion patentrelate proceeding competition lead midsingle digit percentage decline group involve description resolution business performance ep constant exchange rate prior proceeding affect date generic version group product introduce risk uncertainty inherent business affect future performance include project anticipate sale generic drug manufacturer seek market generic version growth expect earning growth discuss risk group important product prior factor expiration group patent exhibit readiness product future launch generic risk factor product compete coreg zofran flonase wellbutrin significant impact group overall turnover risk uncertaintie relevant group business earning financial condition result operation factor list group think cause group potential change intellectual property law actual result differ materially expect historical result regulation risk uncertainty currently know proposal change exist patent datum exclusivity law group group currently deem immaterial regulation major market group sell product continue feature political process country risk deliver commercially successful include proposal effect make prosecution new product patent new product difficult timeconsuming continue development commercially viable new product adversely affect exclusivity period group product development additional use exist product critical include biological product proposal enact group ability replace sale old product decline adverse impact group future sale result expiration exclusive right increase overall sale operation develop new product costly lengthy uncertain process new product candidate fail stage process latestage product candidate fail receive regulatory approval gsk annual report srotcerid eht troper srotcaf ksir dna kooltuobusiness review outlook risk factor continue weakness intellectual property protection instance party perform analysis publish certain country clinical trial result necessarily accurate country group operate patent meaningful raise question safety pharmaceutical protection significantly weak usa product publicise medium result european union addition effort control public health product liability claim group currently defendant crisis develop country south africa brazil number product liability lawsuit include class action consider plan substantial reduction scope involve substantial claim damage relate group patent protection pharmaceutical product particular pharmaceutical product litigation particularly usa country facilitate competition market inherently unpredictable excessive verdict justify generic manufacturer unable introduce evidence occur class action sweep compete product number year person prescribe group product inflate potential liability force number claim pain loss patent protection include abrogation patent right suffer punitive damage frequently assert product compulsory licensing likely affect adversely group liability action allow represent potentially open operating result national market expect end exposure material group overall absence adequate patent protection limit opportunity look market antitrust litigation future sale growth usa increasingly common follow publicity government investigation adverse outcome risk substantial adverse outcome litigation prosecution patent infringement action defendant government investigation direct indirect purchaser payer initiate antitrust note financial statement legal proceeding action claim direct indirect purchaser discussion proceeding governmental investigation involve payer typically file class action relief seek matter prove rise civil andor criminal liability include treble damage restitution claim damage adverse group currently involve unfavourable resolution antitrust verdict subject automatic trebling usa similar future proceeding investigation similarly antitrust claim bring follow settlement material adverse effect group financial condition patent litigation allege settlement anticompetitive result operation group material provision violation antitrust law relate legal proceeding investigation reduce earning group additional sale marketing regulation significant provision relate legal proceeding investigation group operate globally complex legal regulatory future reduce earning case environment vary jurisdiction failure practice plaintiff bar claim damage amount bear comply applicable law rule regulation relationship underlie harm accordingly potentially jurisdiction result civil criminal legal proceeding mislead quantify potential exposure claim proceeding rule regulation change governmental interpretation investigation type describe note financial rule regulation evolve prior conduct call statement legal proceeding question usa example group respond federal state governmental investigation price recent insurance loss experience include pharmaceutical product marketing reimbursement prescription drug product liability exposure increase cost narrow investigation result related restitution civil false coverage afford insurance pharmaceutical company claim act litigation behalf federal state government generally include group relate proceeding initiate group order contain insurance cost recent year group behalf consumer private payer proceeding continue adjust coverage profile accept great degree result trebling damage award fine respect uninsured exposure addition claim violation law criminal proceeding initiate insurance policy insurer reserve right deny coverage group company individual ground denial coverage ultimately uphold risk competition price control limitation sale claim result material additional charge party competition group earning group operate highly competitive business product liability litigation pharmaceutical business face competition proprietary preclinical clinical trial conduct development product large international manufacturer producer potential product determine safety efficacy generic pharmaceutical significant product innovation technical product use human follow approval regulatory advance intensification price competition competitor body notwithstanding effort drug vaccine adversely affect group operating result group introduce marketplace unanticipated effect predict timing impact competitive product evident potential impact sale group product continue consolidation pharmaceutical industry adversely affect group competitive position continue consolidation group customer increase pricing pressure gsk annual report srotcerid eht troper srotcaf ksir dna kooltuobusiness review outlook risk factor continue group product million annual global regulatory control sale product augmentin respect group comply broad range regulatory control group generic competition avandia imitrex test approval manufacturing marketing lamictal valtrex respect group intellectual pharmaceutical consumer healthcare product particularly property right usa currently subject litigation usa countries european union affect settlement agreement relate litigation group cost product development time require generic competition usa coreg significant reach market uncertainty successfully health product september authority increase focus safety assess benefit riskbalance drug context initial product group major product approval context approval additional indication subject problem unplanne loss patent protection review information market product strict unexpected effect regulatory proceeding publicity affect regulatory control heighten risk change product doctor patient confidence pressure competitive product profile withdrawal regulator basis postapproval new effective treatment introduce concern product safety reduce revenue adverse impact group revenue operating result result product recall product liability lawsuit significant particular group face intense competition great regulatory scrutiny especially usa advertising manufacturer generic pharmaceutical product major promotion particular directtoconsumer advertising market generic product enter market expiration patent datum exclusivity period group product addition case group voluntarily cease marketing introduction generic product typically lead dramatic loss product face decline sale base concern efficacy sale reduce group revenue margin proprietary safety example decline sale avandia follow product expiration date patent group major publicity question risk associate product description litigation settlement affect product scientifically justify absence date generic version group product regulatory action development postapproval adverse introduce set legal proceeding involve event profile product product class major patent challenge set note financial statement impact marketing sale product legal proceeding risk interruption product supply governmental payer control manufacture pharmaceutical product constituent pharmaceutical product subject price control pressure material require compliance good manufacturing practice restriction market include japan germany regulations group manufacture site subject review spain france italy government intervene directly approval fda regulatory agency compliance set price addition market major purchaser failure supplier key service material group pharmaceutical product governmental agency private manufacturing facility lead product recall seizures health care provider economic power exert substantial interruption production delay approval new product pressure price term access formulary pende resolution manufacturing issue noncompliance result fine disgorgement profit interruption group predict exist control pressure supply fine disgorgement remedy materially adversely restriction increase new control pressure restriction affect group financial result example resolution introduce reduce group margin affect fda observation deficiency manufacturing practice adversely ability introduce new product profitably group cidra puerto rico facility refer note example usa group high margin financial statement legal proceeding supply certain product sale country pricing pressure significantly manufacture site curtail constrict increase experience develop outpatient pharmaceutical adverse impact sale programme cover medicare beneficiary begin group undertake business continuity plan single private insurer coverage offer source certain component bulk active material finish enormous purchasing power programme demand product create risk failure supply event regulatory discount implicitly create price control prescription noncompliance physical disruption manufacturing site drug change enable legislation afford government direct role negotiate price medicare risk concentration sale wholesaler programme additionally number state propose usa line pharmaceutical company group implement scheme control price senior sell product small number wholesaler addition citizen programme include importation country hospital pharmacie physician group sale bulk purchase drug growth number patient large wholesaler amount approximately cover large manage care institution usa group pharmaceutical sale december group increase implementation medicare benefit trade receivable wholesaler total increase pricing pressure group product trend million december million group expose adversely affect group revenue margin sale concentration credit risk respect wholesaler usa affect financial difficulty materially adversely affect group financial result gsk annual report srotcerid eht troper srotcaf ksir dna kooltuobusiness review outlook risk factor continue reliance information technology accounting standard group increasingly dependent information technology new revise accounting standard rule interpretation system include internetbased system internal communication promulgate time time international standard set communication customer supplier board result change recognition income significant disruption system computer expense adversely impact group report financial virus outside incursion materially adversely result international standard change market valuation affect group operation certain financial instrument equity collar link group investment quest diagnostic impairment taxation equity investment reflect group report result effective tax rate group earning benefit fact gain loss actually realise portion earning tax favourable rate significant impact income statement give period jurisdiction outside change tax law account defer taxation intercompany inventory application respect matter transfer pricing foreign rise volatility depend ownership inventory dividend control company restriction tax relief allow balance sheet date interest intragroup debt increase group effective tax rate adversely affect financial result group regulator regularly review financial statement list open issue revenue authority usa company like gsk compliance accounting regulatory japan canada matter discuss note requirement financial statement taxation group believe complie appropriate regulatory disruption pandemic influenza requirement concern financial statement disclosure event pandemic influenza group subject company experience investigation disruption range factor national government potential noncompliance accounting disclosure willing abrogate intellectual property right medicine requirement result restatement previously short supply country afflict report result significant penalty pandemic flu risk employee family human resource affect consequence sale distribution group approximately employee manufacturing activity shut supply continuity world subject law regulation concern active ingredient finish good affect employee range discrimination harassment environmental liability personal privacy labour relation vary significantly environmental law jurisdiction impose actual jurisdiction jurisdiction group face intense competition potential obligation group remediate contaminate site qualified individual pharmaceutical biotechnology group identify potentially responsible party company university governmental entity comprehensive environmental response compensation research institution failure continue recruit retain liability act number site remediation cost relate right people maintain culture compliance group use ownership site failure manage properly significant adverse effect group environmental risk result additional remedial cost materially adversely affect group operation note financial statement legal proceeding discussion environmentalrelate proceeding group involve global political economic condition group conduct substantial portion operation outside group management foreign exchange rate discuss business review foreign exchange management fluctuation exchange rate sterling currency especially dollar euro japanese yen materially affect group financial result group control change inflation interest rate foreign currency exchange rate control economic factor affect business possibility political unrest legal regulatory change nationalisation jurisdiction group operate factor materially affect group future result operation gsk annual report srotcerid eht troper srotcaf ksir dna kooltuobusiness review financial review accordance sec disclosure requirement pharmaceutical turnover follow discussion compare result year december growth rate include review turnover constant result year december exchange rate cer state sterling growth growth rate constant exchange rate cer rate find table pharmaceutical turnover total state sterling growth rate find pharmaceutical turnover million compare table pharmaceutical turnover therapeutic area million increase cer sterling term total pharmaceutical turnover increase cer exchange principally strength sterle major international currency currency influence group result dollar euro japanese yen pharmaceutical turnover therapeutic area dollar fall pound gsk ability deliver continue pharmaceutical turnover yearend yearend rate euro weaken growth primarily exceptionally broad product portfolio japanese yen sterle highvalue growth product couple sale marketing excellence growth product include seretideadvair world market pharmaceutical avandia product group vaccine lamictal valtrex coreg requip global pharmaceutical sale increase avodart boniva billion respiratory world market value growth gsk continue global leader respiratory pharmaceutical geographic region total sale key product seretideadvair flixotideflovent serevent amount billion total sale usa seretideadvair asthma copd rise billion europe usa sale grow billion europe sale grow france billion international market sale grow germany million market share value antiasthma copd therapy class europe usa increase italy percentage point europe flat market share growth japan usa reflect low prescription volume label change asia pacific early restrict gsk ability promote product offset latin america favourable pricing change middle east africa canada cns cns sale increase billion sale increase usa total international decline europe generic competition total seroxatpaxil sale grow million strong growth market increase represent growth paxil usa paxil japan partly offset global prescription pharmaceutical market compare generic competition paxil europe decade early total wellbutrin sale grow million sale september gsk hold second position world wellbutrin oncedaily product grow million pharmaceutical market market share pfizer december generic competition wellbutrin market share gsk world tablet approximately wellbutrin sale enter pharmaceutical product avandia lamictal seretide market advair valtrex wellbutrin zofran sale lamictal treatment epilepsy bipolar disorder world market value growth grow billion benefit new indication therapeutic class total cer treat form epilepsy primary generalise cardiovascular tonicclonic seizure lamictal medicine long central nervous system term clinical datum demonstrate delay onset alimentary tract metabolic depressive episode bipolar disorder antiinfective bacterial sale requip parkinson disease restless leg syndrome viral fungal exclude rls grow million vaccine respiratory note datum base month september gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis infanrix pediarix boostrix cardiovascular urogenital coreg levitra avodart arixtra fraxiparine antibacterial augmentin zinnatceftin oncology emesis zofran hycamtin zantac cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue antiviral oncology emesis total sale hiv product billion competition sale zofran grow million drive market old product combivir million epivir million europe international sale decline million offset strong sale respectively generic competition generic growth new product epzicomkivexa double competitor zofran enter market november million lexivaagenerase million cardiovascular urogenital sale valtrex rise million sale sale coreg heart disease grow million avodart million drive patient switch suppression therapy benign prostatic hyperplasia enlarge prostate strong year sale increase million metabolic gsk launch avandia treatment type diabetes antibacterial combination product avandamet blood sugar control antibacterial sale decline reflect generic competition product group expand february weak flu season launch usa fixeddose combination treatment therapeutic area avandaryl combine avandia sulfonylurea sale zantac fall million decline europe sale avandia product group grow international partially offset growth usa billion usa europe sale grow million drive consumer healthcare sale increase use avandamet sale international market analysis consumer healthcare sale set rise million avandia product group achieve follow table market share value oral antidiabetic growth usa europe percentage point respectively cer usa avandamet prescription volume growth adversely otc medicine impact product supply issue year analgesic resolve dermatological december gsk present datum landmark adopt study gastrointestinal demonstrate avandia effective metformin respiratory tract sulphonylurea longterm blood sugar control type smoking control diabete datum addition recently present natural wellness support dream study show avandia reduce risk progression type diabete datum study oral care expect file regulatory agency half nutritional healthcare gsk record turnover million share copromotion income consumer healthcare sale grow billion sale bonivabonviva new oncemonthly oral bisphosphonate international europe perform total treatment postmenopausal osteoporosis develop sale usa flat improve performance roche launch fourth quarter sale vaccine otc medicine overall vaccine sale increase billion good overthecounter medicine sale grow billion performance region sale rise million panadol smoking control perform european sale grow million sale international million key contributor infanrix oral care pediarix gsk combination vaccine child sale oral care sale grow million sensodyne grow strongly million sale hepatitis vaccine grow year million sale aquafresh million benefit strong performance havrix million follow approval year broad paediatric use nutritional healthcare sale new vaccine helped drive overall sale growth total nutritional healthcare product sale grow million sale rotarix rotavirus boostrix prevention diphtheria lucozade grow million horlick grow tetanus whooping cough influenza vaccine fluarix million ribena sale million flulaval reach million year sale flulaval follow acquisition biomedical late gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue operate profit operating profit overall operate profit margin increase percentage point analysis operate profit subsequent discussion operating profit increase sterling term million compare result result operate profit increase constant exchange rate growth margin increase percentage point reflect sga growth cer rate turnover growth partially offset high cost turnover relate programme deliver future cost saving low operating income cost sale sell general gain asset disposal million million administration cost legal matter million million research fair value movement quest collar theravance option development result income million million charge operate relate costsave programme million income million total operating profit impact item million charge compare million charge operating profit cost sale profit taxation cost sale decline percentage turnover percentage point constant exchange rate decline percentage discussion compare result point reflect favourable price regional mix impact result sell general administration net finance cost sell general administration sga cost percentage turnover reduce percentage point constant exchange rate finance income decrease percentage point reflect flat expenditure interest finance income compare prior year turnover growth sga fair value adjustment hedge cost flat high advertising promotion sell expenditure offset low general administration expenditure advertising promotion sell increase account increase total sga general administration expenditure finance cost decline account decline total sga interest cost percentage point low charge relate unwind discount liability legal matter percentage point low cost fair value adjustment hedge relate programme deliver future cost saving research development expenditure increase partly result high charge finance income increase compare predominantly related restructuring programme exclude restructuring cost increase income extend credit receivable increase grow broadly inline turnover pharmaceutical interest income high dollar interest rate finance cost expenditure exclude restructuring cost represent reduce refinance expensive bond december pharmaceutical turnover january low swap cost result reduce interest rate differential operating income operating income include royalty income equity investment share tax profit associate joint venture disposal impairment product disposal fair value share profit associate arise principally group adjustment quest collar theravance option hold quest diagnostic inc operate income million compare million decrease primarily low product asset disposal profit partially offset favourable fair value movement quest collar theravance option gsk annual report srotcerid eht troper weiver laicnanifbusiness review financial review continue taxation profit year million increase sterling term profit attributable minority interest million profit attributable shareholder million corporation tax increase sterling term interest cost overseas taxation share buyback adversely impact group earning benefit earning share ep eps increase reflect high current taxation profit reduction weight average number defer taxation share result group share buyback programme total actual rate exchange earning share increase unfavourable currency impact ep percentage point charge taxation profit amounting million reflect strengthen sterle major currency represent effective tax rate compare percentage point unfavourable currency group balance sheet december include tax payable impact turnover liability million tax recoverable asset million integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority intragroup transaction particular price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit tax individual territory resolution issue continue fact life gsk group significant open issue revenue authority usa japan canada september gsk internal revenue service agree resolution dispute profit year growth cer profit taxation year profit attributable shareholder earning share penny earning ad weight average number share million diluted earning share penny dilute earning ad weight average number share million gsk annual report srotcerid eht troper weiver laicnanifcorporate governance corporate governance section discuss glaxosmithkline management structure governance procedure contain company report disclosure corporate governance require combined code corporate governance financial reporting council combine code include require statement compliance section contain company report compliance law regulation apply board corporate executive team governance policy dialogue shareholder share capital control donation political organisation political expenditure annual general meeting internal control framework committee report combine code law regulation gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue board sir deryck maughan age appoint june nonexecutive director sir deryck sir christopher gent age managing director kohlberg kravis roberts appoint june chairman sir christopher chairman ceo citigroup international chief executive officer vodafone group plc retirement salomon brothers inc nonexecutive director reuters july nonexecutive director lehman brothers group plc blackrock inc holdings inc nonexecutive director ferrari spa member kpmgs chairman advisory group senior adviser bain daniel podolsky age member advisory board reform appoint july nonexecutive director podolsky mallinckrodt professor medicine chief gastroenterology jeanpierre garnier age massachusetts general hospital harvard medical school appoint retire chief chief academic officer partner healthcare system executive officer garnier appoint executive director chairman board scientific cofounder smithkline beecham plc chief executive officer company april nonexecutive director united technologies corporation member board overseer weill sir ian prosser aged cornell medical college appoint senior independent director sir ian nonexecutive director smithkline beecham plc andrew witty age nonexecutive deputy chairman plc nonexecutive appoint january ceo designate succeed director sara lee corporation member cbi garnier witty join group president committee hold senior position asia africa europe usa january appoint president pharmaceuticals europe ronaldo schmitz aged serve board member singapore economic appoint nonexecutive director schmitz development board member insead council nonexecutive director glaxo wellcome plc director office strategic coordination health research nonexecutive director legal general group plc member sit imperial college commercialisation advisory board board director rohm haas company cabot member health innovation council corporation supervisory board sick professor sir roy anderson age moncef slaoui aged appoint october nonexecutive director professor appoint chairman research development anderson professor infectious disease epidemiology slaoui join gsk biological engineer faculty medicine imperial college london september development robust vaccine pipeline phd molecular chief scientific adviser ministry defence biology immunology universit libre bruxelles rector imperial college july tom swaan age stephanie burn age appoint january nonexecutive director appoint february nonexecutive director burns swaan member managing board chief financial chairman president chief executive officer dow corning officer abn amro january member corporation member american chemical society board director zurich financial services vice chairman sit executive committee society chemical supervisory board chairman audit committee industry america section serve board director royal ahold member supervisory board royal dsm american chemistry council board directors corporate express vice chairman supervisory board society womens health research burns hold phd vanlanschot bankier organic chemistry iowa state university christopher viehbacher aged lawrence culp age appoint january president pharmaceuticals appoint july nonexecutive director culp viehbacher join group hold variety president chief executive officer danaher corporation senior position europe canada appoint prior join danaher hold position accenture previously president pharmaceuticals january serve andersen consulting european commission approve working group restore competitiveness pharmaceutical industry sir crispin davis aged board member phrma ceo roundtable cancer appoint july nonexecutive director sir crispin chief researchamerica executive reed elsevi plc prior chief executive aegis group plc join guinness plc sir robert wilson aged member main board group manage director united appoint november nonexecutive director sir robert distiller spend early career procter gamble nonexecutive chairman group plc economist group previously executive chairman rio tinto julian heslop aged appoint april chief financial officer heslop join detail membership board committee find glaxo wellcome financial controller april january appoint senior vice president operation controller prior join group hold senior finance role grand metropolitan gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue corporate executive team cet duncan learmouth senior vice president corporate communication garni community partnership chief executive officer learmouth responsible group investor relation chief executive officer garnier responsible internal external communication image partnership management group oversee operational aspect global community join glaxo vice group include establish policy objective initiative president global investor relation appointment direct longterm strategy chief executive current position july officer smithkline beecham join group bill louv andrew witty chief information officer ceo designate louv succeed calhoun chief information officer witty appoint ceo designate october january responsible information technology global succeed garni ceo andrew join glaxo function enable key business process part career company hold role group join group hold number vice president general manager marketing glaxo wellcome increasingly senior role include pharmaceuticals inc senior vice president asia pacific gsk function appoint president pharmaceuticals europe glaxosmithkline january dan phelan senior vice president human resource rupert bondy phelan responsible benefit compensation recruitment senior vice president general counsel organisation development leadership development succession bondy responsible legal matter group plan human resource information system employee health environment health safety issue security management lawyer private practice join lawyer private practice join smithkline beecham smith kline french leave gsk march david pulman john clarke president global manufacturing supply president consumer healthcare pulman responsible global manufacturing supply clarke responsible consumer healthcare business organisation global procurement train microbiologist produce oral overthecounter nutritional healthcare product join glaxo broad experience manufacturing join beecham president future operation previously lead primary supply european group current appointment january manufacture north american manufacture global logistics marc dunoyer manufacturing strategy organisation president pharmaceutical japan moncef slaoui dunoyer appoint president pharmaceutical japan march chairman research development join group senior vice president slaoui lead group complex drug discovery development regional director japan current appointment activity join group senior vice president eddie gray worldwide business development current appointment president pharmaceuticals europe june gray responsible group operation europe chris viehbacher january join beecham prior current president pharmaceuticals appointment senior vice president general manager viehbacher responsible pharmaceutical join pharmaceutical wellcome responsible gsk european russell greig pharmaceuticals business current appointment president pharmaceutical international member greig lead pharmaceutical operation outside usa calhoun retire chief information officer january japan europe cover country stout left group february ingram continues join group senior vice president worldwide act special consultant group attend cet meeting business development prior current appointment capacity march julian heslop chief financial officer heslop chief financial officer april head finance function heslop responsible activity financial reporting control tax treasury finance system internal audit insurance real estate join glaxo wellcome financial controller april gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue governance policy board process board authority accountable shareholders board corporate executive team ensure company appropriately manage director list board achieve strategic objective set board discharge board responsible group system corporate responsibility annual programme meeting governance ultimately accountable group activity include approval overall budgetary planning business strategy financial performance strategy board review company internal control risk management policy approve governance structure chief executive officer ceo responsible executive code ethic management group assist cet cet meet time year necessary member board appraise approve major financing investment responsibility list corporate executive team licensing decision excess define threshold addition board evaluate monitor performance group board comprise executive nonexecutive director include board consider nonexecutive director independent character judgement schmitz serve board engage board meeting ceo executive year appoint board glaxo wellcome director members cet appropriate financial plc january consideration annual review operating performance gsk external issue material board effectiveness meeting december board group prospect conclude schmitz remain independent notwithstanding evaluate progress achievement group length service opinion board schmitz continue financial business objective annual plan demonstrate characteristic independence objectively challenge management take rigorous debate monitoring report receive directly time possess outstanding knowledge company committee significant risk face group business affair experience gain chairman board overall responsibility succession planning audit committee long cycle investment business ceo executive director board give ceo gsk consider particularly important experienced broad authority operate business group ceo members board sir christopher gent appoint accountable report board performance board deputy chairman determined board business independent take chairmanship board january accordance combine code cet member regular presentation board area exclude determination half board responsibility board meet cet member independent nonexecutive director sir christopher gent annual basis discuss collectively group strategy hold position board committee independence primary element induction process new nonexecutive require combined code appoint director undertake member cet nonexecutive member remuneration committee effective january director encourage separate informal discussion follow recent change combine code discretion cet members board consider professor sir roy anderson burns board meet time member attend culp sir crispin davis sir deryck maughan podolsky sir ian prosser follow schmitz swaan sir robert wilson independent accordance recommendation combine code number meeting number hold whilst board member meeting attend date publication majority sir christopher gent board member exclude chairman independent non garni executive director heslop slaoui sir christopher gent succeed sir christopher hogg january professor sir roy anderson chair company garni ceo burn retire board end agm culp andrew witty succeed ceo wittys biographical sir crispin davis detail find witty appointed board sir deryck maughan january chairman lead board represent podolsky board ceo cet member necessary board sir ian prosser meeting ceo manage group implement strategy schmitz policy adopt board chairman chairmen swaan board committee communicate regularly ceo cet sir robert wilson members division responsibilitie role chairman ceo set writing agree board professor anderson join board october burns join appear company website february addition schedule meeting board meet sir ian prosser appoint senior independent director sid quorate basis occasion january hold role gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue business environment development remuneration committee ensure board keep uptodate important remuneration committee determine term service matter include legal governance regulatory development remuneration executive director member cet presentation regular basis external assistance external independent advisor evaluate internal adviser make recommendation board overall executive remuneration policy committee consist entirely independent independent advice nonexecutive director chairman accordance board recognise occasion combined code meet time year director feel necessary independent necessary information remuneration director legal andor financial advice company expense give remuneration report page agree procedure enable explain corporate governance section company website chairman company ceo responsible evaluating make recommendation board indemnification director remuneration nonexecutive director qualify party indemnity provision define section company act force benefit nomination committee director director hold office nomination committee review structure size composition board appointment member company secretary board cet make recommendation board company secretary responsible board available appropriate committee monitor plan succession individual director respect board procedure company board senior management committee consist entirely secretary simon bicknell appoint nonexecutive director majority independent barrister join group secretary meet year necessary nomination board committee committee report give page board committee corporate responsibility committee board establish number committee provide corporate responsibility committee consist entirely non sufficient resource enable undertake duty executive executive director provide boardlevel forum regular director member audit remuneration nomination review external issue potential impact corporate responsibility committee invite group business reputation oversight attend meeting director member corporate reputation view external stakeholder committee administration transaction financial result committee responsible governance oversight group worldwide membership committee show table donation community support committee meet formally corporate time year necessary corporate audit remuneration nominationsresponsibility responsibility committee report give sir christopher gent professor sir roy anderson financial results committee burn financial result committee review approve behalf culp board annual report form annual review sir crispin davis convene annual general meeting sir deryck maughan preliminary quarterly statement trading result director member committee quorum meeting podolsky member quorate meeting include sir ian prosser chairman chairman audit committee ceo schmitz chief financial officer cfo committee meet necessary swaan sir robert wilson corporate administration transaction committee corporate administration transaction committee review key chairman member approve matter connection administration follow summary role term reference group business certain corporate transaction committee committee current term reference committee consist director cet members company secretary obtain company secretary corporate committee meet necessary governance section company website evaluation board board committee director audit committee performance evaluation chairman board audit committee review financial internal reporting committee director undertake sid process system internal control management risk implement collaboration committee chairman external internal audit process committee support company secretary board consider review propose shareholder appointment external auditor conclusion meeting december agree number directly responsible remuneration oversight minor improvement procedure operate methodology work committee consist entirely independent non audit committee chairman undertake review audit executive director meet time year committee building work undertake external necessary audit committee report page consultant review committee gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue dialogue shareholder holder ordinary share entitle receive dividend declare company report account attend financial result announce quarterly speak general meeting company appoint proxy company report formally shareholder twice year exercise voting right halfyear fullyear result announce fullyear result restriction transfer limitation hold include company annual report annual review ordinary share requirement obtain prior approval publish shareholder company half transfer ordinary share carry special right regard year result publish national newspaper shortly control company restriction voting release ceo cfo presentation fullyear result right major shareholder voting right share institutional investor analyst medium shareholder know arrangement webcast teleconference release financial right hold person holder second quarter result institutional investor analyst share know agreement restriction share transfer medium annual report annual review quarterly voting right result available company website share acquire gsk share scheme plan rank equally annual general meeting agm take place london formal share issue special right trustee notification send shareholder month advance company employee share ownership plan esop trust meet business presentation shareholder waive right dividend share hold esop trust director able attend available formally agm change control informally question committee chairman ordinarily company party significant agreement attend agm respond shareholder question entire board effect alter terminate change control follow attendance company agm resolution takeover bid agm decide poll require company article association result poll announce london stock company agreement director officer exchange post company website detail provide compensation loss office employment agm set section annual general meeting result takeover provision company notice agm publish company website share plan cause option award grant plan vest takeover ensure nonexecutive director aware understand view major shareholder company interest voting right board place process focus sectorspecific issue state far company aware general shareholder preference person significant direct indirect holding company information provide company pursuant ceo cfo maintain dialogue institutional shareholder financial service authority fsa disclosure transparency performance plan objective programme rule dtrs publish regulatory information service regular meeting company website group investor relation department office london february company receive notification philadelphia act focal point contact investor accordance fsa dtrs follow notifiable interest year voting right company issue share capital chairman meet regularly institutional investor hear percentage issue view discuss issue mutual importance share capital chairman remuneration committee meet annually legal general management major shareholder discuss executive remuneration policy limited barclays plc nonexecutive director include new appointee available meet major shareholder request ercentage ordinary share issue exclude treasury share february company website provide access current financial business information group bank new york mellon depositary company adrs list new york stock exchange ordinary share capital control share represent company adr program manage depositary register bny detail company authorise issue share capital nominee limit detail number ordinary share hold number share hold treasury december depositary find find note financial statement share capital share premium account gsk share list london stock company acquire disposed interest exchange quote new york stock exchange share connection company share buyback form american depositary share adss ad represent programme detail share purchase cancel hold ordinary share treasury disclose note financial statement share capital share premium account gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue director officer donation political organisation interest director officer connect person political expenditure issue share capital company give remuneration agm shareholder authorise company report page donation political organisation incur political rule appointment replacement director expenditure provision political party election contain company article association company referendum act year authority article approve shareholder accordance renew annually company legislation force time time intend payment donation political party normal meaning expression article provide director appoint ordinary definition legislation political organisation wide resolution member resolution director provide extend body company subsidiary wish instance director appoint way retire support include concerned policy review law reform agm follow appointment representation business community special interest group article provide agm concerned environment donation director retire rotation detail circumstance political organisation group donation reelect company member noneu political organisation totalling remove director pass ordinary resolution special notice give director automatically cease donation usa director bankrupcy order canada nil make arrangement composition creditor apply australia usa large recipient political donation interim order connection voluntary arrangement iii reflect political system candidate sponsor solely suffer mental disorder miss director donation individual ngos company party meeting continuous period month permission director resolve shall cease director line law corporate donation gsk prohibit director law resign vii federal level candidate political party state offer resign director accept offer viii local level donation accept practice usa director require resign major employer heavily regulate industry important gsk engage fully political process donation company article amend special resolution way gsk support candidate seek member environment appropriately reward highrisk highinvestment power director determine legislation industry believe free market principle intellectual company memorandum articles association available property right gsk website provide article director exercise situation similar canada donation follow company power provide article applicable guideline rest world donation rare legislation stipulate power exercise low value member director authorise issue allot ordinary share pursuant article authority gsk political action committee pac usa market purchase share pursuant article power give political donation pac employee organisation article refer shareholder agm allow employee contribute fund political donation renewal shareholder request renew director employee decide recipient pac donation power market purchase share agm share total donate political purchase cancel hold treasury share organisation gsk pac share buyback programme annual general meeting company repurchase billion share cancellation hold treasury share billion agm hold wednesday spend queen elizabeth conference centre broad sanctuary westminster london swp business transact july programme total billion share repurchase meeting include year commence programme cover purchase company share cancellation hold treasury share receive adopt glaxosmithkline accordance authority renew shareholder annual report company agm pprove remuneration report company authorise purchase maximum remuneration report page set million share detail share purchase held remuneration policy operate glaxosmithkline disclosure treasury share cancel disclose note director remuneration include require financial statement share capital share premium account company act director remuneration report regulation resolution propose approve exact time future purchase extent remuneration report repurchase share hold treasury share cancel determine company dependent market condition factor gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue etirement election reelection director extensive financial control procedure selfassessment exercise witty viehbacher professor sir roy anderson risk activity review group internal auditor appoint director agm offer commercial financial responsibility clearly delegate election board sir christopher gent sir ian prosser local business unit support regional management structure schmitz retire offer reelection principle design provide environment central board article company article association leadership couple local operating autonomy framework garni retire rotation seek exercise accountability control group reappointment retiring board group attach importance clear principle procedure conclusion agm design achieve appropriate accountability control group eappointment remuneration auditor policy risk management legal compliance mandate resolution propose reappoint pricewaterhousecooper business unit establish process manage monitoring risk llp auditor authorise audit committee determine significant business group remuneration internal control framework rely follow pecial business oversee report risk compliance issue company seek authority risk oversight compliance council rocc donation political organisation incur rocc council senior executive authorise board political expenditure cap assist audit committee oversee risk management internal control activity group membership comprise allot ordinary share company cet member head department internal director authority disapply preemption right control risk management audit compliance responsibility allot new share connection right issue rocc meet regular basis review assess significant maximum current issue share capital risk mitigation plan provide oversight internal purchase ordinary share maximum control ensure compliance applicable law regulation current issue share capital internal gsk policy rocc respond group policy adopt new article association reflect change refer provide business unit framework introduce new company act risk management upward report significant risk mitigation planning identification manager overall shareholder entitle appoint proxy attend responsibility management give risk requirement agm speak vote behalf risk management compliance board rmcbs detail appoint appoint corporate representative risk management compliance board rmcbs establish proxy find notice agm major business unit membership comprise member publish company website senior executive team respective business unit augment specialist appropriate rmcbs oversee management internal control framework risk consider important respective business unit board recognise responsibility present balanced include risk designate significant glaxosmithkline understandable assessment group position prospect increase number risk actively manage structure accountability audit operate gsk group follow rmcb regularly report status significant risk board accountability review approve adequacy rocc effectiveness internal control operate group include compliance function financial operational compliance control risk management number risk area specific standard meet exceed board delegate responsibility review audit requirement applicable law establish specialist audit committee receive report individual identify compliance function example corporate environment committee report page responsibility health safety global quality assurance worldwide regulatory management cet implement board policy compliance assist dissemination implementation audit risk control cet responsible identify approve standard monitor enforce key policy heart group conduct business internal control framework include corporate ethic compliance cec central direction resource allocation risk management key rocc support corporate ethic compliance activity research development manufacturing marketing department responsible support development sale legal human resource information system financial implementation practice facilitate employee compliance practice framework comprehensive planning law group policy system annual budget approve board result thrust group compliance effort diligence operating unit report monthly compare budget prevent detect misconduct noncompliance law forecast prepare regularly year regulation promote ethical behaviour compliance law regulation corporate responsibility level effective compliance system gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue cec manage corporate compliance officer committee receive regular report member cet report directly ceo corporate compliance officer chair senior manager cover key compliance activity rocc provide summary report roccs activity group include concern manufacture sale group significant risk cet audit committee marketing ehs regular basis corporate compliance officer direct reporting committee member exception podolsky bring line audit committee provide mechanism bypass considerable financial accounting experience committee executive management need arise work member past employment experience finance area potentially significant risk accounting role comparable experience corporate activity detail risk affect group risk factor page podolskys background worldrenowne researcher enable note financial statement legal proceeding bring scientific expertise committee deliberation effectiveness control swaan join board committee effect internal control framework operation january succeed schmitz chairman year review continue operate committee effect september appointing date approval report system internal control swaan committee board determine design manage eliminate risk recent relevant financial experience accordance achieve business objective provide reasonable combine code come conclusion board pay absolute assurance material misstatement loss particular attention swaans role chief financial officer abn amro retire december audit committee receive report area significant board consider swaan audit committee risk group relate internal control follow financial expert define sarbanesoxley consideration report audit committee report annually board effectiveness control control sir deryck maughan managing director kohlberg kravis mitigate eliminate risk addition area roberts kkr chairman kkr asia chairman group business necessary risk achieve ceo citigroup international vice chairman citigroup satisfactory return shareholder investment inc prior creation citigroup chairman cochief acquire new product business executive officer salomon smith barney chairman chief executive officer salomon brothers inc case group objective apply expertise prudent management elimination risk director sir ian prosser cfo later ceo bass plc member review relate company subsidiary extend institute charter accountant england wale material associate undertaking joint venture investment schmitz chairman committee april board audit committee review september prior appointment nonexecutive assessment risk internal control framework operate director company nonexecutive director glaxo glaxosmithkline consider effectiveness wellcome plc serve audit committee schmitz system internal control operation group year member executive board director cover report date approval board deutsche bank retired board process follow board review system internal charge investment banking schmitz member control accord guidance internal control issue executive board director basf turnbull committee include cfo hold mba insead sir robert wilson begin professional career economist committee report chairman group plc hold senior management position rio tinto plc culminate appointment executive chairman audit committee report retire audit committee role flow directly board oversight function authorise board investigate activity podolsky appoint committee effect term reference committee write term january worldrenowne researcher advanced reference approved board committee knowledge underlie mechanism disease new therapy report regularly board performance activity gastrointestinal disorder mallinkrodt professor medicine assign committee main responsibility include chief gastroenterology massachusetts general hospital review corporate accounting financial reporting process harvard medical school chief academic officer monitor integrity financial statement evaluate partner healthcare system background enable system internal control management risk oversee bring scientific financial accounting expertise activity group compliance audit function committee deliberation oversee compliance law regulations ethical code committee support company secretary attend practice committee oversight role require address committee meeting corporate compliance regularly relationship management internal officer available financial resource independent external auditor understand monitor report professional advice consider necessary meeting relationship tier accountability committee attend chairman ceo cfo general counsel head global internal audit gia external auditor gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue committee work structure programme external auditor management report regularly activitie standing item committee require committee extent service provide accordance consider meet matter focus preapproval fee service perform coincide key event annual financial reporting cycle committee preapprove additional service caseby external auditor report committee critical case basis expenditure audit nonaudit services set accounting policy significant judgement practice note financial statement operate profit company alternative accounting treatment guideline set company policy engage discuss management resultant conclusion external auditor provide nonaudit service include ascertain external auditor material write communication skill experience external auditor management restriction access information suitable supplier nonaudit service adequate safeguard cfo report financial performance company place objectivity independence audit technical financial accounting matter compromise fee level relative annual audit fee limit set committee general counsel report material litigation company wellestablishe policy include code company secretary corporate compliance officer ethic available website helpline facility report corporate governance activity undertake reporting investigation unlawful conduct waivers rocc code head group compliance audit group report audit scope annual coverage audit resource committee meet session time time result audits conduct year quorate basis session attend member sir deryck maughan unable attend meeting company secretary chairman disclosure committee report matter affect quality timely disclosure nomination committee report financial material information board nomination committee term reference include responsibility public market shareholder enable committee propose appointment board committee member review clarity completeness disclosure committee main focus selection publish annual financial statement interim report quarterly new ceo succeed garni sir robert wilson swaan preliminary result announcement formal culp attend committee meeting purpose announcement relate financial performance prior consider garnier successor implement process release board select new ceo committee take external advice audit committee management internal auditor executive search company conduct search identify board work ensure quality company potential external candidate addition internal candidate corporate accounting financial reporting committee identify executive search company serve primary link board external conduct degree analysis candidate internal auditor facilitate necessary independence chairman conduct interview number key individual management encourage external internal auditor outside company gain perspective communicate freely regularly committee candidate addition garnier provide committee committee meet collectively separately external analysis candidate auditor head gia corporate compliance officer member management present consider chairman ceo feedback external advice benchmarking committee conclude make committee primary responsibility make recommendation board witty appoint recommendation shareholder appointment reappointment company ceo removal external auditor annually assess qualification expertise resource independence external committee recommendation board auditor effectiveness audit process appointment burns nonexecutive director professor sir roy anderson nonexecutive director scientific making assessment committee consider paper medical expert appointment viehbacher detail relevant regulatory requirement relate external auditor executive director evaluate report external auditor compliance requirement external auditor provide non audit service committee ensure auditor objectivity independence safeguard policy require preapproval audit committee service service include audit service auditrelated service tax service service preapproval detailed particular service category service subject specific budget gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue follow recommendation committee stephanie burns committee member select relevant appoint nonexecutive director february expertise contribute committee activity professor sir roy anderson october professor sir roy anderson committee member sir christopher gent chairman burns appoint board scientificmedical expert sir ian prosser podolsky swaan committee support company secretary attend committee recruit nonexecutive director committee consider meeting ceo general counsel senior vice president particular skill knowledge experience benefit corporate communication community partnership board significantly appointment broad selection head corporate responsibility attend meeting criterion focus achieve balance chairman report board committee activity representation european market individual ceo experience skill develop year committee review gsk activity number sector speciality particular focus place responsibility area include access medicine community recruit nonexecutive scientific medical expertise partnership reputation management human right supply nonexecutive ceo experience usa professional chain efficiency manufacturing process climate change search agency engage specialise recruitment high risk management process transparency clinical trial datum calibre nonexecutive director dossier potential nonexecutive inform consent procedure clinical trial financial interaction appointee provide committee candidate short health care professional animal research testing ethic list interview consider relevant qualification compliance initiative policy violation discipline use social medium tool employment practice customise induction process conduct new nonexecutive director focus particular experience committee meet time meeting take account different background process includes attend committee member meet member cet senior executive visit gsk corporate responsibility report access particular operational facility group website appoint new executive director cet members committee consider skill knowledge experience require combine code particular executive position committee consider company comply code provision potential external internal candidate recommend combined code follow board approve new appointment new director offer election company agm design scheme performancerelate remuneration appointment announce publicly remuneration committee follow provision schedule code item schedule state general end committee recommend appointment basic salary pensionable company position podolsky audit committee appointment sir explain remuneration report page christopher gent remuneration committee effect january law regulation committee recommend appointment burn number provision law regulation apply gsk corporate responsibility committee december company share quote new york stock committee meet time member exchange nyse form adss present meeting schmitz unable nyse rule attend meeting general nyse rules permit company follow corporate remuneration report governance practice instead apply usa provide remuneration report find page company explain significant variation explanation company website nyse rule come effect corporate responsibility committee report require company file annual interim write affirmation main responsibility corporate responsibility committee concern audit committee company statement review gsk policy practice anticipate significant difference corporate governance manage external issue potential impact seriously group business reputation committee term sarbanesoxley act reference approve board publish follow number corporate accounting scandal gsk website usa congress pass sarbanesoxley act sarbanesoxley sarbanesoxley wide range piece committee meet time year rolling legislation concern largely financial reporting agenda ensure progress meeting gsk corporate corporate governance responsibility principle review appropriate basis principle access medicine standard ethical conduct recommend security exchange commission sec research innovation global community partnership gsk establish disclosure committee committee report review annually principle discuss ceo cfo audit committee chair year committee review approve annual company secretary member consist senior manager corporate responsibility report committee receive regular finance legal compliance corporate communication report member cet senior manager investor relation cover key corporate responsibility area gsk gsk annual report srotcerid eht troper ecnanrevog etaroproccorporate governance continue external legal counsel external auditor invite attend meeting periodically responsibility consider materiality information timely basis determine disclosure information responsibility timely filing report sec formal review annual report form committee meet time sarbanesoxley require annual report contain statement member company audit committee audit committee financial expert explanation detail basis board judgement matter refer additional disclosure requirement arise section section respect disclosure control procedure internal control financial reporting section corporate responsibility financial report sarbanesoxley introduce requirement ceo cfo complete formal certification confirm hey review annual report form ased knowledge contain material misstatement omission base knowledge financial statement financial information fairly present material respect financial condition result operation cash flow date period present annual report form responsible establish maintain disclosure control procedure ensure material information known evaluated effectiveness control procedure yearend result evaluation contain annual report form responsible establish maintain internal control financial reporting provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle disclose annual report form change internal control financial reporting period cover annual report form materially affect reasonably likely affect materially company internal control financial reporting disclose base recent evaluation internal control financial report external auditor audit committee significant deficiency material weakness design operation internal control financial reporting reasonably likely affect adversely company ability record process summarise report financial information fraud regardless materiality involve person significant role company internal control financial reporting group carry evaluation supervision participation group management include ceo cfo effectiveness design operation group disclosure control procedure december gsk annual report srotcerid eht troper ecnanrevog etaroproc inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective ceo cfo expect complete certification report conclusion effectiveness disclosure control procedure february follow certificate file sec group form section management annual report internal control financial reporting accordance requirement section sarbane oxley follow report provide management respect company internal control financial reporting define rule securities exchange act management responsible establish maintain adequate internal control financial reporting group internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance ifrs management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organisation treadway commission change group internal control financial reporting materially affect reasonably likely affect materially group internal control financial reporting management assess effectiveness internal control financial reporting december conclusion file group form pricewaterhousecooper llp audit consolidated financial statement group year end december assess effectiveness group internal control financial reporting auditing standard public company accounting oversight board united states audit report file group form fgsk annual report srotcerid eht troper troper noitarenumer remuneration report remuneration report set remuneration policy operate gsk respect director corporate executive team cet member disclosure director remuneration include require director remuneration report regulation regulation accordance regulation follow section remuneration report subject audit annual remuneration nonexecutive director remuneration share option incentive plan performance criterion performance share plan share option pension opinion thereon express remaining section subject audit page refer audit section report submit shareholder board approval annual general meeting reference notice annual general meeting remuneration report executive director cet member refer executive reference glaxosmithkline share adss mean respectively ordinary share glaxosmithkline plc american depository share glaxosmithkline plc ad represent glaxosmithkline share introduction remuneration policy executive director term condition remuneration nonexecutive director term condition fee director senior management remuneration annual remuneration nonexecutive director remuneration director interest share option incentive plan pension director senior management director interest contract remuneration report introduction quorate meeting hold year approve formal grant share option performance share awards remuneration committee committee responsible accordance gsk remuneration policy making recommendation board company remuneration policy term agree policy exception bicknell company secretary employee determine total individual remuneration package company involved conduct committee executive meeting garnier ceo phelan senior vice president human resource invite attend meeting glaxosmithkline remuneration policy design establish committee require framework remuneration consistent company scale scope operation meet recruitment need deloitte touche llp deloitte appoint committee business closely align shareholder guideline provide independent advice executive remuneration december company second large deloitte provide consulting service gsk year pharmaceutical company world revenue operation provide advice executive remuneration matter continent product sell country committee approximately sale generate usa tower perrin provide market datum datum analysis appropriateness gsk remuneration policy keep committee review remuneration committee ongoing commitment committee commence process reassess remuneration policy remuneration policy ensure continue support future direction business company announce principle appointment new ceo effective dialogue remuneration policy gsk design secure begin purpose review alignment outstanding executive talent provide pay performance remuneration structure new business priority set performance transparent robust new ceo lead change consider come governance structure year chairman committee continue regular committee determine gsk remuneration policy dialogue institutional investor gsk remuneration base follow key principle policy material change policy discuss major shareholder disclose remuneration report remuneration structure support need business competitive market place remainder report set gsk current shareholder guideline follow maximum extent remuneration policy consistent need business company remuneration committee maintain regular dialogue shareholder sir robert wilson chairman committee global pharmaceutical company primary pay sir crispin davis culp sir christopher gent comparator group schmitz members committee performance condition base measurable board deem members committee independent delivery strong financial performance delivery nonexecutive director accordance combine code superior return shareholder compare exception chairman company sir christopher gent pharmaceutical company independent appointment company high proportion total remuneration opportunity base performancerelate remuneration deliver committee meet time member medium long term attending follow remuneration determined project value number meeting number meeting method benchmarking hold whilst attend committee member committee member remuneration structure executive director cet performance condition apply sir robert wilson equally longterm incentive awards culp exgratia payment sir crispin davis pay structure simple consistent sir christopher gent business need schmitz overall policy intend provide median total remuneration meeting item committee consider median performance opportunity earn upper term service remuneration level new executive quartile total remuneration exceptional performance poor appointment competitiveness company total performance result total remuneration significantly reward package include level annual longterm pay comparator group median incentive opportunity strong alignment performance demonstrably policy aspect discuss chairman interest shareholder provide executive chairman committee annual meeting unambiguous signal importance deliver success institutional investor company shareholder gsk annual report srotcerid eht troper troper noitarenumerremuneration report continue commitment performance line expectation total remuneration committee apply policy consistent transparent target median pay comparator group way significant change measure assess longterm incentive opportunity set way provide performance discuss shareholder use position total remuneration median group comparator pay benchmarke committee use valuation method discretion ensure remuneration level reasonable project value method benchmark total remuneration believe change cause concern method project future value remuneration package shareholder position discuss shareholder prior different performance scenario method take implementation assessment pay comparator group incentive policy pay performance comparator year moderate impact market fluctuation follow table set company pay short term strengthen focus performance performance comparison committee use project value method pay market benchmarking purpose enable comparison package capitalisation company country different structural characteristic provide insight value gear different equity instrument abbott laboratories usa individual element remuneration amgen usa balance fix base salary variable annual astrazeneca bonus longterm incentive element remuneration change bristolmyers squibb usa performance chart show anticipate normal eli lilly usa range mix fix variable pay different level glaxosmithkline performance heslop slaoui year johnson johnson usa range higher low depend performance merck usa company individual novartis switzerland pfizer usa roche holdings switzerland sanofiaventis france scheringplough usa takeda pharmaceutical company japan wyeth usa include performance comparison benchmarking base salary benchmarking purpose total remuneration incorporate base salary set reference median relevant base salary annual bonus longterm incentive market executive pharmaceutical pay comparator set pay committee regard executive group actual salary level review annually influence pension arrangement executive experience responsibility market value global pharmaceutical industry primary pay change usually effect april comparator executive appropriate marketplace table set current base salary company senior executive talent effect april instance pay benchmarke publicly available base salary percentage base salary remuneration datum company provide additional april increase april context reference tower perrin annual global garni pharmaceutical pay survey pharmaceutical human resource heslop association phra ensure global pharmaceutical industry slaoui benchmark subject scrutiny review committee regularly consider pay datum global business primarily garni retire board consumer manufacturing sector hese base salary increase reflect committee assessment performance respective role appointment prior determine annual longterm incentive opportunity witty viehbacher appoint board committee consider range payout level effect january salary time achieve base different assumption share price growth respectively performance level etc gsk annual report srotcerid eht troper troper noitarenumer base salary annual bonus longterm incentive gsk annual report srotcerid eht troper troper noitarenumer remuneration report continue annual bonus committee consider performance share provide strong annual cash bonus determine basis formal alignment shareholder interest remuneration review annual performance stretch financial target policy place great emphasis use performance share base profit interest tax subject detailed lti award determine ontarget performance assessment individual business unit group achievement half lti reward derive objective bonus payable financial performance performance share target maximum annual cash bonus annual grant lti award plan consistent executive earn base solely corporate performance practice pay comparator group lead approximately twothirds maximum bonus opportunity company lti awards cet provide basis individual performance objective increase decrease executive director level annual lti opportunity bonus level factor range zero bonus consider carefully yearonyear committee context subject upper limit executive market practice gsk policy market position ceo range base salary ceo performance period start january year award maximum bonus opportunity january award february aim remuneration policy deliver annual cash performance share share option deliver resident remuneration line median pay comparator group executive form adss award deliver form ontarget business performance ordinary share executive resident country case ceo bonus target set board award plan incorporate dilution limit set objective ceo board take account consistent guideline provide association british strategy develop company set insurers national association pension fund annual report shareholder representative body current estimate dilution exist award gsk employee share scheme reason commercial sensitivity specific objective set merger approximately company share capital strategic business driver set december keep confidential follow end financial year board review ceo performance generally set performance share objective committee determine bonus payable executive level performance share vest base executive ceo make recommendation company total shareholder return tsr relative committee performance level achieve performance comparator group threeyear objective recommendation consider measurement period tsr choose appropriate committee determine resultant bonus comparative measure focus return shareholder wellunderstood test mechanism measure performance objective set focus particular allow comparison company operate continued development launch latestage pipeline asset different country delivery commercial plan acceleration operational excellence programme tsr measure sterling performance period represent change value share bonus measure employee include slaoui link value reinveste dividend pay order remove impact pipeline robust governance structure establish vary tax treatment dividend different jurisdiction ensure bonus payable fairly reflect productivity dividend reinveste gross performance profit target committee review new arrangement follow year implementation table set performance share award agree continue establish february disclosure remuneration report committee take account company success achieve market price objective individual executive performance executive director performance share award date grant determine bonus award garnier look forward order drive necessary change witty shares business committee set additional target associate heslop share bonus achievement specific operational goal slaoui adss incremental bonus form gsk share defer viehbacher adss period exceed salary garni retire board longterm incentive gsk rank median performance comparator group executive eligible annual longterm incentive lti awards share vest ranking point result remuneration policy provide normally share vest gsk company performance share award share option award share vest determine vest level committee regard company underlie financial performanceremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer graph set vest schedule award set eps target committee consider prior executive base performance comparator grant company internal projection analyst forecast group comprise company exclude gsk gsk tsr gsk ep performance analyst forecast performance fall company vest increase pharmaceutical industry straightline basis extensive careful consideration committee agree annualise growth eps achieve vest share option award grant february rpi follow key principle govern use ep performance measure adjustment consider major item adjustment judgement committee purpose adjustment ensure performance measurement fair reasonable participant shareholder discretion exercise committee disclose shareholder annual report committee set basis decision consider appropriate significant adjustment table set share option award february disclosure remuneration report provide close link shareholder return payment executive notional dividend reinveste pay executive director share option award option price proportion vest award receipt dividend garnier incorporated benchmarking award level witty share addition performance share earn executive heslop share sell meet relate tax liability year slaoui adss follow end performance period viehbacher adss performance share plan award grant executive director garni retire board exclude slaoui december performance period start january end december share option grant executive vest increase vested gsk relative tsr performance straightline basis ep performance hurdle set place company median comparator group follow graph award senior executive include slaoui dependent tsr performance ep performance tsr portion vest eps portion vest vest table performance share award grant give share option share option allow holder buy share future date share price prevail time grant share option grant manager gsk include executive vest share option grant executive link achievement compound annual eps growth performance period ep measure constant exchange rate cer gsk practice measure performance cer basis committee consider eps key measure performance business fully reflect business measure extend group ensure organisational alignment egatnecrep gnitsev gsk tsr rank maximum threshold median rpi egatnecrep gnitsev eps target exceptional superior baseline threshold rpi rpi rpi paremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer performance condition substantially consistent share ownership requirement shareholder guideline expectation demand align interest executive shareholder compare operate global pharmaceutical executive require build significant holding share company consistent policy provide pay glaxosmithkline maintain requirement performance performance important align interest executive shareholder ceo require acquire share value time base performance measure period financial year salary year appointment executive director performance period start year award base year require build shareholding value time base salary precede financial year performance reteste member cet require build shareholding value performance condition meet threeyear period time base salary executive group option lapse require build shareholding value time base salary share option grant vested require confirm hold audit kpmg annual basis individual recruit promote new pension shareholding requirement expect meet year executive participate glaxosmithkline senior executive pension plan pension arrangement structure accordance share qualify share ownership requirement plan operate executive country hold personally executive spouse executive likely retire detail individual arrangement spouse employ gsk subject executive director set response requirement minor child earn defer new pension regime committee carefully consider share programme operate company impact change legislation decide follow unexercised share option include calculation company continue fulfil obligation exist december garnier hold adss pension arrangement slaouis adss heslops ordinary compensation provide participant adversely share garnier hold excess share ownership affect new pension regime requirement heslop december slaoui december build holding value gsk pension policy executive times base salary ewly employ executive benefit company contribution executive require continue satisfy shareholde base pay define contribution plan requirement minimum month follow retirement opportunity receive company match contribution egacy final salary plan provide twothird final salary remuneration element age grandfathere exist employee new executive participate legacy glaxo wellcome entrant allow smithkline beecham allemployee share plan cap employee benefit excess cap currently usa glaxosmithkline plan replace provide unfunded arrangement sharesave plan sharereward plan revenue nder legacy final salary plan actuarial reduction factor apply custom approve plan open employee participant leave employment accord term witty heslop member sharesave plan age effectively spread value pension earn contribute month provide long life expectancy employment terminate option buy share end threeyear saving period company redundancy reduction factor apply line opportunity available employees usa gsk operate cash balance plan provide witty heslop contribute month buy annual contribution interest sum accumulate share sharereward plan company match cash balance plan contractual promise provide specific number share buy month level retirement income executive receive benefit include healthcare effect january company introduce medical dental personal financial advice life assurance executive pension credit cash balance plan senior cash value benefit receive executive director executive contribution rate plan range show base salary senior executive eligible new executive pension credit garnier provision february company conditional award grandfathere light anticipate retirement adss viehbacher award vest tranche subject continued employment gsk committee cap employee usa benefit cap assessment performance vest period adss provide unfunded nonqualified plan vest december balance vest december number adss adjust reflect dividend accrue period award vest extent adss vestremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer executive director term condition addition retirement garnier entitle receive remuneration year worth pension contribution termination executive director contract term garnier retirement accordance policy set provide framework contract contractual entitlement executive director appoint follow table set detail executive director service contract aspect policy current director date contract effective date expiry date notice period calendar month termination garnier employ company witty executive heslop slaoui termination payment annual salary viehbacher annual ontarget bonus garni retire board mitigation require termination payment respect vest longterm rule relevant equity incentive notice period extend contract expiry date incentive plan individual pension arrangement pension base exist arrangement individual pension arrangement executive director refer term relevant pension plan noncompete clause month termination entitlement notice date addition contractual provision outline event executive director service agreement terminate garnier target bonus salary slaouis salary employ company follow apply heslop salary review level severance payment committee consider investor department business enterprise regulatory case outstanding awards glaxosmithkline annual reform guidance determine line competitive practice investment plan provide agreement terminate appropriate provide payment salary target bonus termination cause defer income gain imposition month noncompete period executive consider automatically distribute soon administratively practicable vitally important company order protect group intellectual property light noncompete clause competitor practice committee believe termination resign retire termination appropriate provide mitigation contract cause defer distribute end minimum threeyear deferral period approve shareholder glaxosmithkline glaxo wellcome smithkline beecham appropriate line policy applicable senior executive garni garnier agree change previous contractual entitle receive continue medical dental insurance term compensation come broadly line new slaoui viehbacher member plan contractual framework include reduction contractual notice eligible future date receive continue medical period calendar month order honour dental cover retirement certain aspect previous contractual term number follow merger participant legacy share individual feature retain option scheme elect exchange legacy option retain individual feature include entitlement option glaxosmithkline share receive additional cash reimbursement excise tax change control relate payment benefit equal grant price original option life insurance benefit fund company age additional benefit trigger new option exercise lapse qualify additional cash benefit participant relation lti awards subject performance testing retain option second anniversary share option performance share award grant effective date merger month termination notice date lapse termination company cause retirement outside appointment executive director resignation good reason resignation outside appointment approve chairman elect retain director company merge behalf board company policy remuneration company result change control provide earn appointment keep individual resignation occur day anniversary executive director change control share option remain exercisable option termremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer nonexecutive director term condition fee nonexecutive director entitle compensation appointment terminate nonexecutive director glaxosmithkline service contract instead letter appointment chairman agree serve company nonexecutive director sir christopher gents letter appointment board date conclusion annual general meeting follow agree serve company anniversary appointment case extend deputy chairman december january term year mutual agreement director chairman conclusion annual general serve term long year offer meeting follow anniversary appointment reelection shareholder company aim provide extended term year mutual agreement nonexecutive director fee competitive receive annum plus allocation company equivalent size complexity share value annum chairman follow table show date initial letter appointment tsr performance graph nonexecutive director follow graph set performance company relative ftse index company constituent nonexecutive date letter performance comparator group january director appointment december graph prepare accordance professor sir roy anderson regulation indication likely vest burns award grant company incentive plan culp sir crispin davis sir deryck maughan tsr performance podolsky sir ian prosser schmitz swaan sir robert wilson fee structure nonexecutive director follow annum standard annual cash retainer fee supplemental fee senior independent director audit committee chairman scientificmedical expert chairman remuneration corporate responsibility committee glaxosmithkline total return index glaxosmithkline pharma peer return index nonexecutive director undertake ftse total return index intercontinental travel meeting meet exchange rate director senior management remuneration fee pay dollar convert rate exchange rate apply july follow table set director glaxosmithkline fee arrangement approve board plc remuneration earn interest share nonexecutive director share allocation plan glaxosmithkline plc interest share option incentive enhance link directors shareholder glaxosmithkline plan pension benefit member cet require nonexecutive director receive significant company secretary know senior management fee form share nonexecutive director participate remuneration plan executive director total fee exclude chairman pay form share aggregate remuneration interest director adss allocate share account nonexecutive director senior management provide opportunity invest balance fee share account share adss notionally award nonexecutive director allocate interest account include director interest table accumulate balance share adss notional dividend subsequently reinveste pay nonexecutive director retirement retirement nonexecutive director receive share adss cash equal value share adss date retirementremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer annual remuneration total total fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director garnier slaoui heslop nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser schmitz swaan sir robert wilson burns culp sir deryck maughan podolsky director coombe barzach sir richard syke yamada shapiro total remuneration analyse executive director nonexecutive director director total remuneration remuneration director payroll report dollar dollar amount include total base conversion sterling average exchange rate year ollowe merger order encourage employee convert nonsaving relate option hold glaxo wellcome smithkline beecham share adss option glaxosmithkline share adss employee grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse market value qualify additional cash benefit participant retain option second anniversary effective date merger year garnier receive eoi payment result exercise option grant march november february august option expire march november exercise detail option exercise give yamada receive coombe receive nil garni nonexecutive director united technologies corporation respect receive form defer stock unit include barzach receive fee glaxosmithkline france healthcare consultancy provide include fee salary lthough shapiro retired board continue member glaxosmithkline scientific advisory board receive fee form adss include fee salary burn join board nonexecutive director february professor sir roy anderson join board october fee pay director receive reimbursement expense year require separate disclosure require regulationsremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer nonexecutive director remuneration total cash sharesadss total cash sharesadss fee current nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser schmitz swaan sir robert wilson burns culp sir deryck maughan podolsky nonexecutive director shapiro total remuneration table set remuneration receive nonexecutive director glaxosmithkline include shapiros fee receive member glaxosmithkline scientific advisory board formation gsk nonexecutive director require total fee form share allocate share account pay retirement board nonexecutive director fee chairman detail take fee allocation arrangement nonexecutive director elect receive remain cash payment form share adss total value share adss date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share adss table set accumulate number share adss hold nonexecutive director relation fee receive board member december movement account year number share adss dividend nonexecutive director share arrangement elect reinveste current nonexecutive director share professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser schmitz swaan sir robert wilson adss burns culp sir deryck maughan podolsky remuneration report continue gsk annual report srotcerid eht troper troper noitarenumer director interest follow interest director connect person company show accordance list rule share adss february december january february december january footnote executive director garnier witty slaoui heslop viehbacher nonexecutive director professor sir roy anderson burns culp sir crispin davis sir christopher gent sir deryck maughan podolsky sir ian prosser schmitz swaan sir robert wilson glaxosmithkline ad represent glaxosmithkline share interest abovementione director february reflect change yearend date nclude adss purchase glaxosmithkline stock fund retirement saving plan executive supplemental saving plan nclude share purchase glaxosmithkline sharereward plan heslop totalling december december share february witty hold share plan february case burn open number share show february date join board rofessor sir roy anderson join board october share gsk date witty viehbacher join board january holding disclose date february witty hold option maximum share grant company share option scheme award maximum share company incentive plan viehbacher hold option maximum share adss grant company share option scheme award maximum adss company incentive plan witty viehbacher actual entitlement gsk share plan depend extent performance condition set time grant award meet end respective performance period nclude share adss receive fee describe nonexecutive director share allocation plan dividend receive share adss convert share adss december share option option share grant footnote date grant exercise period grant price number exercise slaoui heslop option adss grant date grant exercise period grant price number exercise garni slaoui hese detail include interest slaouis connect person employee gsk main option grant occur february vest period february february slaoui award ad option grant price heslop award share option grant price gsk annual report srotcerid eht troper troper noitarenumer remuneration report continue option outstanding december early late vesting lapse date option market price glaxosmithkline share yearend give table nominal vest date lapse date weight average garnier grant price number early latest early late market price underwater yearend vested option unvested option market price yearend vest option unvested option total ad option december nominal vest date lapse date weight average slaoui grant price number early latest early late market price underwater yearend vested option unvested option market price yearend vest option unvested option total share option december market price underwater yearend unvested option total ad option december include share option hold slaouis connect person employee gsk nominal vest date lapse date weight average heslop grant price number early latest early late market price underwater yearend vested option unvested option market price yearend vest option unvested option total share option december subsequent nominal vest date remuneration committee meet determine require performance criterion satisfy gsk grant share option executive director senior manager annual basis director hold option share option plan refer note financial statement employee share scheme director interest option company share table set grant share option respect grant year performance period option vest december performance target performance target vest status annualise growth percentage grant performance period ep ifrs award vest december vest rpi december unvested rpi rpi rpi remuneration report continue gsk annual report srotcerid eht troper troper noitarenumer table set grant share option respect grant year performance period option vest december performance target performance target vest status annualise growth percentage grant performance period ep ifrs award vest february unvested rpi february unveste rpi february unveste rpi rpi rpi grant market option exercise date number price price gain gain garnier heslop aggregate gain option exercise slaoui exercise option period december heslop exercise option eoi benefit pay garni exercise option benefit include table highest low closing price year end december glaxosmithkline share respectively high low price glaxosmithkline adss year end december respectively market price glaxosmithkline share december december glaxosmithkline ad december price february glaxosmithkline share glaxosmithkline ad incentive plan performance share plan psp award market additional garni adss vest deferred number price ad number unvested grant date market dividend unvested grant performance period grant number price gain lapse reinveste garnier hold defer performance share yearend include table increase balance relate dividend reinveste year market additional slaoui share adss vest exercise number price share number unvested grant date market dividend unvested grant performance period grant number price gain lapse reinveste market additional vest exercise number price ad number unvested grant date market dividend unvested grant performance period grant number price gain lapse reinveste include performance share hold slaouis connect person employee gsk gsk annual report srotcerid eht troper troper noitarenumer remuneration report continue incentive plan performance share plan psp award market additional heslop share vest exercise number price share number unvested grant date market dividend unvested grant performance period grant number price gain lapse reinveste psp mediumterm incentive scheme introduce term psp number share actually vest determined following end relevant threeyear measurement period dependent gsk performance period describe page performance share award previously grant annually november december prior start performance period grant grant february year performance period measurement period commence january end year december award performance period commence january subsequent award dividend reinveste performance share award executive performance period date final award dividend reinvestment calculate exdividend date term psp participant defer receipt vested award total gain vest psp award executive director psp award grant executive director exclude slaoui december performance period start january end december vest gsk relative tsr performance place company median comparator group award senior executive include slaoui dependent tsr performance ep performance tsr portion vest eps portion vest follow vest schedule apply award vest schedule award performance period tsr rank company percentage award vest median median follow vest schedule apply award vest schedule award performance period tsr rank company percentage award vest median median tsr measure prorata basis glaxosmithkline performance fall comparator level vest determined actual relative level tsr simple rank dividend treat reinvested performance periodremuneration report continue gsk annual report srotcerid eht troper troper noitarenumer share value plan awards slaoui share adss market vest exercise number price number unvested grant date market unvested grant plan year grant number price gain lapse adss adss gain disclose relate slaoui person connect capacity svp worldwide business development slaoui eligible participate share value plan slaoui connected person employee gsk receive award share value plan follow announcement appointment board february cease eligible receive award plan award subject year vest period vest contingent continue employment gsk vest additional ad vest defer dividend defer participation reinveste participation midterm incentive plan adss garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant final award adss receipt award defer director garnier defer receipt amount vested year defer award additional adss subsequently receive dividend reinvestment include director interest table retain mtip pay pension accrue annual pension benefit transfer value executive director office december retirement set regulation require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value change pension executive director disclose currency pension payable change change personal accrue transfer value accrue accrue accrue contribution transfer transfer change benefit change benefit benefit benefit value value transfer year net accrue year year value inflation benefit executive director garni slaoui heslop show net contribution individual garni member employee cash balance pension plan gsk make annual contribution calculate percentage employee base salary bonus gsk make annual contribution garniers annual salary bonus detailed contract fund increase interest rate set annually advance base year treasury bond rate provide cash sum retirement cash sum purchase pension retirement base annuity rate applicable time plan entitlement spouse pension pension increase reduce executive initial pension transfer value cash sum garnier plan increase year result accumulation interest contribution pay company garni retire company remuneration report continue gsk annual report srotcerid eht troper troper noitarenumer pension director senior management effect june slaoui member information provide compensation interest executive cash balance pension plan gsk director senior management group group make annual contribution calculate percentage purpose group define executive non executive base salary gsk make annual contribution executive director members cet company slaouis annual salary fund increase interest rate set secretary financial year total compensation annually advance base year treasury bond rate pay member group period provide cash sum retirement cash sum purchase serve capacity aggregate increase pension retirement base annuity rate applicable accrue pension benefit net inflation time plan entitlement spouse pension aggregate payment define contribution scheme pension increase reduce executive accrue year initial pension relate compensation loss office respect associate pension contribution transfer value cash sum slaouis plan increase year result accumulation member group grant interest contribution pay company share option ad option share option scheme share adss performance slaoui active participant belgium fortis plan share plan award share adss plan define benefit plan lump share value plan member group award sum payable normal retirement age plan share adss reinvestment dividend year age transfer value cash sum slaouis plan performance share plan increase year result accumulation interest february group comprise person own share adss constitute heslop participates glaxo wellcome define benefit issue share capital company group hold plan accrual rate final pensionable salary date option purchase share annum benefit accrue glaxo wellcome adss share adss award pension arrangement augment trustee performance share plan include share adss plan reflect distribution surplus augmentation vest defer vested deferred adss apply element heslops pension earning legacy smithkline beecham midterm incentive plan march share adss award share value heslops transfer value calculate basis plan holding issue executive share actuarial advice accordance actuarial guidance note option plan describe note financial statement transfer value represent present value future payment employee share scheme pension plan heslops annual accrue benefit increase exclude effect director interest contract inflation transfer value personal contribution describe note financial statement relate increase year increase heslops party transaction end financial year pensionable salary primary reason increase director connect person material interest transfer value contract significance relation group business garni slaoui member retirement group company saving plan saving scheme open employee executive supplemental saving plan saving scheme open executive accrue benefit government limit impose director remuneration report approve retirement saving plan contribution plan board director sign behalf invest range fund value accumulate fund pay retirement contribution pay scheme gsk respect garni respect slaoui contribution sir christopher gent pay scheme chairman february gsk annual report stnemetat laicnanif financial statement director statement responsibility independent auditor report financial statement consolidated income statement consolidate balance sheet consolidate cash flow statement consolidate statement recognise income expense note financial statement presentation financial statement accounting policy key accounting judgement estimate new accounting requirement exchange rate segment information restructuring cost operate income operating profit employee cost finance income finance cost associate joint venture taxation earning share dividend property plant equipment goodwill intangible asset investment associate joint venture investment noncurrent asset inventory trade receivables cash cash equivalent asset hold sale trade payable pension postemployment benefit provision noncurrent liability contingent liability net debt share capital share premium account movement equity relate party transaction reconciliation profit tax operating cash flow reconciliation net cash flow movement net debt acquisition disposal commitment post balance sheet event financial instrument relate disclosure employee share scheme principal group company legal proceeding financial statement glaxosmithkline plc prepare gaap director statement responsibility director statement responsibility relation director remuneration consolidated financial statement remuneration report page set remuneration director responsible policy operate glaxosmithkline disclosure director remuneration disclosable information relate director ensure maintenance proper accounting record officer interest prepare accordance disclose reasonable accuracy financial position group company act complie section time financial statement prepare combine code corporate governance comply company act article ias regulation go concern basis prepare financial statement financial period make enquiry director reasonable true fair view accordance ifrs adopt expectation group adequate resource continue use european union state affairs group operational existence foreseeable future reason end financial period profit loss continue adopt go concern basis prepare period financial statement ensure operation system internal control take reasonable step safeguard asset group internal control prevent detect fraud irregularity board audit committee review director confirm comply assessment risk internal control framework operate requirement prepare financial statement glaxosmithkline consider effectiveness system internal control operation group year financial statement year end december cover report date approval comprise principal statement support note set board director financial statement page report director confirm suitable accounting policy combine code consistently apply preparation financial statement board consider glaxosmithkline plc apply principle support reasonable prudent judgement estimate combine code corporate governance financial necessary reporting council describe corporate governance responsibility auditor relation financial page comply provision statement set independent auditor report describe opposite require listing rule financial service authority financial statement year end december auditor consider director statement compliance include annual report publish hard relation point combine code specify copy print form available website director review responsible maintenance integrity annual report website accordance legislation govern annual report preparation dissemination financial statement access annual report year end december website available outside comparable comprising report director remuneration report legislation different financial statement additional information investor approve board director sign behalf disclosure information auditor director office date report confirm far aware relevant audit information company auditor unaware director take step heshe ought take director himselfherself aware relevant sir christopher gent audit information establish company auditor chairman aware information february confirmation give interpret accordance provision section company act gsk annual report stnemetat laicnanif ytilibisnopser stnemetat srotceridindependent auditor report members glaxosmithkline plc audit group financial statement glaxosmithkline basis audit opinion year end december comprise primary conduct audit accordance international standard financial statement consolidated income statement audit ireland issue auditing practice board consolidate balance sheet consolidate cash flow statement audit include examination test basis evidence relevant consolidate statement recognise income expense amount disclosure group financial statement relate note group financial statement include assessment significant estimate judgement prepared accounting policy set director preparation group financial statement report separately parent company financial accounting policy appropriate group statement glaxosmithkline year end december circumstance consistently apply adequately disclose information director remuneration report plan perform audit obtain describe audit information explanation consider necessary order provide sufficient evidence reasonable respective responsibility director assurance group financial statement free material auditor misstatement cause fraud irregularity error director responsibility prepare annual report form opinion evaluate overall adequacy group financial statement accordance applicable law presentation information group financial statement international financial reporting standard ifrss adopt european union set statement director opinion responsibility opposite opinion responsibility audit group financial statement group financial statement true fair view accordance relevant legal regulatory requirement accordance ifrss adopt european union international standard audit ireland report state group affair december include opinion prepare company profit cash flow year end member body accordance section company act purpose give opinion group financial statement properly prepare accept assume responsibility purpose accordance company act article ias person report show hand come regulation save expressly agree prior consent write information give report director consistent report opinion group financial group financial statement statement true fair view group financial statement properly prepare accordance separate opinion relation ifrss company act article ias regulation report explain note group financial statement group opinion information give report addition comply legal obligation comply director consistent group financial statement ifrss adopt european union comply addition report opinion receive ifrss issue international accounting standard board information explanation require audit opinion group financial statement true fair information specify law director remuneration view accordance ifrss state group affair transaction disclose december profit cash flow year review corporate governance statement reflect end company compliance provision combine code specify review list rule financial service authority report require consider board statement internal pricewaterhousecooper llp control cover risk control form opinion charter accountant register auditor effectiveness group corporate governance procedure london risk control procedure february read information contain annual report consider consistent audit group financial statement note information comprise financial summary joint maintenance integrity glaxosmithkline website statement chairman chief executive financial trend responsibility director work carry auditor involve consideration matter accordingly auditor accept ratio business review corporate governance statement responsibility change occur financial consider implication report aware statement initially present website apparent misstatement material inconsistency legislation united kingdom govern preparation dissemination group financial statement responsibility extend financial information differ legislation jurisdiction information gsk annual report stnemetat laicnanif troper srotidua tnednepedni gsk annual report stnemetat laicnanif tnemetat emocni detadilosnoc consolidated income statement year end december business restructuring note performance cost total turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny calculation business performance supplemental nonifrs measure describe note presentation financial statementsconsolidate balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest total equity approve board february sir christopher gent chairman gsk annual report stnemetat laicnanif teehs ecnalab detadilosnoc gsk annual report stnemetat laicnanif tnemetat wofl hsac detadilosnoc consolidate cash flow statement year end december note cash flow operating activity cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment proceed sale intangible asset purchase intangible asset purchase equity investment proceed sale equity investment share transaction minority shareholder purchase business net cash acquire disposal business interest associate investment associate joint venture interest receive dividend associate joint venture net cash outflow investing activity cash flow financing activity increasedecrease liquid investment proceed share employee share option share acquire esop trust issue share capital purchase share cancellation purchase treasury share increase longterm loan repayment longterm loan net increase inrepayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder dividend pay minority interest finance cash flow net cash outflow financing activity increasedecrease cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft consolidated statement recognise income expense year end december exchange movement overseas net asset tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment exchange movement goodwill reserve actuarial gainslosse define benefit plan defer tax actuarial movement define benefit plan fair value movement cash flow hedge defer tax fair value movement cash flow hedge net profitslosse recognise directly equity profit year total recognise income expense year total recognise income expense year attributable shareholder minority interest gsk annual report stnemetat laicnanif esnepxe dna emocni desingocer tnemetat detadilosnoc gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement presentation financial statement accounting principle policy preparation financial statement conformity description business generally accept accounting principle require management glaxosmithkline major global healthcare group engage estimate assumption affect report amount creation discovery development manufacture asset liability disclosure contingent asset liability market pharmaceutical product include vaccine overthe date financial statement report amount counter otc medicine healthrelate consumer product revenue expense report period actual result gsk principal pharmaceutical product include medicine differ estimate follow therapeutic area respiratory central nervous system antiviral antibacterial metabolic vaccine cardiovascular financial statement prepare accordance urogenital antibacterial oncology emesis group accounting policy approve board describe note accounting policy information application compliance applicable law ifrs accounting policy include area estimation judgement financial statement prepare accordance give note key accounting judgement estimate company act article ias regulation group implement ifrs financial instrument international accounting standard ias international financial disclosure amend add previous disclosure relate reporting standard ifrs relate interpretation adopt financial instrument european union parent company financial statement financial statement compliance ifrs issue financial statement parent company glaxosmithkline international accounting standard board plc prepare accordance gaap composition financial statement accounting presentation company balance sheet present consolidated financial statement draw sterling functional currency glaxosmithkline plc accordance ifrs accounting presentation financial statement comprise accounting policy consolidate income statement consolidation consolidated balance sheet consolidated financial statement include consolidated cash flow statement asset liability result cash flow consolidated statement recognise income expense company subsidiary include esop trust note financial statement group share result net asset associate accounting convention joint venture financial statement prepare historical cost financial statement entity consolidate convention modify revaluation certain item state december year accounting policy entity group power govern financial financial period operating policy account subsidiary financial statement cover financial year january group ability exercise joint control entity december comparative figure financial year account joint venture group ability january december appropriate exercise significant influence account associate january december result asset liability associate joint venture composition group incorporate consolidated financial statement list subsidiary associate undertakings opinion equity method accounting director principally affect profit net interest acquire entity consolidated date asset group give note principal group company group acquire control interest sell deconsolidate presentation business performance date control cease columnar presentation adopt income transaction balance subsidiary eliminate statement order illustrate underlie business performance profit tax take sale subsidiary sale business performance supplemental nonifrs measure joint ventures associate product sell customer primary performance measure management outside group defer tax relief unrealise intragroup profit present exclude cost relate new operational account extent consider recoverable excellence programme commence october significant acquisition management believe exclusion goodwill arise acquisition interest subsidiarie joint item provide well reflection way business ventures associate represent excess acquisition manage give useful indication underlie cost group share fair value identifiable performance group information provide asset liability contingent liability acquire capitalise addition total result prepare ifrs given assist separate item case subsidiarie cost shareholder gain clear understanding underlying investment case joint venture associate goodwill performance business increase comparability denominate currency operation acquire period present cost acquisition fair value net asset acquire difference recognise directly income statementnote financial statement continue accounting policy continue research development research development expenditure charge income foreign currency translation statement period incur development foreign currency transaction book functional currency expenditure capitalise criterion recognise asset group company exchange rate ruling date meet usually regulatory filing major transaction foreign currency monetary asset liability market approval consider highly probable property plant retranslate functional currency rate exchange rule equipment research development depreciate balance sheet date exchange difference include accordance group policy income statement environmental expenditure consolidation asset liability include related goodwill environmental expenditure relate exist condition result overseas subsidiary associate joint venture translate past current operation current future sterling rate exchange rule balance sheet date benefit discernible charge income statement group result cash flow overseas subsidiary associate joint recognise liability sitebysite basis reliably venture translate sterling average rate exchange estimate liability include group portion total cost exchange adjustment arise open net asset portion potentially responsible party cost profit year retain overseas subsidiary associate probable able satisfy respective joint venture translate sterling exchange difference share cleanup obligation recovery reimbursement arise related foreign currency borrowing hedge record asset virtually certain group net investment operation take separate component equity legal dispute provision anticipate settlement cost legal translating sterling asset liability result cash dispute group outflow resource flow overseas subsidiary associate joint venture consider probable reasonable estimate reported currency hyperinflationary economy adjustment likely outcome addition provision legal reflect current price level loss net monetary expense arise claim receive dispute asset charge consolidated income statement respect product liability claim relate product revenue sufficient history claim settlement incur revenue recognise income statement good report ibnr actuarial technique determine service supply available external customer reasonable estimate group exposure unasserted claim order receive title risk loss pass customer product provision basis reliable estimate relevant deduction turnover provision unasserted claim represent net invoice value deduction discount obligation exist dispute possible allowance give accrual estimate future rebate reasonable estimate cost associate claim return methodology assumption estimate rebate group party charge income statement return monitor adjust regularly light incur contractual legal obligation historical trend past experience project market condition market condition evaluate pension postemployment benefit wholesaler thirdparty analysis market research cost provide pension define benefit scheme datum internally generate information turnover include calculate project unit credit method spread promotion income group record share revenue period benefit expect derive relate cost sale value add tax sale taxis employee service accordance advice qualify exclude revenue actuary pension obligation measure present value estimate future cash flow discount rate reflect yield expenditure high quality corporate bond expenditure recognise respect good service receive supply accordance contractual term provision pension scheme asset measure fair value balance sheet obligation exist future liability respect date actuarial gain loss difference expect past event obligation actual return asset effect change actuarial reliably estimate manufacturing startup cost validation assumption recognise statement recognise income achievement normal production expense expense year arise group contribution incur advertising promotion expenditure charge define contribution plan charge income statement income statement incur shipment cost intercompany incur transfer charge cost sale distribution cost sale cost postemployment liability calculate customer include sell general administrative similar way define benefit pension scheme spread expenditure restructuring cost recognise provide period benefit expect derive appropriate respect direct expenditure business employee service accordance advice reorganisation plan sufficiently detail qualified actuary advance appropriate communication affect undertaken gsk annual report stnemetat laicnanif stnemetat laicnanfi eht setonnote financial statement continue accounting policy continue goodwill goodwill state cost impairment goodwill deem employee share plan indefinite useful life test impairment annually incentive form share provide employee share option share award scheme fair value interest acquire entitys asset liability contingent liability exceed consideration fair value option award calculate pay excess recognise immediately gain grant date blackschole option pricing model charge income statement income statement relevant vesting period intangible asset group provide finance esop trust purchase company intangible asset state cost provision amortisation share open market meet obligation provide share impairment employee exercise option award cost run esop trust charge income statement share hold licence patent knowhow marketing right separately esop trust deduct reserve transfer acquire acquire business combination amortise reserve retain earning vest estimate useful life straightline basis period relate share option award reflect ultimate time available use estimate useful life proceed receivable employee exercise determine amortisation charge account patent live applicable value obtain period property plant equipment nonexclusivity asset life review appropriate property plant equipment ppe state cost purchase adjust annually development cost incur group construction provision depreciation impairment associate acquire licence patent knowhow marketing financing cost capitalise right write income statement incur depreciation calculate write cost residual value criterion recognition internally generate intangible asset ppe exclude freehold land straightline basis meet usually regulatory filing major expect useful life residual value life review market approval consider highly probable appropriate adjust annually normal expect useful acquire brand value independently fair value live major category ppe business acquire party brand value substantial longterm brand freehold building year sell separately rest business acquire brand leasehold land lease term year amortise estimate useful life building consider useful economic life indefinite plant machinery year fixture equipment year cost acquire develop computer software internal use internet site external use capitalise intangible disposal ppe cost relate accumulate depreciation fix asset software site support significant business impairment remove financial statement system expenditure lead creation durable asset net proceed take income statement erp system software amortise seven year lease computer software year lease agreement transfer group substantially impairment noncurrent asset benefit risks ownership asset treat finance carry value noncurrent asset review lease asset purchase outright asset impairment indication asset include ppe computer software capital element impair additionally goodwill intangible asset indefinite leasing commitment show obligation finance useful life intangible asset available use lease asset hold finance lease depreciate basis test impairment annually provision impairment consistent similar own asset lease term shorter charge income statement year concern interest element lease rental include income statement lease operating lease rental cost investment associate joint venture charge income statement straightline basis investment associate joint venture carry lease term consolidate balance sheet group share net asset date acquisition postacquisition retain profit loss goodwill arise acquisition gsk annual report stnemetat laicnanif stnemetat laicnanfi eht setonnote financial statement continue accounting policy continue taxation current tax provide amount expect pay apply availableforsale investment tax rate enact substantively enact liquid investment investment classify available balance sheet date forsale investment initially record fair value plus transaction cost remeasure subsequent reporting defer tax provide liability method date fair value unrealised gain loss availablefor temporary difference arise tax basis asset sale investment recognise directly equity impairment liability carry amount financial statement arise significant prolong decline fair value defer tax asset recognise extent probable investment reduce carrying asset directly future taxable profit available temporary charge income statement disposal impairment difference utilise investment gain loss defer defer tax provide temporary difference arise equity recycle income statement dividend equity investment subsidiary associate joint venture investment recognise income statement time reversal temporary difference group right receive payment establish equity investment control probable temporary difference record noncurrent asset expect reverse foreseeable future sell year defer tax provide rate tax enact purchase sale equity investment account substantively enact balance sheet date defer tax trade date purchase sale availableforsale liability asset discount investment account settlement date derivative financial instrument hedge inventory derivative financial instrument manage exposure inventory include financial statement low market risk treasury operation principal derivative cost include raw material direct labour direct cost instrument glaxosmithkline foreign currency swap relate production overhead net realisable value cost interest rate swap forward foreign exchange contract generally determine basis prelaunch inventory group hold issue derivative financial instrument hold asset high probability regulatory trading speculative purpose approval product point provision carry value recoverable provision derivative financial instrument classify heldfortrading reverse point high probability regulatory carry balance sheet fair value derivative designate approval determine hedging instrument classify inception cash flow hedge net investment hedge fair value hedge trade receivable trade receivables carry original invoice change fair value derivative designate cash flow provision doubtful debt provision hedge recognise equity extent hedge evidence risk nonpayment take account age effective ineffective portion recognise profit loss previous experience general economic condition immediately amount defer equity recycle income trade receivable determine uncollectable write statement hedge item affect profit loss firstly provision available income net investment hedge account similar way cash statement subsequent recovery amount previously provide flow hedge credit income statement longterm receivable discount effect material change fair value derivative designate fair value hedge record income statement trade payable change fair value hedge asset liability trade payable hold amortise cost equate nominal value longterm payable discount effect change fair value derivative instrument material qualify hedge accounting recognise immediately income statement cash cash equivalent cash cash equivalent comprise cash hand current balance discount bank similar institution highly liquid investment time effect money material balance discount original maturity month readily current value appropriate rate interest unwind convertible know amount cash insignificant discount record finance incomecost risk change value gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue key accounting judgement estimate company director take legal advice establish provision take account relevant fact prepare financial statement management require circumstance matter accordance accounting estimate assumption affect amount asset requirement provision product liability claim certain liability revenue expense report financial statement product incur report basis actual amount result differ estimate sufficient history claim settlement available follow consider key accounting judgement estimate provision unasserted claim claim reasonable estimate likely outcome turnover ultimate liability pende unasserted claim revenue recognise title risk loss pass vary amount provide dependent customer reliable estimate relevant deduction outcome litigation proceeding investigation possible gross turnover reduce rebate discount allowance settlement negotiation product return give expect give vary product arrangement buy group arrangement property plant equipment purchasing organisation dependent submission carry value property plant equipment review claim time initial recognition sale accrual impairment indication value time sale estimate rebate discount asset impaired impairment determine reference allowance payable return base available high fair value cost sell value use measure market information historical experience amount assess riskadjuste future cash flow discount appropriate estimate fully reflect final outcome interest rate future cash flow base business forecast amount subject change dependent inherently judgemental future event cause thing type buy group product sale mix level assumption impairment review change accrual review adjust regularly light contractual consequent adverse effect future result group legal obligation historical trend past experience project intangible asset market condition market condition evaluate wholesaler intangible asset acquire gsk party thirdparty analysis market research datum internally cost acquisition capitalise licence compound generate information future event cause assumption development amortise point accrual base change affect available use estimate useful life future result group include period nonexclusivity estimate useful life review group copromote product party record annually impairment test undertake event occur sale group record share revenue copromotion question carry value asset brand acquire income turnover nature copromotion activity business capitalise independently group record cost sale pharmaceutical turnover separable expect life year brand include copromotion revenue million million amortise estimate useful life exceed million year end useful economic life foresee brand amortise subject taxation annual impairment test impairment test base riskadjuste current tax provide amount expect pay future cash flow discount appropriate interest rate defer tax provide temporary difference future cash flow base business forecast tax basis asset liability carry amount inherently judgemental future event cause value rate enact substantively enact intangible asset impair adverse balance sheet date effect future result group group open tax issue number revenue authority pension postemployment benefit gsk use good advice determine transfer pricing cost provide pension postemployment benefit methodology seek manage transfer pricing issue charge income statement accordance ia satisfactory conclusion basis external professional period benefit derive employee advice continue believe adequate provision service cost assess accordance advice receive liability likely arise open assessment open issue independent actuary basis assumption select exist ultimate liability matter vary amount management assumption include future earning provide dependent outcome negotiation pension increase discount rate expect long term rate relevant tax authority necessary litigation proceeding return asset disclose note pension legal dispute postemployment benefit expect long term rate return gsk provide anticipate settlement cost reasonable bond determine base portfolio mix indexlinke estimate likely outcome dispute legal government corporate bond equity risk premium add expense arise claim group equitiesnote financial statement continue key accounting judgement estimate continue ifrs revise business combination issue january apply business combination arise january discount rate base appropriate longterm index include change new standard require iboxx year index moodys index recognition subsequent change fair value contingent usa sensitivity analysis provide note pension consideration income statement goodwill postemployment benefit reduction transaction cost recognise immediately income discount rate lead increase net pension statement fair value gain loss exist investment deficit approximately million increase annual acquire company recognise income statement pension cost approximately million selection different date acquisition assumption affect future result group ias revise consolidated separate financial statement new accounting requirement issue january implement time ifrs revise respect transaction non follow ifrs ifric interpretation issue control interest group entity result change iasb likely affect future annual report control revise standard require difference expect material impact result financial position consideration pay receive record noncontrolle group interest recognise equity case divestment ifric ifrs group treasury share transaction issue subsidiary retain interest remeasure fair value november require implement gsk difference fair value previous carrying value january interpretation provide guidance recognise immediately income statement sharebase transaction involve group entity ifrs revise ias revise apply prospectively account equity settle cash settle transaction transaction occur implementation date ifric ias limit define benefit asset minimum possible assess advance impact financial funding requirement interaction issue july statement group effective january interpretation exchange rate provide general guidance pension surplus recognise asset group use average exchange rate prevail period translate result cash flow overseas subsidiary ifrs operating segment issue november joint venture associate undertaking sterling period require implement gsk january end rate translate net asset undertaking standard replace ia align segmental reporting currency influence translation relevant requirement equivalent standard new exchange rate standard adopt management approach segmental information disclose basis internal reporting purpose average rate ia revise borrowing cost issue march euro implement prospectively january require yen borrowing cost attributable acquisition construction certain asset capitalise option currently take gsk period end rate expense cost incur long available euro ias revise presentation financial statement issue yen september effective january amendment standard mandate presentation format disclosure adopt gsk movement equity present statement change equity note financial statement amendment ifrs sharebase payment relate vest condition cancellation issue january amendment apply retrospectively january specifies cancellation sharebase payment arrangement include employee counterparty receive accounting treatment require immediate recognition income statement charge recognise remainder service period gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue segment information group primary segment report business sector geographical report secondary format business sector consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oral care otc medicine nutritional healthcare geographical sectors usa europe international rest world market reflect group significant regional market consistent group regional market management reporting structure business sector datum include allocation corporate cost sector appropriate basis sale business sector group activity organise global basis geographical sector figure influence location group operate resource particular manufacturing research variation time intragroup trading funding arrangement turnover show business sector location customer location subsidiary operating profit show business sector location subsidiary geographic information give location subsidiary turnover business sector pharmaceutical consumer healthcare turnover profit business sector pharmaceutical consumer healthcare operate profit finance income finance cost share tax profit associate joint ventures pharmaceutical consumer healthcare profit taxation taxation profit taxation year investment associate joint venture business sector pharmaceutical consumer healthcare investment associate joint venture property plant equipment intangible asset business sector addition pharmaceutical consumer healthcare total addition depreciationamortisation pharmaceutical consumer healthcare total depreciationamortisation impairment pharmaceutical consumer healthcare total impairment impairment reversal pharmaceutical consumer healthcare total impairment reversal note financial statement continue segment information continue total asset business sector pharmaceutical consumer healthcare total operating asset investment associate joint venture liquid investment derivative financial instrument cash cash equivalent current defer taxation tangible asset hold sale total asset total liability business sector pharmaceutical consumer healthcare total operating liability shortterm borrowing longterm borrowing derivative financial instrument current defer taxation total liability net asset business sector pharmaceutical consumer healthcare net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation tangible asset hold sale net asset turnover location customer usa europe international turnover gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue segment information continue turnover location subsidiary undertaking usa europe international turnover include intersegment turnover usa europe international intersegment turnover usa europe international external turnover operate profit location subsidiary undertaking usa europe international operating profit property plant equipment intangible asset addition location usa europe international total addition total asset location usa europe international intersegment trading balances total operating asset gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue segment information continue net operating asset location usa europe international net operating asset segment include group europe market region turnover location customer turnover include intersegment turnover intersegment turnover turnover location subsidiary noncurrent asset gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue restructuring cost gsk undertake significant new operational excellence programme improve effectiveness productivity operation programme expect deliver total annual pretax saving million saving realise business manufacturing gsk reduce overall number site operate network simplify process site activity reduce capacity group continue seek opportunity outsource manufacture exist product lowcost source material whilst focus capability new product gsk conduct sale force pilot initiative assess new sale structure sell technique result initiative provide gsk new opportunity evolve traditional selling method competitively include adopt tailor customise sale approach develop emerge market gsk continue invest development promising latestage pipeline increase investment key area future growth biopharmaceutical oncology vaccine neuroscience emerge market china cost saving focus simplification streamline support infrastructure total oneoff cost implementation new programme expect approximately billion incur period addition december gsk acquire reliant pharmaceuticals inc usa rationalisation restructuring programme initiate integration reliant pharmaceutical group cost incur programme asset staff impairment reduction total cost sale sell general administration research development effect profit taxation effect taxation effect earning restructuring cost report middle column income statement operate income royalty milestone income impairment equity investment disposal equity investment disposal asset legal settlement fair value adjustment derivative financial instrument income royalty milestone income principally core recur income outlicense intellectual property fair value adjustment derivative financial instrument include movement quest collar theravance optionsnote financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment amortisation intangible asset net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor audit parent company consolidated financial statement fee payable company auditor associate service reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration fee payable company auditor associate service audit account group overseas subsidiary relate pension scheme company pursuant legislation assurance service pursuant legislation tax service service include regulatory compliance treasury relate service december pricewaterhousecooper llp associate fee invoice million comprise statutory audit million taxation service million service million fee respect glaxosmithkline pension scheme include audit service gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet company secretary aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables realise gain liquid investment fair value adjustment derivative fair value profit loss net investment hedge ineffectiveness unwind discount asset derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest income arise derivative fair value profit loss relate swap interest incomenote financial statement continue finance cost interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value adjustment derivative designate hedge instrument fair value adjustment hedge item fair value adjustment derivative fair value profit loss unwind discount provision derivative fair value profit loss designate effective hedging instrument classify heldfortrade financial instrument ia associates joint ventures associate share tax profit quest diagnostic inc share tax loss associate share tax profitslosse joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover total profit gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue taxation taxation charge base profit year corporation tax statutory rate double taxation relief overseas taxation current taxation defer taxation reconciliation taxation rate group profit statutory rate taxation overseas taxis benefit special tax status credit intercompany stock profit impact share base payment tax profit associate difference prior year item restructure tax rate group operate country tax rate differ tax rate impact overseas taxis company overall rate tax show profit arise certain operation singapore puerto rico ireland accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice gaap result difference accounting treatment group tax rate ifrs decrease decrease increase result change workinprogress finished good integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue continue fact life gsk group main open tax issue canada japan gsk continue dispute hmrc primarily respect transfer pricing control foreign company cfc matter year date hmrc formalise claim respect matter gsk seek resolve discussion hmrc continue wide difference group hmrc position ultimately need settle litigation follow audit period irs notice propose adjustment challenge deduction arise intercompany financing arrangement year gsk disagree vigorously cont gsk estimate irs claim tax interest december net federal tax relief year million gsk believe support external professional advice claim merit adjustment warrant contrary gsk view irs prevail argument court company expect additional liability year unaudite period proportionate liability year audit period event company able resolve issue irs court decision expect low court japan uphold claim tax authority yen billion million relate japanese cfc legislation company pay fully provide tax pursuing claim refund japanese supreme court canada court hearing respect transfer pricing early complete july gsk await court judgementgsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue taxation continue gsk use good advice determine transfer pricing methodology seek manage transfer pricing taxation issue satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment ultimate liability matter vary amount provide dependent outcome litigation proceeding negotiation relevant tax authority provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain december require way incremental tax arise aggregate unremitte profit balance sheet date approximately billion billion payable recoverable net movement current tax account january exchange adjustment charge year cash pay transfer tofrom defer tax movement december movement defer tax asset liability pension manu share accelerate intra post legal facture stock option net offset defer taxation capital group retirement tax restruct valuation award temporary allowance intangible profit benefit loss dispute ure adjustment scheme difference country total assetliability defer tax asset january defer tax liability january january exchange adjustment creditcharge income statement creditcharge equity transfer tofrom current tax acquisition december defer tax asset december defer tax liability december defer tax credit income relate change tax rate million defer tax movement arise origination reversal temporary difference net temporary difference include accrue expense provision december group recognise defer tax asset million million respect income tax loss approximately million million loss million million expire million nil expire million million expire million million available indefinitely december group recognise defer tax asset respect income tax loss approximately million million million million expire million million expire million million available indefinitely group capital loss december approximately billion respect defer tax asset recognise substantial income tax capital loss subject agreement relevant tax authority defer tax asset recognise probable future taxable profit available utilise loss gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue earning share pence pence pence basic earning share adjustment restructuring cost business performance earning share basic diluted earning share adjustment restructuring cost business performance earning share dilute basic adjust earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share adjust earning share calculate business performance earning calculation business performance supplemental nonifrs measure describe note presentation financial statement dilute earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option dilute share hold esop trust exclude trustee waive right dividend share hold esop trust dividend interim second interim interim fourth interim total total dividend dividend share penny paidpayable july october january april total dividend dividend share penny pay july october january april total dividend dividend share penny pay july october january april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination disposals writeoff reclassification transfer asset hold sale cost december exchange adjustment addition addition business combination disposals writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation december exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment impairment december exchange adjustment disposal writeoff impairment loss reversal impairment impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december net book value december group land building comprise freehold property million million property lease year million million property lease year million million gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue property plant equipment continue include land building december lease asset cost million million accumulate depreciation million million net book value million million include plant equipment vehicle december lease asset cost million million accumulate depreciation million million net book value million january million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost sell value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital adjust appropriate country specific risk impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate impairment loss charge cost sale million million sga million reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale principal component reversal relate suzhou pharmaceutical manufacturing facility plan withdrawal manufacturing key product terminate recoverable calculate apply value use calculation discount rate goodwill cost january exchange adjustment addition business combination impairment cost december net book value january net book value december addition year comprise million acquisition reliant pharmaceuticals inc million acquisition domantis limited million acquisition praecis pharmaceuticals inc note acquisition disposal detail impairment year million relate europharm business locate romania determine fair value cost sell model carry value goodwill balance arise acquisition follow company biomedical corporation reliant pharmaceuticals inc domantis limited cns inc glaxosmithkline polfa poznan corixa corporation goodwill allocate cash generating unit test impairment annually recoverable amount cash generating unit assess value use fair value cost sell model depend nature unit value use calculate net present value project riskadjusted fiveyear posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate base group weight average cost capital adjust appropriate country specific risk apply calculate net present value posttax cash flow indicate recoverable value unit close carrying value impairment test reperforme pretax discount rate pretax cash flow order determine impairment exist establish magnitude fair value calculate discount cash flow approach case base group acquisition valuation model posttax discount rate base group weight average cost capital apply adjust appropriate country specific risk rate apply project riskadjuste posttax cash flowsgsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue goodwill continue cash generating unit carry goodwill allocate unit significant comparison total goodwill balance vaccine consumer healthcare pharmaceuticals worldwide pharmaceutical japan poland total goodwill million million principally relate acquisition biomedical corixa allocate vaccine unit recoverable value unit determine fair value cost sell model goodwill arise acquisition minority interest glaxosmithkine million million acquisition polfa poznan million million allocate japan poland cash generating unit respectively recoverable value unit determine value use model goodwill arise acquisition cns inc december allocate consumer healthcare cash generating unit domantis limited research operation goodwill arise acquisition allocate worldwide pharmaceutical cash generating unit goodwill arise acquisition reliant pharmaceuticals inc december allocate pharmaceutical cash generating unit intangible asset computer licence amortise indefinite life software patent etc brand brand total cost january exchange adjustment addition addition business combination disposal asset writeoff cost december exchange adjustment addition addition business combination disposal asset writeoff transfer asset hold sale cost december amortisation january exchange adjustment provision year disposal asset writeoff amortisation december exchange adjustment provision year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss disposal asset writeoff impairment december exchange adjustment impairment loss disposal asset writeoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue intangible asset continue amortisation impairment charge income statement follow amortisation impairment cost sale sell general administration research development total amortisation impairment addition business combination year million include million respect lovaza acquire acquisition reliant pharmaceutical note acquisition disposal include addition internally generate cost million million relate computer software million nil relate intangible asset december net book value include million million internally generate cost million million relate computer software million nil relate intangible asset amortise brand include otc right relate alli acquire roche million million indefinite life brand comprise portfolio product acquire acquisition sterling winthrop inc block drug company inc cns inc book value major brand follow panadol sensodyne breathe right polident corega poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment apply fair value cost sell methodology year posttax cash flow forecast terminal value calculation discount rate equal group posttax weight average cost capital adjust appropriate countryspecific risk main assumption include future sale price volume product contribution future expenditure require maintain product marketability registration relevant jurisdiction product useful economic life assumption review management budget strategic planning cycle change market condition sale erosion competition investment associate joint venture joint associated venture undertaking total total january exchange adjustment addition fair value adjustment retain lossprofit year december principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange investment book value december million million market value million million december group own quest group hold ownership interest voting control quest group ability exercise significant influence significant shareholding nominate director active participation quest board director board subcommitteesnote financial statement continue investment associate joint venture continue summarise balance sheet information respect group associate set total asset total liability net asset group share associate net asset investment joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiglaxosmithkline holding develop specify chemical compound glaxosmithkline shire canada primarily comarket combivir trizivir epivir certain territory interest joint venture pharmaceutical insurance limit mutual insurance company cover pharmaceutical property risk gsk hedge equity value hold quest diagnostic inc series variable sale forward contract contract equity collar renew structure series million quest share mature fair value contract december liability million million second series hedge contract additional million share enter february contract structure series million quest share mature fair value contract december asset million investment january exchange adjustment addition net fair value movement impairment disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate reference current market value similar instrument reference discount cash flow underlie net asset equity investment record noncurrent asset expect sell year case record current asset group hold number equity investment entity group enter research collaboration investment include list investment million million offer group opportunity return dividend income fair value gain disposal investment fair value movement reclassify reserve income statement base average cost impairment loss record table recognise income statement year operate income amount recycle fair value reserve note operate income recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement december impair assets fair value million million include investment noncurrent asset amount recoverable insurance contract pension scheme surplus receivables gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million associate joint venture bad doubtful debt provision january exchange adjustment charge year subsequent recovery amount provide utilise december cash cash equivalent cash bank hand shortterm deposit commercial paper asset hold sale land building plant equipment vehicle equity investment trade payables trade payable wage salary social security payable defer income customer return rebate accrual accrual gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue trade payable continue customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa provision time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome amount subject change dependent thing type buy group product sale mix level provision review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption provision base change affect future result group pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme postemployment cost cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section contribution define benefit scheme determine accordance advice independent professionally qualified actuary pension cost define benefit scheme accounting purpose assess accordance independent actuarial advice project unit method certain country pension benefit provide unfunded basis administer trustee company liability generally assess annually accordance advice independent actuary formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement recognise income expense discount rate base iboxx year index discount rate base corporate bond yield reflect term expect benefit payment expect rate return bond reflect portfolio mix indexlinke government corporate bond equity risk premium add long term government bond yield expect rate return equity project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line medium cohort improvement recently observe high level assume continue minimum improvement year male females usa mortality rate calculate fully generational table project scale white collar adjustment mortality assumption scheme set follow review december gsk expect review december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow usa male female male female year year year year current project asset fund scheme generally hold separately administer trust insured asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment follow asset liability study group decide adopt strategy reduce gradually allocation investment equity propose strategy link funding level scheme consider trustee scheme allocation equity property scheme reduce total define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group apply follow financial assumption assess define benefit liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate amount record income statement statement recognise income expense year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gain record statement recognise income expense postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gain record statement recognise income expense gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial loss record statement recognise income expense total actuarial loss record statement recognise income expense january million fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow usa rest world group december average expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset usa rest world group december average expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue usa rest world group december average expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset postretirement pension benefit usa rest world group group movement define benefit obligation obligation january exchange adjustment service cost interest cost settlement curtailment actuarial loss scheme participant contribution benefit pay obligation december exchange adjustment service cost interest cost settlement curtailment actuarial lossesgain scheme participant contribution benefit pay obligation december exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer recognise balance sheet december unrecognise past service cost obligation december define benefit scheme include define contribution section obligation total million december million milliongsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation reduce year postretirement healthcare scheme amend main change increase cap company cost yearend plan obligation million accordance ias unvested benefit improvement recognise immediately balance sheet recognise gradually income statement yearend unrecognised million recognise balance sheet million million million group provide certain medical benefit disabled employee spouse usa obligation benefit transfer value million show provision define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded postretirement pension benefit usa rest world group group movement fair value asset asset january exchange adjustment expect return asset actuarial gain employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million group special funding contribution pension scheme total million million pension scheme gsk formalise agreement trustee define benefit pension scheme additional contribution million year addition normal contribution fouryear period end december order eliminate pension deficit ias basis employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue postretirement pension benefit usa rest world group group history experience gain loss experience gainslosse scheme asset percentage scheme asset december experience gainslosse scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset december experience loss scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset december experience lossesgain scheme liability percentage scheme obligation december fair value asset present value scheme obligation deficit scheme gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption annual define benefit pension postretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation provision integration legal new operational employee excellence relate manufacturing dispute programme provision reorganisation provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement december settle year settle year december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue provision continue legal dispute gsk involve number legal dispute include notification possible claim set note legal proceeding provision legal dispute include amount relate antitrust product liability contract termination selfinsurance environmental cleanup property rental company director take legal specialist advice establish provision take account insurance agreement regard relevant fact circumstance matter accordance accounting requirement discount provision decrease million million increase calculate riskadjuste project cash flow riskfree rate return movement include decrease million arise change discount rate year number product history claim settlement make possible use ibnr incur report actuarial technique determine reasonable estimate group exposure unasserted claim relation product apart ibnr provision provision unasserted claim ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation nature group business number matter include provide ibnr actuarial technique subject negotiation litigation year large individual amount provide expect settle year december expect million million provision legal dispute reimburse party insurer include current noncurrent asset discussion legal issue refer note legal proceeding new operational excellence programme october gsk announce significant new billion operational excellence programme improve effectiveness productivity operation new programme expect deliver annual pretax saving million gsk expect realise majority annual saving year programme approximately million expect million saving partly mitigate expect impact earning generic competition low avandia sale associate adverse impact gsk gross margin cost recognise provision principally respect identify severance site announce manufacturing activity reduce cease expect incur mainly asset retirement obligation recognise provision million year cost asset writedown recognise impairment property plant equipment employee relate provision employee relate provision include exchange offer incentive programme operate time merger encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option incentive pay employee exercise relevant option option lapse discount provision increase million million calculate riskfree rate return group provide certain medical benefit disabled employee spouse usa transfer postretirement benefit value million year reflect total reclassification movement figure million december provision benefit amount million employee benefit reflect variety provision severance cost jubilee awards longservice benefit integration manufacture reorganisation group recognise cost previous year respect plan integration glaxo wellcome smithkline beecham business implementation integration follow merger substantially complete cost recognise remain merger integration provision respect identify severance expect incur small costsaving initiative merger include category noncurrent liability accrual defer income payable contingent liability december contingent liability comprise guarantee letter credit discount bill item arise normal course business amount million million december million million financial asset pledge collateral contingent liability discussion tax legal issue refer note taxation note legal proceedingsgsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue net debt current asset liquid investment cash cash equivalent shortterm borrowing medium term note european medium term note european medium term note commercial paper bank loan overdraft loan obligation finance lease longterm borrowing european medium term note european medium term note european medium term note european medium term note european medium term note medium term note european medium term note european medium term note european medium term note medium term note european medium term note loan stock bank loan loan private financing obligation finance lease net debt current asset liquid investment classify availableforsale investment december include redeemable share collateralise highly rate bond billion million billion million government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float fix rate million million respectively million million effective interest rate cash cash equivalent december approximately approximately cash cash equivalent balance december earn interest float fix rate million million respectively million million july onwards gsk tighten criterion hold cash equivalent liquid investment response credit crisis gsk suffer loss principal result crisis gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue net debt continue shortterm borrowing commercial paper comprise billion programme billion billion issue december nil back commit facility day duration billion billion million million renewable annually liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year longterm borrowing repayable year carry interest effective rate repayment date range average effective interest rate note december approximately approximately secure loan gsk loan secure charge noncurrent current asset year nil finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation finance lease obligation december bear interest float fix rate million million respectively million milliongsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue share option scheme december issue share option scheme december issue share option scheme share capital purchase cancel december december december december number share issuable outstanding option note number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme july group increase share buyback programme billion expect complete twoyear period exact time future purchase repurchased share hold treasury share cancel determined company dependent market condition factor group commence close period share buyback operate specific irrevocable agreement place broker prior start close period total billion spend company january december buying share cancellation hold treasury share billion spend million share purchase cancel period january february cost million purchase publicly announce buyback programme table set monthly purchase share buyback programme average share price exclude number share commission stamp duty month january february march april june july august september october november december total share purchase million million hold treasury share million million cancel detail substantial shareholding refer substantial shareholding gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue movement equity shareholder equity share share retain total minority total capital premium earning reserve interest equity january recognise income expense year change minority shareholding distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase held treasury share ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax share base incentive plan december recognise income expense year change minority shareholding distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase held treasury share ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december recognise income expense year distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share purchase held treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue movement equity continue retain earning reserve amount million december million million million million million relate company million million million relate joint venture associate undertaking cumulative translation exchange equity show follow table net translation exchange include total fair value retain minority translation reserve earning interest exchange january exchange movement overseas net asset exchange movement goodwill reserve december exchange movement overseas net asset exchange movement goodwill reserve december exchange movement overseas net asset exchange movement goodwill reserve december analysis reserve follow cash flow esop trust fair value hedge share reserve reserve reserve total january transfer income expense year disposal net fair value movement year ordinary share transfer esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share transfer esop trust writedown share hold esop trust december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust december reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue related party transaction glaxosmithkline hold interest quest diagnostics inc december group quest diagnostic party longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group clinical trial testing requirement worldwide quest diagnostic provide service million million group december balance payable glaxosmithkline quest diagnostic million million group shionogi ltd enter transaction joint venture company support research development activity conduct joint venture company glaxosmithkline provide service joint venture million million december balance glaxosmithkline joint venture million million shapiro nonexecutive director glaxosmithkline plc receive fee form adss subsidiary company membership group scientific advisory board fee include annual remuneration remuneration report page aggregate compensation director cet company secretary give note employee cost reconciliation profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance incomecost depreciation impairment asset write amortisation intangible asset profit sale property plant equipment profit sale intangible asset profit sale equity investment change work capital increasedecrease inventory increase trade receivables decreaseincrease trade payable decrease pension provision sharebase incentive plan cash generate operation reconciliation net cash flow movement net debt net debt begin year implementation account financial instrument ia increasedecrease cash bank overdraft cash outflowinflow liquid investment net increase longterm loan net increase inrepayment shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue reconciliation net cash flow movement net debt continue exchange acquisition cash flow analysis change net debt liquid investment cash cash equivalent overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt note net debt acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture business give acquisition reliant pharmaceuticals inc december group acquire issue share capital reliant pharmaceuticals inc pharmaceutical company base usa cash consideration million company specialise development marketing speciality medicine combat heart disease include right lovaza treatment adult patient high level triglyceride transaction account purchase method accounting goodwill arise acquisition reflect potential product growth usa puerto rico expect synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax relate period acquisition include group account fair value set base provisional valuation subject change future book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue acquisition disposal continue domantis limit january group acquire issue share capital domantis limited drug discovery company base cash consideration million company develop generation antibody therapy transaction account purchase method accounting goodwill arise acquisition reflect potential combine worldleading technology domantis development programme place gsk group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration praecis pharmaceuticals inc february group acquire issue share capital praecis pharmaceuticals inc biopharmaceutical company base usa cash consideration million company develop efficient method identify drug lead target human disease proprietary technology transaction account purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax asset liability goodwill total consideration reliant domantis praecis total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition reliant domantis praecis acquire beginning year combine group turnover year million combine group profit year milliongsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue acquisition disposal continue acquisition cns inc december group acquire issue share capital cns inc consumer healthcare company base usa cash consideration million company market breathe right nasal dilator strip fiberchoice dietary fibre supplement key intangible asset acquire value discount cash flow calculation transaction account purchase method accounting goodwill arise acquisition reflect potential expansion brand overseas market expect synergies group cns inc turnover million million profit million profit million million turnover nil profit relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration euclid partner additional million invest euclid partner associate group share shionogiglaxosmithkline holdings ltd additional million invest shionogi glaxosmithkline holdings ltd joint venture group share pliva research institute ltd group purchase entire share capital pliva research institute ltd cash consideration million million defer payment phase clinical trial initiate glaxosmithkline august japanese subsidiary group cash payment million complete purchase remain share capital hold minority shareholder payment precede year dividend minority shareholder million represent additional consideration shionogi pliva euclid glaxosmithkline research glaxosmith cns partner holdings ltd institute kline total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition net cash proceed disposal gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue acquisition disposal continue acquisition biomedical corporation december group acquire issue share capital biomedical corporation biotechnology company base canada specialise development manufacture vaccine particularly influenza vaccine cash consideration million transaction account purchase method accounting goodwill arise acquisition result benefit separately quantify record include immediate access additional flu vaccine manufacturing capacity particularly event pandemic skilled workforce good relation canadian government supply flu vaccine biomedical corporation turnover million million loss million loss million year million turnover million loss relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset defer tax provision liability goodwill total consideration total consideration include directly attributable cost million corixa corporation july group acquire issue share capital corixa corporation biotechnology company specialise develop vaccine adjuvant immunology base product cash consideration million investment increase group hold corixa group number business relationship corixa prior acquisition date principally relation adjuvant developed corixa group vaccine transaction account purchase method account exist investment corixa book value million previously classify availableforsale investment form investment subsidiary exist issue share capital acquire previous year cash consideration million corixa corporation turnover million loss million year million turnover million loss relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset asset liability goodwill exist investment total consideration total consideration include directly attributable cost milliongsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue acquisition disposal continue euclid partner additional million invest euclid partner associate group interest glaxosmithkline consumer healthcare limited april indian subsidiary group purchase share capital hold minority shareholder cash consideration million glaxosmithkline pharmaceutical limited june indian subsidiary group purchase share capital hold minority shareholder cash consideration million glaxosmithkline biological shanghai limited chinese subsidiary group purchase share capital hold minority shareholder cash consideration million disposal ideapharm december group dispose ideapharm subsidiary locate romania cash proceed million receive january net asset dispose year include cash million aseptic technology april group dispose aseptic technology societe regionale dinvestissement wallonie cash proceed million gsk gsk gsk biological aseptic pharma consumer euclid cash flow shanghai tech ceutical healthcare ideapharm corixa biomedical total cash consideration cash cash equivalent acquire net cash payment acquisition cash cash equivalent dispose net cash proceed disposal gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue commitment contractual obligation commitment contract provide financial statement intangible asset plant property equipment investment purchase commitment business combination pension theravance option agreement commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development represent maximum pay milestone achieve number commitment licensing agreement include arrangement anacor pharmaceuticals inc oncomed pharmaceuticals inc santaris pharma targacept inc gsk formalise agreement trustee pension scheme additional contribution million year addition normal contribution fouryear period end december order eliminate pension deficit ias basis point table show commitment exclude normal ongoing annual funding requirement approximately million gsk commit eliminate future deficit arise rolling fiveyear period commitment past december december group party option agreement theravance shareholder sell half theravance share gsk predetermine price give maximum number share subject option group obligation cap million option expire unexercised august group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment operating lease post balance sheet event january fda issue approvable letter respect merck nda seek approval overthecounter mevacor trigger repayment gsk upfront fee gsk pay merck otc right february gsk longterm standard poor debt rating revise negative outlook stable standard poor revise gsk shortterm rating paper issue group commercial paper programme agsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure liquidity risk group manage net borrowing requirement glaxosmithkline plc report sterling pay dividend portfolio longterm borrowing include bond sterling profit role corporate treasury gsk manage shortterm finance billion commercial paper monitor group external internal funding requirement programme december group billion financial risk support group corporate objective treasury commit undrawn bank facility activity govern policy procedure approve board director recently october group european medium term note programme billion billion issue december treasury management group tmg chair group shelf registration billion december chief financial officer meet monthly basis review treasury billion billion issue tmg monitor cashflow activity member receive management information relate forecast gsk monthly basis treasury activity corporate executive team cet review monthly finance report focus operational finance issue group longterm borrowing mature date group internal auditor review treasury internal control february gsk longterm standard poor environment regularly debt rating revise negative outlook stable time standard poor revise gsk shortterm rating gsk use variety financial instrument include derivative paper issue group commercial paper programme finance operation manage market risk moodys investor service rate gsk negative operation derivative principally comprise forward foreign outlook longterm debt shortterm debt currency contract interest rate currency swap change gsk rating moodys july swap borrowing liquid asset currency require group purpose manage exposure funding risk change light likely increase commercial paper issuance result foreign exchange rate interest rate increase share buyback programme gsk increase committed bank facility million billion addition gsk hold issue derivative financial instrument group maintain substantial cash liquid investment speculative purpose group treasury policy specifically december amount billion prohibit activity transaction financial instrument undertake manage risk arise underlie business market risk activity speculation interest rate risk management gsk policy interest rate risk management require minimum capital management net borrowing fix rate increase ratio capital structure group consist net debt note forecast interest payable trading profit fix float ratio net debt shareholder equity note movement review monthly tmg equity group manage capital ensure entity group able operate go concern optimise group use limited number interest rate swap return shareholder appropriate balance debt redenominate external borrowing interest rate coupon equity july gsk announce increase share buyback require group purpose duration swap match programme billion period july duration principal instrument interest rate derivative result substantially increase borrowing board review instrument account fair value cash flow hedge group dividend policy funding requirement annually relevant asset liability gsk operate globally primarily subsidiary company foreign exchange risk management establish market group trade foreign currency transaction exposure arise normal trade flow significant level patent trademark protection group respect external intragroup trade hedge product compete largely product efficacy price exposure overseas operating subsidiary transaction risk sell margin sufficient cover normal operating cost minimise match local currency income local currency group operating subsidiary generally cash generative cost purpose intragroup trading transaction match entity group subject externally impose capital centrally intragroup payment term manage reduce risk requirement exceptional foreign currency cash flow hedge selectively management corporate treasury operate cash flow fund investment research development new product routine group manage centrally shortterm cash surplus borrow outflow capital expenditure tax dividend repayment requirement subsidiary company use forward contract mature debt hedge future repayment originate currency group policy borrow centrally variety capital group seek denominate borrowing currency market issue borrow facility meet anticipated funding principal asset cash flow primarily denominate requirement dollar euro sterle certain borrowing swap currency require group purpose borrowing cash generate operation onlent group contribute equity certain subsidiary fund group billion share buyback programme gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure fair value financial asset liability continue table present carry amount fair value group financial asset liability december borrowing denominate swap foreign currency december match investment overseas group asset treat hedge relevant asset ratio borrowing asset fair value financial asset liability include review currency month month basis tmg instrument exchange current transaction willing party force credit risk liquidation sale follow method assumption group consider maximum credit risk million estimate fair value million total group financial asset exception investment bear cash cash equivalent approximate carry credit risk treasury bill bond note classify cash cash equivalent liquid investments iquid investment base quote market price case marketable security base principal amount case treasury bill bond note hold directly nonmarketable security short repricing period treasuriesonly money market fund bear credit exposure government detail group total investment investment trade active market financial asset determine reference relevant stock exchange quote bid price investment determine reference treasuryrelate credit risk current market value similar instrument reference credit risk increase follow global subprime crisis gsk discount cash flow underlie net asset suffer loss investment principal result crisis hortterm loan overdraft approximate carry group invest centrally manage liquid asset government bond short maturity instrument shortterm corporate debt instrument minimum shortterm credit rating bank deposit treasuriesonly money market ongterm loan base quote market price case fund credit rating aaaaaa standard poorsmoodys eurobond fix rate borrowing approximate investor service structure investment carry case float rate bank loan loan report relationship bank credit rating present forward exchange contract base market price exchange annually tmg approval rate balance sheet date aggregate credit risk respect financial instrument currency swap base market datum balance sheet date group counterparty limited reference longterm credit rating assign counterparty moodys u equity collar theravance option base standard poor blackschole option pricing model use assumption respect price volatility dividend yield interest rate wholesale retail credit risk nter rate swap base net present value discount usa line pharmaceutical company group cash flow sell product small number wholesaler addition hospital pharmacie physician group sale receivable payable approximate carry large wholesaler approximately group lease obligation approximate carry pharmaceutical sale december group trade receivable wholesaler total million fair value investment gsk share million group expose concentration december esop trust held gsk share credit risk respect wholesaler carry value million million fair encounter financial difficulty materially adversely value million million base quote affect group financial result market price share represent purchase esop trust satisfy future exercise option award employee group credit risk monitoring activity relate wholesaler incentive scheme carry value low cost includes review quarterly financial information standard expect proceed share recognise poor credit rating development gsk internal risk rating deduction reserve december gsk hold establishment periodic review credit limit group treasury share cost million million believe credit risk provision require excess deduct retain earning normal provision bad doubtful debt note trade receivables outside usa customer account commit facility trade receivable balance group commit facility commercial paper programme billion billion million million day duration renewable annually december undrawn commit facility total billion billion million milliongsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value cash cash equivalent availableforsale investment liquid investment redeemable share government bond total liquid investment investment loan receivables trade receivables noncurrent asset scope ias heldfortrade financial asset derivative designate accounting hedge derivative total financial asset financial liability measure amortise cost borrowing bond designate hedge relationship bond commercial paper bank loan overdraft loan private financing obligation finance lease total borrowing trade payable noncurrent liability scope ias heldfortrade financial liability derivative designate accounting hedge derivative total financial liability net financial asset financial liability note financial statement continue financial instrument relate disclosure continue trade receivables noncurrent asset scope ias follow table reconcile trade receivables noncurrent asset fall scope ia relevant balance sheet amount asset include tax receivables pension surplus balance prepayment outside scope ias financial asset predominantly noninterest earn trade receivables note noncurrent asset note analyse financial asset scope ia asset follow table show age financial asset past provision bad doubtful debt raise past day past day past day past day past day amount past great day total million million balance million million relate receivable state hospital authority certain european country group raise bad doubtful debt provision amount consider recoverable trade payable noncurrent liability scope ias follow table reconcile trade payable noncurrent liability fall scope ia relevant balance sheet amount liability include payment account tax social security payable outside scope ia financial liability predominantly noninterest bear trade payable note noncurrent liability note analyse financial liability scope ias liabilities gsk annual report stnemetat laicnanif stnemetat laicnanfi eht setonnote financial statement continue financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing sensitivity analysis sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation place december financial instrument affect market risk include borrowing deposit derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change relevant foreign exchange interest rate foreign exchange sensitivity table show group sensitivity foreign exchange rate dollar euro yen financial instrument exclude trade payable trade receivables nonderivative financial instrument net debt obligation finance lease present material exposure currency major currency gsk financial instrument denominate gsk consider movement currency year conclude movement rate reasonable benchmark table financial instrument consider sensitive foreign exchange rate functional currency entity hold intercompany loan fully hedge maturity currency swap exclude analysis increase reduction increase reduction income equity income equity appreciation dollar appreciation euro appreciation yen depreciation state currency equal opposite effect movement income statement relate primarily hedge instrument dollar legal provision whilst economic hedge provision financial instrument include table movement equity relate foreign exchange position hedge group asset denominate dollar euro yen depreciation currency swap rise correspond appreciation group asset foreign exchange sensitivity group asset financial instrument include gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure continue interest rate sensitivity table show group sensitivity interest rate float rate sterling dollar euro financial instrument currency gsk historically issue debt hold investment gsk consider movement interest rate year conclude increase reasonable benchmark debt maturity year float rate calculation movement interest rate deem material effect equity increasedecrease increasedecrease income income increase sterle interest rate increase dollar interest rate increase euro interest rate decrease interest rate equal opposite effect interest rate movement obligation finance lease foreign currency interest rate derivative trade payable trade receivables financial instrument net debt present material exposure group balance sheet base increase decrease interest rate contractual cash flow nonderivative financial liability derivative instrument follow analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis purpose table debt define class borrowing obligation finance lease interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance charge trade obligation obligation interest finance finance payable debt debt lease lease net debt total december year year year year year great year gross contractual cash flow finance charge trade obligation obligation interest finance finance payable debt debt lease lease net debt total december year year year year year great year gross contractual cash flow follow table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option undiscounted cash flow cash flow foreign currency translate spot rate december receivables payable receivables payable year year year year year great year gross contractual cash flow gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure continue derivative financial instrument hedge programme follow table set principal amount fair value derivative hold gsk fair value fair value principal principal asset liability asset liabilitie cash flow hedge cross currency swap fair value hedge interest rate swap net investment hedge foreign exchange contract cross currency swap derivative designate accounting hedge foreign exchange contract equity relate instrument option warrant equity collar embed derivative derivative total derivative instrument analyse current noncurrent total derivative financial instrument principal foreign exchange contract calculate base outstanding position balance sheet date calculate net currency buysell position majority contract period month include equity relate instrument variable sale forward contract quest diagnostic inc equity warrant december group hold option theravance inc information quest theravance derivative provide gsk hedge equity value holding quest associate undertaking series variable sale forward contract contract equity collar renew structure series million quest share mature fair value contract december liability million million million million second series hedge contract additional million share enter february contract structure series million quest share mature fair value contract december asset million million december group hold option agreement theravance shareholder sell half theravance share gsk predetermine price december option record liability million million option expire unexercised august december group hold option agreement purchase half outstanding theravance share issue predetermine price december option record asset million million option expire unexercised july december group hold outstanding foreign exchange contract consist primarily currency swap total fair value million million liability represent hedge intercompany loan deposit designate accounting hedge change fair value take profit loss period offset exchange gain loss relate intercompany lending borrowing gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue financial instrument relate disclosure employee share scheme continue group operate share option scheme option cash flow hedge grant employee acquire share adss glaxosmithkline plc group enter cross currency swap designate grant price savingsrelate share option scheme share cash flow hedge convert fix euro interest payable annually award scheme award grant employee fix yen payment bond mature risk hedge acquire share adss glaxosmithkline plc cost subject variability cash flow arise currency fluctuation achievement group specify performance target ineffectiveness assume hedge group introduce new share award scheme share value plan award grant employee acquire cash flow relate hedge expect occur share adss glaxosmithkline plc cost year year amount recognise equity recycle vest period grant restrict share award replace income statement offset exchange gain loss grant option certain employee cost period underlie bond result revaluation scheme readily equate potential gain balance sheet date employee recognise equity cross currency interest grant share option scheme normally exercisable rate swap million credit million credit year date grant grant restrict share recycle equity income statement share award normally exercisable end cross currency interest rate swap offset exchange loss year vestingperformance period grant savingsrelate share underlie bond recognise income statement million option scheme normally exercisable year save million net fair value movement cash flow option share option scheme grant market hedge disclose consolidated statement recognise price ruling date grant accordance practice income expense majority option savingsrelate share option scheme fair value hedge grant price market price ruling group designate interest rate swap interest date grant element cross currency swap fair value hedge share option award director effect risk hedge variability fair value bond grant cet subject performance criterion arise interest rate fluctuation gain loss fair value hedge disclose note finance cost net investment hedge foreign exchange contract currency element group cross currency swap designate net investment hedge respect foreign currency translation risk principally arise consolidation group net investment dollar euro yen foreign operation addition euro loan capital issue year billion million previous year designate nonmonetary net investment hedge respect foreign currency translation risk principally arise consolidation group net investment euro operation net investment hedge ineffectiveness disclose note finance incomegsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue employee share scheme continue option pricing purpose value option arrive stockbase compensation charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option scheme year year year weight average share price grant year ordinary share adss volatility determine base year share price history fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option share option share option savingsrelate option outstanding scheme share scheme adss share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option lapse december option grant option exercise option lapse december option grant option exercise option lapse december range exercise price weight average remain contractual life year year year gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue employee share scheme continue order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share adss glaxosmithkline share adss programme establish additional cash benefit exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expiry option outstanding share option share option savingsrelate december scheme share scheme adss share option scheme weight late weight late late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share adss grant savingsrelate share option grant change effective exercise price outstanding option year option exercisable share option share option savingsrelate december scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price december december december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period performance condition consist part apply award award grant condition compare gsk total shareholder return tsr period tsr company ftse index period award grant subsequent year condition compare gsk tsr period tsr pharmaceutical company comparator group period awards second performance condition compare gsk earning share growth increase retail price index year performance period award grant director member cet december subject single performance condition compare gsk tsr period tsr company comparator group period share weight adss weight number share adss issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach share weight adss weight number share adss issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december gsk annual report stnemetat laicnanif stnemetat laicnanfi eht seton note financial statement continue employee share scheme continue employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group december detail give principal country operation location headquarters business segment business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary segment activity england brentford glaxosmithkline holdings limited phch brentford glaxosmithkline holding limited phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc brentford smithkline beecham plc phch brentford wellcome limited phch greenford glaxo group limit greenford glaxo operation limit brentford glaxo wellcome international phch brentford glaxo wellcome investment phch brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline limit brentford smithkline beecham investments limited phch brentford setfirst limited phch greenford wellcome foundation limit cambridge domantis limit brentford smithkline beecham overseas limit brentford smithkline beecham holdings limit brentford glaxosmithkline netherlands austria vienna glaxosmithkline pharma gmbh belgium genval glaxosmithkline rixensart glaxosmithkline biological czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare brndby glaxosmithkline pharma finland espoo glaxosmithkline france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxo wellcome production sas marly roi glaxosmithkline sante grand public sas germany buehl glaxosmithkline consumer healthcare gmbh munich glaxosmithkline gmbh greece athens glaxosmithkline aebe phch guernsey peter port setfirst limited phch hungary budapest glaxosmithkline medicine healthcare product limited phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare spa verona glaxosmithkline manufacturing spa luxembourg mamer glaxosmithkline international luxembourg phch netherlands zeist glaxosmithkline utrecht glaxosmithkline consumer healthcare gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue principal group company continue europe location subsidiary segment activity norway oslo glaxosmithkline poland poznan glaxosmithkline pharmaceuticals poznan gsk services spzoo warsaw glaxosmithkline consumer healthcare spzoo portugal alge glaxosmithklineprodutos farmaceuticos limitada republic carrigaline smithkline beecham cork limited ireland cork glaxosmithkline trading services limited dublin glaxosmithkline consumer healthcare ireland limited dublin glaxosmithkline ireland limit russian moscow glaxosmithkline trading zao federation moscow glaxosmithkline healthcare zao spain madrid glaxosmithkline madrid glaxosmithkline consumer healthcare aranda duero glaxo wellcome sweden solna glaxosmithkline switzerland muenchenbuchsee glaxosmithkline usa usa hamilton corixa corporation pittsburgh cns inc philadelphia smithkline beecham corporation phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline holdings americas inc phch liberty corner reliant pharmaceuticals inc wilmington glaxosmithkline capital inc americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc oakville glaxosmithkline consumer healthcare inc laval biomedical corporation laval biomedical corporation quebec asia pacific australia boronia glaxosmithkline australia pty ltd phch china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceutical limit nabha glaxosmithkline consumer healthcare limited iii malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd petale jaya glaxosmithkline consumer healthcare sdn bhd new zealand auckland glaxosmithkline limited phch pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd phch mgsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue principal group company continue asia pacific location subsidiary segment activity south korea seoul glaxosmithkline korea limited thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch brazil rio janeiro glaxosmithkline brasil ltda phch colombia bogota glaxosmithkline colombia phch mexico delegacion tlalpan glaxosmithkline mexico phch puerto rico guaynabo glaxosmithkline puerto rico inc cidra pharmco puerto rico inc venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae south africa bryanston glaxosmithkline south africa pty ltd phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret usa location associate business usa madison quest diagnostic incorporate clinical testing incorporate netherlands exempt provision section company amendment act ireland iii onsolidate subsidiary undertaking accordance section company act ground dominant influence equity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc key business segment pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding complaint base threat market salmeterolfluticasone combination product germany prior patent expiry basic patent group involve significant legal administrative cover combination product seretide expire september proceeding principally product liability intellectual property subject supplementary protection certificate extend tax antitrust governmental investigation relate private protection september action early stage litigation group make provision proceeding regular basis summarise note group argatroban additional significant provision legal proceeding require december encysive pharmaceuticals inc mitsubishi kasei event development matter consistent corporation group file action district court generally accept accounting principle litigation particularly southern district new york barr laboratories inc usa inherently unpredictable excessive award infringement mitsubishis pharmaceutical composition patent justify evidence occur group cover argatroban pursuant license mitsubishi encysive future incur judgement enter settlement claim develop argatroban treatment heparininduce result payment exceed current provision thrombocytopenia hold new drug application approve material adverse effect group fda encysive license marketing right argatroban financial condition result operation andor cash flow group mitsubishi patent expire june barr file abbreviate new drug application anda fda intellectual property claim include challenge validity certification invalidity unenforceability noninfringement enforceability group patent product process mitsubishi patent fda approval anda stay early assertion noninfringement patent loss resolution patent infringement action case case result loss patent protection product early stage issue consequence loss significant decrease sale product materially affect future avandia avandamet avandaryl result operation group august group file action district court district new jersey teva pharmaceuticals usa inc legal expense incur provision relate legal claim infringement group patent relate maleate salt charge sell general administration cost provision form rosiglitazone active ingredient avandia expire take appropriate legal specialist advice september group file comparable action reasonable estimate likely outcome court reddys laboratory allege infringement dispute group establish actuarially determine patent action file response anda filing provision product liability claim incur report fda reddys laboratories teva certification describe note provision december group maleate salt patent invalid unenforceable group aggregate provision legal dispute infringe teva subsequently file similar certification include tax matter describe note taxation challenge group basic compound patent rosiglitazone billion ultimate liability legal claim vary january group commence action teva amount provide dependent outcome litigation court infringement patent proceeding investigation possible settlement negotiation january group file action district court significant matter describe district new jersey teva infringement intellectual property patent basic compound maleate salt patent advairseretide rosiglitazone teva file anda fda generic september group apply patent version avandamet certification patent trademark office uspto reissue combination patent invalid unenforceable infringe advair inhale combination salmeterol fluticasone group file action district court propionate expire september follow district new jersey teva infringement internal review conclude language patent group patent relate maleate salt form rosiglitazone accurately describe circumstance group basic patent rosiglitazone teva file anda invention claim invention precisely fda generic version avandaryl certification objective seek reissuance strengthen patent invalid unenforceable infringe protection afford patent uspto reissue patent february reissue patent september june group voluntarily dismiss infringement claim expiration date original composition patent list respect patent cover maleate salt form rosiglitazone register pharmaceutical patent maintain fda reddys challenge basic compound patent orange book dismissal maleate salt claim dismiss claim reddys respect avandia october group file complaint patent dispute chamber regional court dsseldorf germany neolab infringement german patent claim composition contain combination salmeterol fluticasone propionate seretide know viani germanygsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue group action urlmutual amend include claim infringement reissue patent fda approval url respect group patent infringement action teva mutuals anda stay early june resolution respect basic compound maleate salt form patent patent infringement action event approval august party reach settlement provide issue prior expiration datum exclusivity period april teva enter market generic version avandia case early stage avandamet avandaryl oral tablet late quarter term settlement remain confidential paxilseroxat usa number distributor generic drug file application avodart fda market generic version paxilseroxat paroxetine february group file action district court hydrochloride prior expiration group district delaware barr laboratories infringement patent paroxetine hyrdrochloride hemihydrate response basic patent cover active ingredient avodart group file number patent infringement action compound generally use treat benign prostate hypertrophy concluded resolve describe bph basic compound patent expire november distributor apotex launch generic product usa patent expire september barr file september additional generic product launch anda fda certification invalidity unenforceability defendant march noninfringement patent fda approval barrs anda stay early july resolution group file separate patent infringement action patent infringement action case early stage apotex district court northern district illinois eastern district pennsylvania appeals boniva group court appeal federal circuit cafc september roche laboratory commence action hear appeal district court patent matter district court district new jersey seven generic case remand matter panel drug manufacturer district court northern case relevant claim patent paroxetine hydrochloride district illinois eighth manufacturer case hemihydrate rule invalid claim patent allege infringement roche patent relate boniva tablet rule invalid andor infringe case appeal defendant file anda fda certification pende plan claim pende trial invalidity unenforceability noninfringement roche patent manufacturer challenge basic europe generic product contain paroxetine hydrochloride compound patent expire march final fda approval market european country whilst andas stay early november resolution product subject continue litigation action relevant patent infringement action group participate conclude settle respect manufacturer marketing boniva pursuant copromotion agreement synthon fal litigation ongoing counterclaim roche case early stage unfair competition assert group combivir follow litigation canada apotex november group file action district court patent relate paroxetine apotex launch generic product district delaware teva pharmaceuticals infringement canada october apotex allege result patent relate combivir patent cover litigation enjoin launch product combination azt lamivudine treat hiv expire receipt regulatory approval action apotex recover damage teva file anda fda certification relate delay occasion injunction ongoing invalidity unenforceability noninfringement combination paxil patent teva challenge patent relate combivir november mylan pharmaceutical file anda paxil expire case early stage paroxetine hydrochloride control release formulation coreg certification invalidity unenforceability noninfringement february group file action district court patent list fda orange book certification eastern district pennsylvania united research respect patent cover paroxetine hydrochloride hemihydrate laboratory incmutual pharmaceutical company inc respect mylan admit active ingredient product patent group patent relate crystalline salt form carvedilol expire june give effect grant paediatric exclusivity active ingredient coreg url mutual file anda fda group file patent infringement action fda certification invalidity unenforceability mylan day period provide hatchwaxman noninfringement patent cover crystalline salt form month stay fda approval mylan anda delay release technology manufacturing product new patent covering delay control release formulation expire respectively january uspto paroxetine hydrochloride paxil issue group june issue group patent method use administration list fda orange book group file carvedilol therapeutic agent reissue patent action district court district new jersey listed orange book expire mylan infringement newly issue patent gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue march biovail announce following review federal trade commission ftc request party subsequently party reach settlement permit mylan comprehensive settlement anchen pharmaceutical impax enter market strength paxil later laboratories watson pharmaceuticals teva pharmaceutical october term settlement remain confidential industry certain aspect settlement remain confidential requip party disclose define exception anchen impax april group commence action district watson teva market generic version court district delaware teva pharmaceutical usa inc strength wellbutrin allege infringement group compound patent ropinirole fda give final approval anchen anda generic hydrochloride active ingredient requip method use version wellbutrin impax generic tablet patent treatment parkinson disease list product generic product launch usa fda orange book compound patent expire december end december generic version tablet method use patent expire defendant launch date report file anda fda certification patent invalid unenforceable infringe december uspto action judge rule conclusion trial group patent october group file action patent method use ropinirole treat parkinson disease novel trademark office district court eastern nonobvious reject tevas claim ground tevas original district virginia request court enjoin office challenge group basic compound patent withdraw implement new regulation affect substantive right relate teva accept fda approve product prior filing obtain patent regulation expiration patent addition teva stipulate effective november october group method use patent valid enforceable tevas court issue order enjoin implementation rule generic version infringe teva waive right appeal hearing hold party crossmotion summary december judgement favour group agree judgement final decision render hearing hold wait expiration group patent february decision report launch generic product date report valtrex product liability group commence action district court preclinical clinical trial conduct development district new jersey ranbaxy laboratory allege potential product determine safety efficacy infringement group compound patent valacyclovir product use human follow approval regulatory active ingredient valtrex patent expire defendant body notwithstanding effort drug vaccine file anda fda certification group introduce marketplace unanticipated effect compound patent invalid unenforceable infringed evident group currently defendant number case settle term permit ranbaxy enter product liability lawsuit relate group pharmaceutical market late take account expect paediatric exclusivity product significant matter describe respect group basic composition matter patent avandia wellbutrin new england journal medicine nejm publish december biovail commence action district court article avandia author base metaanalysis central district california anchen pharmaceutical clinical trial raise concern use drug rosiglitazone district court southern district florida avandia associate increase risk heart attack abrika pharmaceutical case allege infringement biovail cardiovascular death comparison use placebo formulation patent wellbutrin april biovail file antidiabetic therapy follow publication nejm article action district court eastern district pennsylvania group name product liability lawsuit behalf impax laboratory infringement patent individual purport class action case assert consumer fraud patent expire anchen abrika impax file andor personal injury claim behalf purchaser user anda fda certification invalidity noninfringement avandia federal case multidistrict litigation mdl biovail patent group licensee patent proceed pende district court eastern district pennsylvania case file state court august judge grant anchen motion rule litigation early stage anchen anda product infringe biovail patent biovail appeal decision cafc group party action september biovail commence action district court southern district new york watson laboratory allege infringement biovail formulation patent watson party counterclaim group base listing activity associate fda orange book dismiss october gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue group receive numerous claim lawsuit allege treatment paxil cause homicidal suicidal behaviour exhibit baycol user product class certification deny january august bayer withdraw baycol cerivastatin sodium purport personal injury class action lawsuit january worldwide light report adverse event include death fda approve box warning antidepressant increase involve rhabdomyolysis group participate marketing risk suicidal thought behaviour paediatric patient baycol usa pursuant copromotion agreement bayer strengthen warning ssri product include paxil licence holder manufacturer product class paxil label update warn young follow withdrawal bayer group name adult especially major depressive disorder defendant thousand lawsuit file state federal court increase risk suicidal behaviour treatment paroxetine usa behalf individual putative class august fda require update label antidepressant baycol user number suit allege plaintiff class state box warning antidepressant increase suffer personal injury include rhabdomyolsis risk suicidal think behaviour child adolescent use baycol claim person take baycol young adult increase show age injure risk future injury suffer reduction risk adult age old economic damage purchase baycol plaintiff seek depression psychiatric disorder associate remedy include compensatory punitive statutory damage increase risk creation fund medical monitoring group receive lawsuit file state federal court group bayer corporation principal subsidiary usa canada behalf thousand plaintiff include bayer sign allocation agreement purport class action allege paroxetine active ingredient bayer corporation agree pay settlement paxil addictive cause dependency withdrawal reaction compensatory damage judgement party retain federal case consolidate mdl proceeding responsibility attorney fee punitive damage january conditional settlement agreement effective federal case consolidate mdl proceeding group admit liability respect allegation district court district minnesota date state lawsuit virtually action resolve wide class action certify medical monitoring case purport class action consumer fraud lawsuit focus pennsylvania consumer fraud deceptive business practice discontinuation symptom appeal denial class act case illinois medical monitoring action dismiss certification california state court purport class action court summary judgement class action litigation canada group defend litigation gsk name defendant certify oklahoma commence behalf hundred plaintiff claim death injury settle allege paroxetine cause suffer withdrawal thousands allege muscle ache pain reaction dependency voluntarily involuntarily dismiss thimerosal paxil paxil group number pharmaceutical company group receive lawsuit claim allege use paxil name defendant numerous individual personal injury paroxetine pregnancy result birth child lawsuit state federal district court usa allege birth defect health issue separately group receive thimerosal preservative manufacture vaccine cause lawsuit claim patient take paxil commit neurodevelopmental disorder injury include autism attempt commit suicide andor act violence group case purport class action receive lawsuit claim file behalf patient allege determination case permit suffer symptom discontinue treatment paxil proceed class action number purport class action jurisdiction withdraw dismiss plaintiff seek group receive numerous lawsuit claim allege remedy include compensatory punitive statutory damage use paxil pregnancy result birth child cost fund medical monitoring research congenital malformation persistent pulmonary hypertension date report limited number case newborn september label paxil update approach trial date vaccine manufacturer manufacturer reflect new information suggest increase risk thimerosalcontaine medicinal product congenital malformation particularly cardiovascular malformation successful exclude testimony plaintiff expert witness infant bear mother take paxil trimester causation ground plaintiff fail establish pregnancy december paxil label update hypothesize link thimerosal neurodevelopmental include new datum strengthen pregnancy warning disorder generally accept reliable relevant scientific category category indicate evidence risk community date report case schedule foetus potential benefit use drug trial group defendant pregnant woman outweigh risk paxil label update include class warning concern persistent pulmonary hypertension newborn arise mother take selective serotonin reuptake inhibitor ssri antidepressant week pregnancy gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue group agree pay government civil settlement million respect marketing zofran kytril sale marketing regulation include settlement amount states claim marketing promotion settle settlement corporate integrity february group receive subpoena agreement group party amend address attorney office colorado group sale issue raise course government investigation promotional practice relate large selling product period january present particular subsequent initial subpoenas number state government inquire allege promotion drug respective attorney general county new offlabel use group sponsor continue medical york state file civil lawsuit state federal court gsk education programme speaker event special issue board drug company action claim behalf advisory board speaker training programme clinical study state payer case behalf instate relate grant fee travel entertainment original patient consumer damage restitution awpbase subpoena issue attorney office colorado price report pharmaceutical product cover state scope inquiry nationwide government inquire medicaid programme case governmental group response october letter programme addition private payer class action lawsuit fdas division drug marketing advertising communication file gsk multiple federal district state court request information group allege promotion federal case consolidate mdl proceed wellbutrin offlabel use group cooperate district court district massachusetts investigation provide request information august judge mdl proceeding grant february verona public prosecutor commence criminal deny privatepayer plaintiff motion class investigation group sale marketing practice italy certification narrow scope class claim specific area investigation include medical education programme august group reach civil settlement resolve class clinical study congresse interaction action litigation certain state attorney general claim group representative physician public prosecutor group agree nationwide settlement million propose number physician representative resolve claim approve trial court august group face criminal charge hear set group separately resolve potential awp claim state october securities exchange commission sec medicaid programme twothirds state staff initiate investigation allegation group procedure establish doj settlement awp lawsuit cooperate investigation file threatened number state attorney general fully resolve litigation concern awp issue continue follow united nations report allege bribe pay state new york county iraqi government official connection oil food programme group receive subpoena sec february nominal pricing respect group participation programme group respond letter request senate department justice initiate investigation december committee finance date april february fraud office issue formal notice document information relate nominal price exception group require production document relate group good price reporting requirement medicaid drug rebate participation programme group cooperate programme january committee release finding investigation provide document responsive subpoena pharmaceutical manufacturer inappropriately notice nominal price exception contrary committee interpretation congressional intent group advise average wholesale price department justice investigate certain gsk respond subpoenas office inspector group nominal pricing bundle sale arrangement determine general department health human service hhs arrangement qualify exception good department justice states texas california price reporting requirement violate civil statute law connection allegation pharmaceutical company include gsk violate federal fraud abuse law group cooperate investigation provide federal false claim act comparable state law respect document information department justice texas california result way average wholesale arrangement number group product march price awp determine report certain drug group receive subpoena delaware attorney way medicare medicaid programmes reimburse general office seek document relate nominal price contract drug september group reach civil settlement hospital healthcare provider locate delaware department justice attorney district pharmaceutical company receive similar subpoena massachusetts office inspector general hhs group provide document responsive subpoena doj settlement addition governmental investigation allegation concern nominal pricing certain government payer awp litigationgsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue april group receive subpoena attorney office boston request production record paxilseroxat manufacture cidra site cover information follow announcement new york state attorney general similar seize government puerto rico office state lawsuit subsequently settle august subsequently august january group receive allege failure disclose datum use paxil child additional subpoena government relate cidra adolescent similar case purport class action facility group cooperate attorney office file state federal canadian court private produce record responsive subpoena addition plaintiff seek recover amount pay paxil purchase use july group learn district court district patient age canadian litigation dismiss massachusetts unseal complaint bring group reach class settlement agreement illinois state employee federal false claim act claim monetary court action include person usa buy paxil damage result allege failure cidra facility age group deny liability comply gmp manufacture product agreement relate cost purchasing paxil use paediatric patient include personal injury claim group name purport consumer fraud class settlement approve court april remain action lawsuit file california state court lawsuit seek recovery behalf insurance company district court district puerto rico allege paxil thirdparty payer payment prescription paxil product manufacture accord gmp plaintiff seek child adolescent group grant partial summary economic statutory punitive damage request judgement dismissing class claim case discovery injunctive relief determination underway state court action california pende hearing case permit proceed class action class certification antitrust investigation remain pende medicine paxilseroxat healthcare product regulatory agency mhra determine paroxetine patent infringement action bring group group comply pharmacovigilance describe intellectual property apotex certain obligation report datum clinical trial seroxatpaxil company file antitrust unfair competition counterclaim child adolescent group district court eastern district pennsylvania base allegation group monopolise market cidra puerto rico manufacturing site paxil bring allegedly sham patent litigation allegedly follow fda inspection october november abuse regulatory procedure list patent fda result observation possible deficiency manufacturing orange book whilst apotex matter remain discovery stage practice group manufacture facility cidra puerto rico matter company resolve march fda seize certain lot paxil avandamet manufacturing issue fda observation relate certain aspect november ftc staff advise group production control process validation laboratory investigation conduct nonpublic investigation determine group violate section federal trade commission april group reach agreement fda act monopolise attempt monopolise market consent decree consent decree provide independent paroxetine hydrochloride prevent generic competition expert review manufacturing process site compliance paxil request group submit certain information fda good manufacturing practice gmp requirement connection investigation october ftc closed provide consent decree september group investigation basis find action provide report fda deficiency identify warrant follow public reference ftc investigation review set corrective plan timetable completion paxil number governmental private civil action group anticipate completion work identify plan claim initiate usa resolve mid march fda complete general gmp exception private indirect purchaser optout lawsuit bring inspection result inspectional observation minnesota court matter discovery phase group advise fda group response additionally class action file provincial court inspectional observation satisfactory canada behalf direct indirect purchaser case october group announce plan cease operation early stage cidra site expect continue production paxil october competition directorate european site production transfer facility commission initiate inspection concern allegation group currently expect place production group abuse dominant position marketplace product site discontinued end concern enforcement intellectual property right litigation october federal government execute search surround regulatory approval marketing seroxat warrant cidra facility seize record relate europe october commission formal request manufacturing operation site information group respond request end gsk annual report stnemetat laicnanif stnemetat laicnanif eht seton note financial statement continue legal proceeding continue relenza biota holding limit file complaint victorian january european commission announce inquiry supreme court australia allege group fail fulfil certain aspect competition pharmaceutical sector development promotion production obligation zanamivir initiate inspection premise number innovative relenza term licence agreement generic pharmaceutical company include group group group biota biota seek substantial cash damage cooperate commission investigation group believe adhere obligation licence wellbutrin agreement party involve extensive discovery court december january february lawsuit order party mediate end july purport class action file schedule trial commence august district court eastern district pennsylvania overtime claim group behalf direct indirect purchaser wellbutrin december purport class action file complaint allege violation antitrust law sham group behalf group pharmaceutical sale litigation fraud patent office group obtain representative action file transfer enforce patent cover wellbutrin complaint district court central district california allege follow introduction generic competition wellbutrin representative exempt employee california april district appellate court ruling generic law andor fair labor standard act consequently entitle manufacturer infringe group patent party overtime pay suit seek double damage overtime involve discovery allegedly work group sale representative secondary wholesaler year period attorney fee case early july rxusa wholesale inc secondary wholesaler file stage similar action file pharmaceutical suit group pharmaceutical manufacturer company action court find favour wholesaler district court eastern district company dismiss action dismissal new york complaint allege defendant engage appeal conspiracy refuse supply pharmaceutical product rxusa environmental matter violation federal state antitrust law group motion gsk notify potential responsibility relate past dismiss complaint remains pende operation past waste disposal practice certain site commercial corporate primarily usa matter subject security class action litigation include proceeding initiate federal state september attorney represent purport class government waste disposal site remediation cost tort purchaser glaxosmithkline share american depositary action bring private party share adss file second amend security class action complaint gsk advise responsible party group district court southern district approximately site appear national priority new york allege group violate security law list create comprehensive environmental response failure disclose unfavourable clinical datum study paxil compensation liability act superfund misrepresentation remain patent protection paxil augmentin violation federal false claim act basis proceeding seek require operator hazardous group recent awp settlement government october waste facilities transporter waste site generator judge enter order dismiss complaint plaintiff hazardous waste dispose site clean site file appeal court appeal second circuit reimburse government cleanup cost instance gsk oral argument appeal set march involve allege generator hazardous waste site gsk involve current operator november attorney purport represent class facility superfund provide defendant purchaser glaxosmithkline share adss file amend jointly severally liable cleanup cost proceeding consolidate complaint group senior officer frequently resolve basis nature quantity waste district court southern district new york allege dispose site generator gsk proportionate liability group individual defendant violate security cleanup cost substantially determine law artificially inflate price glaxosmithkline stock site refer mislead investor safety avandia amend consolidated complaint allege current gsk potential liability vary greatly site site cost senior officer member group engage insider trading investigation study remediation site time motion dismiss complaint file behalf substantial gsk routinely accrue amount related share group individual defendant liability mattersfinancial statement glaxosmithkline plc director statement responsibility director statement responsibility relation director remuneration company financial statement remuneration report page set remuneration director policy operate glaxosmithkline disclosure director remuneration disclosable information relate director responsible ensure maintenance proper accounting officer interest prepare accordance record disclose reasonable accuracy financial company act complie section position company time financial combine code corporate governance statement prepare comply company act go concern basis require law prepare financial statement financial make enquiry director reasonable period true fair view state affair expectation company adequate resource continue company end financial period profit operational existence foreseeable future reason loss period continue adopt go concern basis prepare responsible ensure operation system financial statement internal control take reasonable step safeguard asset company prevent detect fraud combine code irregularity board consider glaxosmithkline plc apply principle balance sheet year end december combine code corporate governance financial support note set page report report council describe corporate governance page comply provision director confirm suitable accounting policy describe consistently apply preparation financial statement support reasonable prudent judgement estimate require listing rule financial service authority necessary applicable accounting standard follow auditor consider director statement compliance financial statement prepare go relation point combine code specify concern basis review responsibility auditor relation financial statement set independent auditor report annual report publish hardcopy print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation sir christopher gent dissemination financial statement access website chairman available outside comparable legislation february different disclosure information auditor director office date report confirm far aware relevant audit information company auditor unaware director take step heshe ought take director himselfherself aware relevant audit information establish company auditor aware information confirmation give interpret accordance provision section company act gsk annual report stnemetat laicnanif ytilibisnopser stnemetat srotceridfinancial statement glaxosmithkline plc independent auditor report members glaxosmithkline plc audit parent company financial statement basis audit opinion glaxosmithkline plc year end december conduct audit accordance international standard comprise balance sheet relate note audit ireland issue auditing practice board parent company financial statement prepare audit include examination test basis evidence relevant accounting policy set audit amount disclosure parent company financial information director remuneration report describe statement director remuneration report audit audit include assessment significant estimate report separately group financial statement judgement director preparation glaxosmithkline year end december parent company financial statement accounting policy appropriate company circumstance consistently respective responsibility director apply adequately disclose auditor plan perform audit obtain director responsibility prepare annual report information explanation consider necessary order director remuneration report parent company financial provide sufficient evidence reasonable assurance statement accordance applicable law united kingdom parent company financial statement accounting standard united kingdom generally accept director remuneration report audit free material accounting practice set statement director misstatement cause fraud irregularity error responsibility form opinion evaluate overall adequacy presentation information parent company financial responsibility audit parent company financial statement statement director remuneration report director remuneration report audit audit accordance relevant legal regulatory requirement international standard audit ireland report opinion include opinion prepare company member body accordance section opinion company act purpose parent company financial statement true fair give opinion accept assume responsibility view accordance united kingdom generally accept purpose person report show accounting practice state company affair hand come save expressly agree prior december consent write parent company financial statement report opinion parent company director remuneration report audit properly financial statement true fair view prepared accordance company act parent company financial statement director remuneration report audit properly prepare information give report director consistent accordance company act report parent company financial statement opinion information give report director consistent parent company financial statement addition report opinion company keep proper accounting record receive pricewaterhousecooper llp information explanation require audit charter accountant register auditor information specify law director remuneration london transaction disclose february read information contain annual report consider consistent audit parent company financial statement information comprise note financial summary joint statement chairman chief maintenance integrity glaxosmithkline website executive financial trend ratio business review corporate responsibility director work carry auditor governance statement unaudited part remuneration involve consideration matter accordingly auditor accept report consider implication report responsibility change occur financial aware apparent misstatement material inconsistency statement initially present website parent company financial statement responsibility legislation united kingdom govern preparation dissemination extend information financial information differ legislation jurisdiction gsk annual report stnemetat laicnanif troper srotidua tnednepednifinancial statements glaxosmithkline plc company balance sheet gaap december note fix asset investment debtor cash bank current asset creditor amount year net current liability net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund approve board february sir christopher gent chairman gsk annual report stnemetat laicnanif paag teehs ecnalab ynapmocfinancial statement glaxosmithkline plc note company balance sheet gaap presentation financial statement share base payment issuance company subsidiary grant description business company option represent additional capital contribution glaxosmithkline plc parent company gsk major global company subsidiary additional investment subsidiary healthcare group engage creation discovery result correspond increase shareholder equity development manufacture marketing pharmaceutical additional capital contribution base fair value grant product include vaccine overthecounter otc medicine issue allocate underlying grant vest period healthrelate consumer product taxation preparation financial statement current tax provide amount expect pay apply financial statement draw accordance generally tax rate enact substantially enact accepted accounting principle gaap accounting balance sheet date presentation december comparative figure december company account taxation defer accelerate reason timing difference originate permit company act profit loss reverse balance sheet date defer tax asset account company present annual report recognise extent consider recoverable accounting convention standard future taxable profit balance sheet prepare historical cost defer tax measure average tax rate expect convention complie applicable accounting standard apply period time difference expect accounting principle policy reverse defer tax liability asset discount preparation balance sheet conformity financial guarantee generally accept accounting principle require management financial guarantee issue company subsidiary estimate assumption affect report hold fair value amortise life guarantee amount asset liability disclosure contingent asset liability date balance sheet actual operating profit amount differ estimate fee relate audit balance sheet prepare accordance company charge operate profit company accounting policy approve board describe note accounting policy foreign currency transaction foreign currency transaction record exchange rate ruling date transaction forward rate hedge forward exchange contract foreign currency asset liability translate rate exchange rule balance sheet date forward rate dividend pay receive dividend pay receive include account period relate dividend actually pay receive expenditure expenditure recognise respect good service receive supply accordance contractual term provision obligation exist future liability respect past event obligation reliably estimate investment subsidiary company investment subsidiary company hold cost provision impairment impairment investment carry value investment review impairment indication investment impair provision result impairment review charge income statement year concern gsk annual report stnemetat laicnanif paag teehs ecnalab ynapmoc eht setonfinancial statement glaxosmithkline plc note company balance sheet gaap continue fix asset share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited capital contribution relate share base payment financial guarantee debtor amount year corporation tax recoverable amount owe group undertaking creditor amount year bank overdraft amount owe group undertaking creditor share capital share premium account share ordinary share premium number share capital authorise december december share capital issue fully pay january issue share option scheme december issue share option scheme purchase cancel december december december number share issuable outstanding option number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme gsk annual report stnemetat laicnanif paag teehs ecnalab ynapmoc eht setonfinancial statement glaxosmithkline plc note company balance sheet gaap continue reserve profit reserve loss account total january profit attributable shareholder dividend shareholder ordinary share purchase hold treasury share capital contribution relate share base payment december profit attributable shareholder dividend shareholder ordinary share purchase cancel ordinary share purchase hold treasury share capital contribution relate share base payment december profit glaxosmithkline plc year million million dividend million million give retain profit million profit million cost share purchase cancel million nil cost share purchase hold treasury share million million profit loss account reserve december stand million million million unrealised million gsk annual report stnemetat laicnanif paag teehs ecnalab ynapmoc eht setoninvestor information investor information section include financial record present historical information prepare accordance ifrs adopt european union section discuss shareholder return form dividend share price movement provide information shareholder financial record quarterly trend year record shareholder information taxation information shareholder gsk annual report noitamrofni rotsevni gsk annual report noitamrofni rotsevni drocer laicnanif financial record quarterly trend unaudite analysis provide quarter group result pharmaceutical sale therapeutic area sterle financial year income statement total month cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny income statement business performance turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny dilute earning share penny calculation business performance supplemental nonifrs measure describe note financial statement presentation financial statementsgsk annual report noitamrofni rotsevni drocer laicnanif financial record continued income statement total month cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny income statement business performance turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny dilute earning share penny gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover total group cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg coreg levitra avodart arixtra fraxiparine vesicare antibacterial augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover include copromotion incomegsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover usa cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg coreg levitra avodart arixtra fraxiparine vesicare antibacterial augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover include copromotion income gsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover europe cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg coreg levitra avodart arixtra fraxiparine vesicare antibacterial augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover include copromotion incomegsk annual report noitamrofni rotsevni drocer laicnanif financial record continued pharmaceutical turnover international cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix relenza metabolic avandia avandamet avandaryl bonvivaboniva vaccine hepatitis influenza infanrix pediarix boostrix rotarix cervarix cardiovascular urogenital coreg coreg coreg levitra avodart arixtra fraxiparine vesicare antibacterial augmentin oncology emesis zofran hycamtin tykerb zantac total pharmaceutical turnover include copromotion income gsk annual report noitamrofni rotsevni drocer laicnanif financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board turnover business segment pharmaceutical consumer healthcare pharmaceutical turnover therapeutic area respiratory central nervous system antiviral metabolic vaccine cardiovascular urogenital antibacterial oncology emesis pharmaceutical turnover geographic area usa europe international asia pacific japan middle east africa latin america canada international pharmaceutical turnover include copromotion income consumer healthcare turnover otc medicine oral care nutritional healthcare gsk annual report noitamrofni rotsevni drocer laicnanif financial record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share financial result business performance turnover operate profit profit taxation profit taxation penny adjust earning share adjust diluted earning share million million million million million weight average number share issue basic diluted return capital employ return capital employ calculated total profit taxation percentage average capital employ year balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity minority interest total equity gsk annual report noitamrofni rotsevni drocer laicnanif financial record continue number employee usa europe international asia pacific japan middle east africa latin america canada international manufacturing sell administration research development number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate february usshareholder information share price dividend ad table set dividend ad dollar year translate dollar applicable exchange rate january high year year low year december decreaseincrease table set middle market closing price derive london stock exchange daily official list company share price decrease price january december compare dividend calendar increase ftse index year share fourth quarter price february exdividend date february market capitalisation record date february market capitalisation base share issue exclude treasury payable april shares glaxosmithkline december billion date gsk fifth large company market capitalisation quarter ftse index exdividend date april smithkline beecham plc float rate unsecured record date loan stock payable july loan stock list exchange holder require smithkline beecham plc redeem loan stock par second quarter loan stock hold business day march june exdividend date july september december holder wish redeem record date august loan stock complete notice loan payable october stock certificate return registrar arrive day relevant redemption date quarter taxation exdividend date october record date october general information concern tax effect share payable january ownership set taxation information shareholder internet dividend information company include detail share price available gsk website wwwgskcom glaxosmithkline pay dividend quarterly continues increase cash return shareholder dividend policy dividend information available website constitute remain essential component total shareholder return gsk annual report commit increase dividend longterm detail dividend declare payment date give investor relation note financial statement dividend investor relation contact follow dividend share table set dividend share great west road brentford middlesex year tel year pence usa franklin plaza box philadelphia tel toll free tel outside gsk annual report noitamrofni rotsevni noitamrofni redloherahsshareholder information continue analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bank new york mellon hold hold bny nominees limited represent company adr programme ad represent ordinary share nominal value february bny nominees limit hold ordinary share represent issue share capital date february number holders shares usa holdings share number register holder adr holding adr certain share adrs hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder document display memorandum articles association company document refer annual report available inspection register office company publication late march gsk publish website corporate responsibility report cover performance area include community investment ethic integrity access medicine environment health safety exchange control limitation affect security holder currently law decree regulation restrict import export capital affect remittance dividend payment holder company share nonresident limitation relate nonresident english law companys memorandum article association right holder vote respect company share gsk annual report noitamrofni rotsevni noitamrofni redloherahsshareholder information continue nature trading market annual general meeting ordinary share company list london stock queen elizabeth conference centre exchange december share list broad sanctuary westminster new york stock exchange nyse form american london swp depositary share adss date annual general meeting company principal forum follow table set period indicate high communication private shareholder addition formal low middle market closing quotation pence share business presentation chief executive officer london stock exchange high low report sale performance group future development price dollar adss nyse opportunity question board chairman board committee question matter relate glaxosmithkline penny share committee high low investor hold share company nominee service quarter end march arrange nominee service appoint february corporate representative proxy respect shareholde january order attend vote meeting december november adr holder wish attend meeting obtain proxy bank new york mellon enable october attend vote business transact adr holder september instruct bank new york mellon way quarter end december share represent adrs vote complete quarter end september return voting card provide bank accordance quarter end june instruction give quarter end march quarter end december financial reporting quarter end september quarter end june financial reporting calendar quarter end march announcement quarter result april year end december announcement quarter result july year end december announcement quarter result october year end december preliminary announcement annual result february dollar ad publication annual reportreview februarymarch high low quarter end march result announcement february result announcement issue london stock exchange january available news service shortly december issue medium available website send november securities exchange commission nyse october financial report september company publish annual report investor quarter end december need detail report annual review quarter end september available date publication website quarter end june annual review send shareholder shareholder quarter end march elect receive annual report write company quarter end december registrar alternatively shareholder elect receive notification quarter end september email publication financial report register quarter end june wwwshareviewcouk quarter end march year end december copy previous financial report available gsk website year end december print copy obtain registrar year end december gsk response center usa query relate receipt duplicate copy gsk publication february address registrar gsk annual report noitamrofni rotsevni noitamrofni redloherahsordinary share company share list london stock exchange registrar company registrar equiniti aspect house spencer road lance west sussex wwwshareviewcouk tel inside tel outside equiniti provide follow service laxosmithkline investment plan laxosmithkline individual saving account laxosmithkline corporate sponsor nominee hareview service hareview deal service ividend reinvestment plan shareview deal service shareholder buy sell share internet telephone shareview deal share deal service provide equiniti internet purchase sale log wwwshareviewcoukdeale telephone purchase sale inside monday friday glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck tel provision detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser american depositary share company share list nyse form american depositary share evidence american depositary receipt adr represent ordinary share general nyse rule permit company follow corporate governance practice instead apply usa provide company explain significant variation explanation provide company website adr programme administrator adr programme administer bank new york mellon shareholder relations box church street station new york wwwadrbnycom tel toll free tel outside administrator provide global buydirect direct ad purchasesale dividend reinvestment plan adr holder gsk response center tel toll free gsk annual report noitamrofni rotsevni noitamrofni redloherah shareholder information continuedtaxation information shareholder gift disposal subject inheritance tax summary main tax consequence estate gift tax estate gift tax convention holders share adrs citizen generally provide tax pay usa credit tax resident usa set payable complete analysis stamp duty possible tax consequence purchase stamp duty stamp duty reserve tax sdrt subject certain exemption payable purchase share rate ownership security intend purchase price minimum charge general guide holder advise stamp duty liability arise consult adviser respect shareholder tax consequence purchase ownership share adr follow summary certain taxation usa federal consequence state local tax income tax consideration relevant holder share adrs summary apply shareholder law usa implication hold share adr capital asset citizen resident current ukus income tax convention usa domestic corporation subject united states federal income taxation net income basis respect share adr resident tax purpose statement base tax law practice hold share purpose trade profession date report vocation carry branch agency holder adr generally treat owner taxation dividend underlying share purpose current usuk double gross dividend receive reduction taxation convention relate income gain income tax withholding tax treat foreign source dividend income convention estate gift taxis estate gift tax convention tax purpose eligible dividend receive deduction purpose internal revenue code allow corporation dividend adr payable amend code dollar dividend share payable sterling dividend pay shareholder pound sterling include income dollar calculate reference exchange rate day dividend taxation dividend receive holder subject certain exception short april rate tax credit reduce ninth term hedge position individual eligible holder result compensating reduction rate tax dividend subject taxation maximum rate respect income increase tax bear resident individual qualified dividend receive shareholder advise shareholder tax credit long repayable consult tax adviser confirm eligibility shareholder tax liability associate tax credit taxation capital gain taxation capital gain generally holder subject capital gain tax shareholder liable tax gain disposal subject tax capital gain realise sale share adr disposal prior april disposal share adrs entitle indexation relief taper relief estate gift taxis sale indexation relief calculate market value share estate gift tax convention shareholder march cost subsequent purchase generally subject inheritance tax date purchase indexation relief individual shareholder cease april taper relief available stamp duty individual shareholder hold deem hold share stamp duty sdrt subject certain exemption year sell capital gain tax payable issue transfer share adr custodian marginal tax rate individual disposal april depository rate price issue propose indexation taper relief available consideration provide transfer sale value capital gain tax flat rate transfer consideration marginal tax rate individual proposal law sdrt payable transfer adr stamp subject change duty payable transfer adr provide inheritance tax instrument transfer execute remain time outside individual shareholder liable inheritance tax transfer stamp duty transfer adr payable share adrs tax charge rate consideration transfer sale value shareholder estate reduce result transfer underlie share result liability stamp duty way gift disposal market value case sdrt rate minimum charge stamp duty liability arise gsk annual report noitamrofni rotsevni sredloherahs rof noitamrofni noitaxatglossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement recognise income expense statement comprehensive income subsidiary entity glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenue gsk annual report noitamrofni rotsevni smret yrassolgindex performance overview intellectual property accounting policy interest rate risk management acquisition disposal internal control framework annual general meeting inventory annual remuneration investment associate joint venture asset hold sale investor information associate joint venture key performance indicator good place good people key accounting judgement estimate good work legal proceeding board movement equity business review net debt cash cash equivalent new accounting requirement chairman ceo summary nonexecutive director term condition fee combine code nonexecutive director remuneration commitment note financial statement committee report operate profit consolidate balance sheet optimising performance market product consolidated cash flow statement intangible asset consolidate income statement investment consolidate statement recognise income expense noncurrent asset consumer healthcare noncurrent liability contact detail operate income contingent liability provision corporate executive team outlook risk factor corporate governance pension postemployment benefit corporate responsibility community investment pharmaceutical turnover critical accounting policy post balance sheet event deliver product pipeline patient presentation financial statement dialogue shareholder principal group company director senior management remuneration product competition director interest property plant equipment director interest contract quarterly trend director statement responsibility reconciliation net cash flow movement net debt dividend reconciliation profit tax operating cash flow earning share regulatory environment employee cost related party transaction employee share scheme remuneration policy exchange rate remuneration report executive director term condition remuneration report director finance cost responsibility environment health safety finance income restructuring cost financial instrument relate disclosure risk factor financial position resource segment information financial record share capital control financial review share capital share premium account financial review share option financial statement shareholder information financial statement glaxosmithkline plc taxation financial trend ratio taxation information shareholder question answer total equity year record trade payable foreign exchange management trade receivables global manufacturing supply trademark glossary term treasury policy goodwill law regulation governance policy world economy improve access medicine world market incentive plan wwwgskcom head office register office glaxosmithkline plc great west road brentford middlesex united kingdom tel register number print midas press paper production document pulp harvest sustainable forest sawmill residue forest thinning elemental chlorinefree